carbidopa, levodopa drug combination has been researched along with levodopa in 683 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 135 (19.77) | 18.7374 |
| 1990's | 147 (21.52) | 18.2507 |
| 2000's | 47 (6.88) | 29.6817 |
| 2010's | 298 (43.63) | 24.3611 |
| 2020's | 56 (8.20) | 2.80 |
| Authors | Studies |
|---|---|
| Bell, RD; Boyar, RM; Carruth, A; Rosenberg, RN | 1 |
| Diamond, SG; Markham, CH; Treciokas, LJ | 2 |
| Adamkov, J; Drobný, M; Fundárek, J; Svaleková, A | 1 |
| Dyck, PJ; Jaradeh, S | 1 |
| Horstink, MW; Jansen, EN; Roos, RA; Wolters, EC | 2 |
| Golubeva, IA; Maslova, LN; Patrusheva, SV; Sklianova, NA | 1 |
| Lieberman, A | 1 |
| Heninger, GR; Kleber, HD; Kosten, TR; McDougle, CJ; Palumbo, JM; Price, LH | 1 |
| Bowes, SG; Charlett, A; Dobbs, RJ; Dobbs, SM; Henley, M; Nicholson, PW; O'Neill, CJ; Purkiss, AG; Weller, C | 1 |
| Collin, C; Eckernäs, SA; Grahnén, A; Ling-Andersson, A; Nilsson, M; Tiger, G | 1 |
| Fenton, ML; Harnett, DS; Rosenthal, SH | 1 |
| Hildebrand, J; Moussa, Z; Przedborski, S; Raftopoulos, C | 1 |
| Caligiuri, MP; Heindel, WC; Lohr, JB | 1 |
| Anderson, TJ; Donaldson, IM; Ewer, TC; Gilchrist, NL | 1 |
| LeWitt, PA | 1 |
| Rodnitzky, RL | 1 |
| Marsden, CD; Pires, M; Quinn, NP; Scaravilli, F; Steiger, MJ | 1 |
| Kleedorfer, B; Poewe, W | 1 |
| Ahlskog, JE; Bailey, PA; Muenter, MD; Stevens, PM | 1 |
| Cutlip, WD; Makela, EH | 1 |
| Karstaedt, PJ; Pincus, JH | 1 |
| Mark, MH; Sage, JI | 3 |
| Hutton, JT; Morris, JL | 1 |
| Jiménez, F; Jurado, J; Olvera, J; Rodríguez Cuevas, H; Velasco, F; Velasco, M | 1 |
| Fritz, VU; Ming, A; Temlett, JA | 1 |
| Findley, L; Prasher, D | 1 |
| Jacobs, MB; Varon, J | 1 |
| Cedarbaum, JM; Green-Parsons, A; Toy, LH | 1 |
| Davis, SS; Evans, DF; Hardy, JG; Melia, CD; Short, AH; Sparrow, RA; Wilding, IR; Yeh, KC | 1 |
| Cedarbaum, JM; Olanow, CW | 1 |
| Bulling, MT; Burns, RJ; Wing, LM | 1 |
| Cedarbaum, JM; Clark, M; Green-Parsons, A; Toy, LH | 1 |
| Glaeske, CS; Hofman, R; Pfeiffer, RF; Wilken, KE | 1 |
| Marsden, CD; Quinn, NP; Steiger, MJ; Toone, B | 1 |
| Coughlin, SS; Karstaedt, PJ; Pincus, JH | 1 |
| Gash, DM; Kim, MH; Kurlan, R | 1 |
| Block, G; Bush, D; Last, B; Liss, C; Manyam, B; Nakano, K; Nausieda, P; Olanow, CW; Tetrud, JA | 1 |
| Hodges, LC; Rapp, CG | 1 |
| Appley, AJ; Apuzzo, ML; Boyd, SD; Couldwell, WT; Neal, JH; Waters, CH; Weiner, LP; Wheelock, VH | 1 |
| Cowan, A | 1 |
| Haig, AJ; Ruess, JM | 1 |
| Cedarbaum, JM; Clark, M; Green-Parsons, A; Harts, A; McDowell, FH; Silvestri, M; Toy, L | 1 |
| Bovingdon, M; Frankel, JP; Kempster, PA; Lees, AJ; Pirtosek, Z; Stern, GM; Webster, R | 1 |
| Meltzer, HY; Parsa, MA; Ramirez, LF; Rohr, T | 1 |
| Campbell, NR; Goodridge, AE; Hasinoff, BB; Kara, M; Rankine, D | 1 |
| Berchou, RC; Galloway, MP; Kareti, D; LeWitt, PA; Nelson, MV | 1 |
| Boyson, SJ | 1 |
| Berger, HJ; Horstink, MW; Pasman, JW; van't Hof, MA; Zijlmans, JC | 1 |
| Baumann, G; Chin, L; Gopinathan, G; Lieberman, A; Miller, E; Neophytides, A | 1 |
| Duvoisin, RC; Heikkila, RE; McHale, DM; Sage, JI; Sonsalla, PK | 1 |
| Frankel, JP; Hughes, A; Lees, AJ; Stern, GM | 1 |
| Barton, N; Burns, RS; Cohen, W; Fink, JK; Hallett, M; Lovenberg, W | 1 |
| Calne, DB; Calne, S; Douglas, J; Postnikoff, D; Poulin, K; Ross, S; Tsui, JK; Woodward, W | 1 |
| Elizan, TS; Moros, D; Yahr, MD | 1 |
| Chase, TN; Cox, C; Fabbrini, G; Fedio, P; Mohr, E; Schlegel, J; Williams, J | 1 |
| Deleu, D; Ebinger, G; Jacques, M; Michotte, Y | 2 |
| Grinio, LP; Mineeva, MF; Shoshina, LM | 1 |
| Gauger, LL; Olanow, CW; Werner, EG | 1 |
| Cedarbaum, JM; Kutt, H; McDowell, FH | 2 |
| Gilley, DW; Goetz, CG; Klawans, HL; Tanner, CM | 1 |
| Aymard, N; Rondot, P; Teinturier, A; Ziegler, M | 1 |
| Rinne, JO; Rinne, UK | 1 |
| Aarli, JA; Gilhus, NE | 1 |
| Gerdes, U; Haagen, K; Ulm, G | 1 |
| Dickins, QS; Dobson, J; Rodnitzky, RL | 1 |
| Cedarbaum, JM; Hoey, M; McDowell, FH | 1 |
| Ahlskog, JE; Bell, GN; Carmichael, SW; Kelly, PJ; Stoddard, SL; van Heerden, JA | 1 |
| Ahlskog, JE | 4 |
| Cedarbaum, JM | 1 |
| Jankovic, J; Schwartz, K; Vander Linden, C | 1 |
| Bush, DF; Liss, CL; Morton, A | 1 |
| Dempski, RE; Oberholtzer, ER; Scholtz, EC; Yeh, KC | 1 |
| August, TF; Bush, DF; Lasseter, KC; Musson, DG; Schwartz, S; Smith, ME; Titus, DC; Yeh, KC | 1 |
| Berchou, RC; Galloway, MP; Kareti, D; Kesaree, N; LeWitt, PA; Nelson, MV; Schlick, P | 2 |
| Davis, SS; Evans, DF; Hardy, JG; Melia, CD; Short, AH; Sparrow, RA; Wilding, IR | 1 |
| Bush, DF; Hutton, JT; Liss, CL; Morris, JL; Reines, S; Smith, ME | 1 |
| Baronti, F; Chase, TN; Fabbrini, G; Heuser, IJ; Juncos, JL; Mouradian, MM | 1 |
| Feldman, RG; Kelly, MR; Mosbach, PA; Saint Hilaire, MH; Thomas, CA | 1 |
| Evtushenko, SK; Mogilevskaia, GS; Osadchiĭ, VG; Ostropolets, SS; Prokhorova, LM; Sadekov, IA; Samsonenko, RA; Va'skovskaia, ME | 1 |
| Reynolds, CM; Riklan, M; Stellar, S | 1 |
| Factor, SA; Ingenito, AM; Sanchez-Ramos, JR; Weiner, WJ | 1 |
| Ingvarsson, PE; Johnels, B; Steg, G; Thorselius, M; Valls, M | 1 |
| Costeff, H; Gadoth, N; Harel, S; Lavie, P | 1 |
| Friedman, JH; Lannon, MC | 1 |
| Connolly, CE; Donlon, J; O'Reilly, U | 1 |
| Critchley, P; Grandas Perez, FJ; Jenner, PG; Marsden, CD; Nomoto, M; Parkes, JD; Quinn, NP; Stahl, S | 1 |
| Koller, WC; Lang, AE; Marsden, CD; Quinn, NP | 1 |
| Critchley, P; Grandas, F; Marsden, CD; Quinn, N; Rohan, A; Stahl, SM | 1 |
| Cummings, JL; Friedenberg, DL | 1 |
| Huber, SJ; Paulson, GW; Shulman, HG; Shuttleworth, EC | 1 |
| Bratton, M; Jost, MG; Lannon, MC; Lockhart-Pretti, P; Thomas, CA | 1 |
| Jankovic, J | 1 |
| Ahlskog, JE; Bailey, PA; Bell, GN; McManis, PG; Muenter, MD | 1 |
| Carlson, HE | 1 |
| Birkmayer, W | 1 |
| Bioulac, B; Doudet, D; Gross, C; Lebrun-Grandié, P | 2 |
| Albers, JW; Albin, RL; Ellis, CN; Silverman, AK; Voorhees, JJ | 1 |
| Carroll, VS; Carvey, PM; Gilley, D; Goetz, CG; Klawans, HL; Shannon, KM; Tanner, CM | 1 |
| Bouchard, S; Gawel, MJ; Libman, I; Riopelle, RJ | 1 |
| Berger, J; Factor, SA; Sanchez-Ramos, J; Weiner, WJ | 1 |
| Como, P; Kurlan, R | 1 |
| Cedarbaum, JM; Hoey, M; Kutt, H; McDowell, FH | 1 |
| Elias, JW; Hutton, JT; Imke, SC; Morris, JL; Román, GC | 1 |
| Carruthers, M; Quinn, N | 1 |
| Bukhanov, VP | 1 |
| Brown, RG; Gotham, AM; Marsden, CD; Nissenbaum, H; Quinn, NP; Toone, B | 1 |
| Janota, I; Marsden, CD; Parkes, D; Quinn, N | 1 |
| Duvoisin, RC; Sage, JI | 1 |
| Luque, FA; Petruska, P; Selhorst, JB | 1 |
| Bouchard, S; Gawel, M; Libman, I; Riopelle, R | 1 |
| Jankovic, J; Orman, J | 1 |
| Alberts, MJ; Olanow, CW | 1 |
| Chase, TN; Fabbrini, G; Juncos, JL; Kask, AM; Mouradian, MM; Serrati, C | 1 |
| Clough, CG | 1 |
| Carroll, VS; Goetz, CG; Klawans, HL; Shannon, KM; Tanner, CM | 2 |
| Sandyk, R | 3 |
| Corbin, DO; Williams, AC | 1 |
| Chase, TN; Fabbrini, G; Juncos, JL; Mouradian, MM | 1 |
| Bamford, CR; Bernick, C; Iacono, RP; Lee, SM; Sandyk, R; Stern, LZ | 1 |
| Breck, L; Cedarbaum, JM; Kutt, H; McDowell, FH | 2 |
| Golubev, VL; Orlova, OR | 1 |
| Bozek, CB; Calne, DB; Calne, S; Purves, S; Suchowersky, O | 1 |
| Muenter, MD | 1 |
| Wilson, JA | 1 |
| Carter, JH; Nutt, JG; Woodward, WR | 1 |
| Adamkov, J; Fundárek, J; Sútorová, D | 1 |
| Doe, J | 1 |
| van der Drift, JH | 1 |
| Ballard, PA; Langston, JW; Tetrud, JW | 1 |
| Amanova, ZN; Badalian, LO; Grinio, ZN; Sadovskaia, IuE; Temin, PA | 1 |
| Koller, WC | 1 |
| Di Battista, G; Di Meo, L; Figà-Talamanca, L; Gualandi, C; Lo Russo, F; Neri, G | 1 |
| Sjølin, SU; Trykker, H | 1 |
| Askenasy, JJ; Yahr, MD | 1 |
| Calne, DB; Jaffe, M; Larsen, TA; LeWitt, PA; Newman, RP | 1 |
| Rae-Grant, A; Spence, JD; Young, GB | 1 |
| Nausieda, PA | 1 |
| Zhou, XD | 1 |
| Yu, HZ | 1 |
| Amanova, ZN; Badalian, LO; Temin, PA | 1 |
| Marsden, CD; Parkes, JD; Quinn, N | 1 |
| Bergmann, KJ; Clough, CG; Yahr, MD | 1 |
| Carvey, P; Goetz, CG; Klawans, HL | 1 |
| Casey, DE; Gerlach, J | 1 |
| Collinson, PO; Kind, PR; Sandler, M; Slavin, B; Weg, MW | 1 |
| Goetz, CG | 3 |
| Iadgarov, IS | 1 |
| Hadjikonstantinou, M; Markianos, M | 1 |
| Calne, DB; Newman, RP; Smallberg, SA; Weingartner, H | 1 |
| Bianchine, JR; Dippel, RL; Hutton, JT; Meyer, PG; Strahlendorf, HK | 1 |
| Calne, DB; Larsen, TA; LeWitt, P; Newman, R | 1 |
| Diamond, SG; Markham, CH | 1 |
| Gerdes, U; Lehmann, K; Ulm, G | 1 |
| Klawans, HL | 1 |
| Kamenetskiĭ, VK | 1 |
| Jacob, RG; Szekely, BC; Turner, SM | 1 |
| Calne, DB; Chuang, LW; Eisler, T; Karoum, F; Klein, DF; Liebowitz, MR; Quitkin, FM; Wyatt, RJ | 1 |
| Caraceni, T; Cocchi, D; Giovannini, P; Martinez-Campos, A; Müller, EE; Novelli, A | 1 |
| Calne, DB; Eisler, T; Kaiser, DL; MacLeod, RM; Thorner, MO | 1 |
| Glantz, RH; Glatt, SL; Goetz, CG; Klawans, HL; Tanner, CM | 1 |
| Goldstein, M; Gopinathan, G; Hiesiger, E; Leibowitz, M; Lieberman, AN; Nelson, J; Neophytides, A; Walker, R | 1 |
| Boshes, B | 1 |
| Brown, GL; Bunney, WE; Ebert, MH; Langer, DH; Rapoport, JL | 1 |
| Agnoli, A; Baldassarre, M; D'Urso, R; De Giorgio, G; Falaschi, P; Rocco, A; Ruggieri, S | 1 |
| Edwards, M | 1 |
| Glantz, R; Goetz, CG; Klawans, HL; Nausieda, PA; Weiner, WJ | 1 |
| Gilden, ER; Hansch, EC; Hirsch, SB; Potvin, AR; Potvin, JH; Syndulko, K; Tourtellotte, WW | 1 |
| James, WP; Jung, RT; Liddell, F; Shetty, PS | 1 |
| Bushenbark, K; Esterlitz, J; Gauger, L; Hauser, RA; Hubble, J; Koller, W; Lilienfeld, D; Malapira, T; Olanow, CW | 1 |
| Gleckman, AD; Wolf, AP | 1 |
| Lang, AE | 1 |
| Heerschap, A; Hinshaw, DB; Holshouser, BA; Kolem, H; Komu, M; Masur, H; Möller, HE; Sonninen, P; Vermathen, P; Zijlmans, J | 1 |
| Lunn, V; Northcott, C; Yatham, LN | 1 |
| Winn, P | 1 |
| Mowry, D; Ockey, RR; Varghese, G | 1 |
| Iacono, RP; Lonser, RR; Yamada, S | 1 |
| Camicioli, R; Joseph, CL; McWhorter, K; Siple, J | 1 |
| Brannan, T; Yahr, MD | 1 |
| Linazasoro, G | 1 |
| Bennett, KM; Castiello, U | 1 |
| Caligiuri, MP | 1 |
| Larner, AJ | 1 |
| Bankiewicz, KS; de Jesus, S; Sheng, J; Takubo, H; Thomas, J; Wang, J | 1 |
| Mahler, ME; Scharre, DW | 1 |
| Chase, TN; Hoff, J; Metman, LV; Mouradian, MM | 1 |
| Brin, IL; Drozdov, AZ; Filatova, TS; Kogan, BM; Kovaleva, IA | 1 |
| Achiron, A; Djaldetti, R; Melamed, E; Ziv, I | 1 |
| Bédard, PJ; Blanchette, P; DiPaolo, T; Falardeau, P; Gagnon, C; Gomez-Mancilla, B | 1 |
| Cetel, M; Guilleminault, C; Philip, P | 1 |
| Abraham, OC; Archana, S; Cherian, AM; Kurien, T; Rajeev, KK | 1 |
| Lammers, GJ; Roos, RA | 1 |
| Calne, DB; Duvoisin, RC; Koller, WC | 1 |
| Fahn, S; Grimes, JD; Hurtig, H; Jankovic, J; Klawans, H; Kurlan, R; Muenter, M; Olanow, CW; Shoulson, I; Stern, M | 1 |
| Lang, AE; Mark, MH; Sage, JI; Zimmerman, TR | 1 |
| Eller, RV; Gash, DM; Greenamyre, JT; Kurlan, R; Ovadia, A; Zhang, Z | 1 |
| Breimer, DD; Roos, RA; Tijssen, MA; van der Velde, EA | 1 |
| Bergen, M; Fowler, SB | 1 |
| Fullerton, T | 1 |
| Bennett, JP; Schuh, LA | 1 |
| Chase, TN; Dambrosia, JM; Peppe, A | 1 |
| Cote, L; Fahn, S; Greene, P | 1 |
| Baraldo, M; Benetello, P; Furlanut, M; Hassan, E; Zara, G | 1 |
| Busenbark, K; Hubble, JP; Huber, SJ; Koller, WC; Michalek, D; Pahwa, R | 1 |
| Bowes, SG; Charlett, A; Dobbs, RJ; Dobbs, SM; Nicholson, PW; O'Neill, CJ; Purkiss, A; Weller, C | 1 |
| Cashaw, JL | 1 |
| Caligiuri, MP; Lohr, JB | 1 |
| Artem'ev, DV; Damulin, IV; Iakhno, NN | 1 |
| Bakhteev, KK; Brin, IL | 1 |
| Childs, NL; Mercer, WN | 1 |
| Ahtila, S; Gordin, A; Heinävaara, S; Kaakkola, S; Karlsson, M; Korpela, K; Männistö, PT; Tuomainen, P; Wikberg, T | 1 |
| Arutiunian, NA; Iakimovskiĭ, AF | 1 |
| Buhrfiend, C; Carvey, PM; Goetz, CG; Lipton, JW; Pappert, EJ; Stebbins, GT | 1 |
| Dethy, S; Goldman, S; Hildebrand, J; Laute, MA; Naini, AB; Przedborski, S; Raftopoulos, C | 1 |
| Pfeiffer, RF | 1 |
| Revell, SP; Shulman, LM; von Graevenitz, KS | 1 |
| Bowes, SG; Charlett, A; Dobbs, RJ; Dobbs, SM; Hunt, WB; Kirollos, C; Kosik, R; Mozol, K; Nicholson, PW; O'Neill, CJ; Purkiss, AG; Weller, C | 1 |
| Koller, WC; Lyons, K; Marjama, J; McGuire, D; Pahwa, R; Silverstein, P; Ward, R; Zwiebel, F | 1 |
| Bulygina, VV; Markel', AL; Maslova, LN; Naumenko, EV; Shishkina, GT | 2 |
| Muilenburg, ND | 1 |
| Simpson, JS | 1 |
| Currier, RD; Subramony, SH | 1 |
| Tesselaar, HJ; Wolters, EC | 1 |
| Block, G; Irr, J; Liss, C; Nibbelink, D; Reines, S | 1 |
| Dike, GL | 1 |
| Lanska, DJ | 1 |
| Amyot, D; Demong, C; Duff, J; Gray, P; Murphy, D; Watson, J; Wilson, W | 1 |
| Blaney, TJ; Emerich, DF; Francis, JM; Lindner, MD; Plone, MA; Salamone, JD | 1 |
| Briner, V; Niedermaier, G | 1 |
| Emerich, DF; Francis, JM; Lindner, MD; Plone, MA | 1 |
| Blaney, TJ; Chandonait, SE; Emerich, DF; Lindner, MD; Mullins, TD; Plone, MA; Sherman, SS; Stott, JA; Winn, SR | 1 |
| Collins, F; Gash, DM; Hilt, D; Kryscio, R; Lapchak, PA; Lebel, C; Miyoshi, Y; Ovadia, A; Zhang, Z | 1 |
| Brin, IL; Mashilov, KV | 1 |
| Block, GA; Cyhan, G; Gancher, ST; Hammerstad, JP; Nutt, JG; Woodward, WR | 1 |
| Barbato, L; Berardelli, A; Bonamartini, A; Manfredi, M; Patsalos, PN; Ruggieri, S; Stocchi, F | 1 |
| De Meirleir, K; Keizer, H; Magnus, L; Meeusen, R; Roeykens, J | 1 |
| Chase, TN; Lenz, FA; van den Munckhof, P | 1 |
| Bieglmayer, C; Birnbacher, R; Blau, N; Frisch, H; Scheibenreiter, S; Waldhauser, F | 1 |
| Alberts, JL; Stelmach, GE; Tresilian, JR | 1 |
| Golubev, VL; Shtul'man, DR; Shvareva, IS; Veĭn, AM; Zhuchenko, TD | 1 |
| Lapchak, PA | 1 |
| Koller, WC; Wasielewski, PG | 1 |
| Grandas, F; Linazasoro, G; Martínez-Martín, P | 1 |
| Capildeo, R | 1 |
| Ruggieri, S; Silver, DE | 1 |
| Carter, JH; Nutt, JG; Thulin, PC; Woodward, WR | 1 |
| Chokroverty, S; Masdeu, JC; Sander, HW; Tavoulareas, G; Walters, A; Zimmerman, T | 1 |
| Dajani, EZ; Dajani, NE; Dayton, MT; Larsen, KR; Moore, JG | 1 |
| Hempel, AG; Maaty, MA; Sage, JI; Wagner, ML | 1 |
| Cailleux, N; Courtois, H; Lévesque, H; Marie, I; Moore, ND; Noblet, C; Verdure, L | 1 |
| Avraham, M; Dabby, R; Djaldetti, R; Melamed, E; Ziv, I; Zoldan, J | 1 |
| Jorga, KM; Nicholl, DJ | 1 |
| Desimone, R; Fiorani, M; Oldfield, EH; Papa, SM | 1 |
| Scheife, RT | 1 |
| Ahlskog, JE; Burnett, OL; Maraganore, DM; Matsumoto, JY; O'Connor, MK; Stark, KF; Turk, MF; Uitti, RJ | 1 |
| Kimber, J; Mathias, CJ; Watson, L | 1 |
| Brousolle, E; Dentresangle, C; Froment, JC; Guerin, J; Lavenne, F; Le Bars, D; Pierre, C; Pollak, P; Veyre, L | 1 |
| Bennett, KM; Bonfiglioli, C; Castiello, U; Peppard, RF | 1 |
| Minagar, A; Shulman, LM; Weiner, WJ | 1 |
| Bremer, DL; Leguire, LE; McGregor, ML; Rogers, GL; Walson, PD | 1 |
| Guy, ME; Johnson, LN; Krohel, GB; Madsen, RW | 1 |
| Brooks, DJ; Gordin, A; Karlsson, M; Korpela, K; Pavese, N; Piccini, P | 1 |
| Bankiewicz, KS; Bringas, J; Budinger, TF; Cunningham, J; Eberling, JL; Harvey-White, J; Jagust, W; Kohutnicka, M; Pivirotto, P | 1 |
| Mark, LP; Mueller, WR; Prieto, TE; Reynolds, NC; Terry, LC | 1 |
| Susman, VL | 1 |
| Ko, CH; Kong, CK; Lam, CW; Tong, SF | 1 |
| Dhanuka, AK; Singh, G | 1 |
| Badarny, S; Djaldetti, R; Giladi, N; Herishano, Y; Honigman, S; Inzelberg, R; Korczyn, AD; Melamed, E; Peretz-Aharon, Y; Rabey, MJ | 1 |
| Sharif, AA | 1 |
| Bilbao Garay, J; Castilla Castellano, V; Dhimes Tejada, P; Mesa Plaza, N | 1 |
| Ghika, J; Solida, A; Vingerhoets, F | 1 |
| Kapustina, MT; Karaban', IN; Karasevich, NV; Lukhanina, EP | 1 |
| Duarte, CA; González, S; Vázquez-Blomquist, D | 1 |
| Hirsch, EC; Muriel, MP; Orieux, G | 1 |
| Borra, S; Hauser, RA; Zesiewicz, TA | 1 |
| Eng, JJ; Inkster, LM; MacIntyre, DL; Stoessl, AJ | 1 |
| Blomgren, M; Goberman, AM | 1 |
| Bakay, RA; Barnhart, H; Chockkan, V; DeLong, MR; Evatt, M; Freeman, A; Green, J; Haber, M; McDonald, W; Mewes, K; Triche, S; Vitek, JL; Wahlay, N; Zhang, JY | 1 |
| Decker, PA; Dousa, MK; Muenter, MD; Offord, KP; Tyce, GM; Weinshilboum, RM | 1 |
| Chaná, P; Fierro, A; Reyes-Parada, M; Sáez-Briones, P | 1 |
| Krahn, M; Lang, A; Marras, C; Naglie, G; Tomlinson, G | 1 |
| Gadkary, CA; Mummaneni, PV; Quinones-Hinojosa, A; Rosenberg, WS | 1 |
| Bruno, MK; Considine, E; Garraux, G; Gwinn-Hardy, K; Hallett, M; Hanson, M; Johnson, J; Ptacek, L; Ravina, B; Singleton, A | 1 |
| Hurka, MR; Leopold, NA; Polansky, M | 1 |
| Burkhard, PR; Flachsbart, KD; Fross, RD; Horvath, J; Kleiner-Fisman, G; Lang, AE; Lerch, R; Liaudat, S; Pache, JC; Rakowski, H; Raskoff, WJ; Stalder, H | 1 |
| Chen, CM; Lee-Chen, GJ; Tang, LM; Wang, CK; Wang, SC; Wu, YR | 1 |
| Bara-Jimenez, W; Chase, TN; Dimitrova, T; Favit, A; Mouradian, MM; Sherzai, A | 1 |
| Delville, Y; Fleming, SM; Schallert, T | 1 |
| Antenor, JA; Kotagal, V; McGee-Minnich, L; Moerlein, SM; Perlmutter, JS; Racette, BA; Videen, TO | 1 |
| Chang, CY; Chang, ML; Chien, HF; Jiang-Shieh, YF; Wei, IH; Wu, CH; Yeh, KY | 1 |
| Arthur, K; Foley, SR; Kelly, BD | 1 |
| Bremen, D; Erdmann, C; Muhlack, S; Müller, T; Przuntek, H; Woitalla, D | 1 |
| Cercy, SP; Walker, RH; Warwick, R | 1 |
| Chigir', IP; Fedorova, NV | 1 |
| Bain, PG; Hensman, DJ | 1 |
| Costa, ER; Dahners, LE; Hooker, JA; Tayrose, GA; Weinhold, P | 1 |
| Ludin, HP; Surber, Ch | 1 |
| aan het Rot, M; Baker, GB; Benkelfat, C; Booij, L; Leyton, M; Young, SN | 1 |
| Chou, KL; Stacy, MA | 1 |
| Young, DK | 1 |
| Delmas, G; Flesch, F; Rothmann, C | 1 |
| Cheyette, BN; Cheyette, SN; Cusmano-Ozog, K; Enns, GM | 1 |
| Doan, JB; Melvin, KG; Suchowersky, O; Whishaw, IQ | 1 |
| Addy, C; Assaid, C; Ellenbogen, A; Gottesdiener, K; Herring, WJ; Hreniuk, D; Jinnah, HA; Kirby, L; Leibowitz, MT; Stewart, RM; Stoch, SA; Stroh, M; Tarsy, D; Tetrud, J; Wagner, J; Xu, Y | 1 |
| Jurjevic, A; Kovacevic, M; Ljubicic, D; Mrsic-Pelcic, J; Perkovic, O; Rudez, J; Vitezic, D; Vitezic, M | 1 |
| Adamiak, U; Bialecka, M; Gawronska-Szklarz, B; Kaldonska, M; Klodowska-Duda, G; Safranow, K; Wyska, E | 1 |
| Eggert, K; Eichhorn, T; Oertel, WH; Ries, V; Selzer, R | 1 |
| Cetas, JS; Fields, JD | 1 |
| García-Horsman, JA; Käenmäki, M; Kambur, O; Karvonen, E; Keisala, T; Kulesskaya, N; Männistö, PT; Rauvala, H; Tammimäki, A | 1 |
| Alvarez-Lueje, A; Bravo, M; Olivieri, AC; Pérez-Ortiz, M; Zapata-Urzúa, C | 1 |
| Hinz, AB; Hoffmann, G; Hörster, F; Klein, C; Neidhardt, K; Opladen, T; Wolf, N | 1 |
| Deuschl, G; Herzog, J; Volkmann, J; Wailke, S; Witt, K | 1 |
| Bugalho, P; Lampreia, T; Santos, L; Soares, P | 1 |
| Ellmén, J; Kailajärvi, M; Korpela, K; Kuoppamäki, M; Lehtinen, T; Sauramo, A; Vahteristo, M | 1 |
| MARKOWITZ, J | 1 |
| Gradl, B; Persson, U; Willis, M; Zoellner, Y | 1 |
| Ferreira, JJ; Sampaio, C | 1 |
| Hawley, JS; Robottom, BJ; Weiner, WJ | 1 |
| Fernandez, HH; Odin, P | 1 |
| Bengel, G; Ebersbach, G; Ehret, R; Jugel, C; Klostermann, F; Muhlack, S; Müller, T | 1 |
| Arami, MA; Ayromlou, H; Najmi, S | 1 |
| Armstrong, J; Artuch, R; Barredo-Valderrama, E; Campistol, J; Castro de Castro, P; Cormand, B; Garcia-Cazorla, A; Ormazabal, A; Serrano, M; Toma, C | 1 |
| Angrisano, S; Lanotte, M; Lopiano, L; Merola, A; Rizzi, L; Zibetti, M | 1 |
| Muhlack, S; Müller, T; Woitalla, D | 1 |
| Hazan, D; Siegert, S; Szyper-Kravitz, M | 1 |
| Chen, C; Cowles, VE; Illarioshkin, SN; Stolyarov, ID; Sweeney, M | 1 |
| Belcastro, V; Calabresi, P; Castrioto, A; Gallina, A; Rossi, A; Tambasco, N | 1 |
| Agarwal, P; Alcalay, R; Black, KJ; Chou, KL; Cote, L; Dayalu, P; Frank, S; Friedman, JH; Hartlein, J; Hauser, RA; Lang, AE; Marsh, L; Marshall, F; Moskowitz, C; Ravina, B; Riley, D; Sanchez-Ramos, J; Simon, DK; Simuni, T; Sutton, J; Tuite, P; Weintraub, D; Zesiewicz, T | 1 |
| Bel'gusheva, ME; Fedorova, NV; Iablonskaia, AIu | 1 |
| Adam, JJ; Duits, A; Scholtissen, B; van Houdt, H; Visser-Vandewalle, V; Winogrodzka, A | 1 |
| Ellenbogen, AL; Gupta, SK; Hauser, RA; Hsu, A; Kell, SH; Metman, LV; Modi, NB; O'Connell, MJ; Yao, HM | 1 |
| Ahlskog, JE; Josephs, KA; Kumar, N; Matsumoto, JY; McKeon, A; Savica, R | 1 |
| Babiuc, RD; Bajenaru, OA; Ene, A; Negreanu, L; Popescu, BO; Smarandache, GC | 1 |
| Buttarelli, FR; Campanelli, D; Fanciulli, A; Misasi, R; Pontieri, FR | 1 |
| Becker, N; Munhoz, RP; Teive, HA | 1 |
| Okun, MS | 1 |
| Grice, T; Stagg, P | 1 |
| Boskovic, R; Clark, M; Houle, S; Kish, SJ; Meyer, JH; Rabiner, EA; Rusjan, P; Sacher, J; Soliman, A; Wilson, AA | 1 |
| Askmark, H; Munro Neville, A; Nyholm, D; Parsons, RW | 1 |
| Añón, MJ; de la Fuente-Fernández, R; Fuster-Sanjurjo, L; Santos-García, D | 1 |
| Hauser, RA | 1 |
| Benko, R; Jain, L; Safranek, S | 1 |
| Coon, EA; Laughlin, RS | 1 |
| Johansson, A; Klangemo, K; Nyholm, D | 1 |
| Bhatia, KP; Dayan, P; Dolan, RJ; Hill, C; Seymour, B; Shiner, T; Wunderlich, K | 1 |
| Bini, V; Bortolato, M; Cannas, A; Marrosu, F; Puligheddu, M; Solla, P | 1 |
| Bartalini, S; Bianco, G; Chieca, R; Rossi, A; Rossi, S; Ulivelli, M; Vuolo, G | 1 |
| Nishijima, K; Saito, S; Shioda, K | 1 |
| Muhlack, S; Müller, T | 1 |
| George, S; Jones, HB | 1 |
| Dizdar, N; Hauge, T; Holmberg, B; Jansson, R; Johansson, A; Linder, J; Nyholm, D; Pålhagen, SE; Sydow, O; Wainwright, M; Widner, H | 1 |
| Belavic, J | 1 |
| Artusi, CA; De Angelis, C; Lopiano, L; Marchisio, A; Merola, A; Montanaro, E; Reggio, D; Ricchi, V; Rizzi, L; Rizzone, M; Zibetti, M | 1 |
| Müller, T; Skodda, S | 1 |
| Nyholm, D | 1 |
| Camargos, S; Cardoso, F; Lees, AJ; Singleton, A | 1 |
| Foote, KD; Hassan, A; Iyer, S; McFarland, NR; Okun, MS; Rodriguez, RL; Sriram, A; Ward, HE | 1 |
| Ahmad, M; Gupta, A; Rizvi, I; Zaidi, N | 1 |
| Agarwala, R; Bennett, SF; Berry, MW; Bick, DP; Chen, B; Chin, EL; Compton, JG; Das, S; Dimmock, DP; Farkas, DH; Ferber, MJ; Funke, BH; Furtado, MR; Ganova-Raeva, LM; Gargis, AS; Geigenmüller, U; Gunselman, SJ; Hambuch, T; Hegde, MR; Johnson, PL; Kalman, L; Kasarskis, A; Kulkarni, S; Lenk, T; Liu, CS; Lu, F; Lubin, IM; Lyon, E; Manion, M; Manolio, TA; Mardis, ER; Merker, JD; Rajeevan, MS; Reese, MG; Rehm, HL; Simen, BB; Voelkerding, KV; Yeakley, JM; Zehnbauer, BA; Zook, JM | 1 |
| Bömelburg, M; Ebersbach, G; Jugel, C; Klostermann, F; Marzinzik, F; Müller, T | 1 |
| Chari, V; Ennis, JD; Graham, A; Harvey, D; Ho, E; Nesathurai, S | 1 |
| Chatamra, K; Dutta, S; Johansson, A; Locke, C; Nyholm, D; Odin, P; Othman, AA | 1 |
| Anderson, LC; Fagerlund, K; Gurvich, O | 1 |
| Datieva, VK; Levin, OS; Makotrova, TA | 1 |
| Benesh, J; Chatamra, K; Espay, AJ; Fernandez, HH; Hass, SL; Hauser, RA; Lenz, RA; Odin, P; Pritchett, Y; Standaert, DG; Vanagunas, A | 1 |
| Arai, M | 1 |
| Gupta, S; Hsu, A; Mao, Z; Modi, NB | 1 |
| Ossig, C; Reichmann, H | 1 |
| Rascol, O | 1 |
| Espay, AJ; Gupta, S; Hauser, RA; Hsu, A; Kell, S; O'Connell, M; Ondo, W; Sethi, K; Stacy, M | 1 |
| Worth, PF | 1 |
| Agarwal, P; Burdick, DJ; Griffith, A | 1 |
| Best, CM; Ifedi, BO; Reichel, LM | 1 |
| Angrisano, S; Artusi, CA; Cocito, D; Lopiano, L; Merola, A; Rizzone, MG; Troiano, M; Zibetti, M | 1 |
| Filipek, B; Pytka, K; Zygmunt, M | 1 |
| Galazky, I; Heinze, HJ; Kluge, C; Kupsch, A; Schoof, J; Stallforth, S | 1 |
| Fahn, S; Gupta, S; Hauser, RA; Hsu, A; Jankovic, J; Kell, S; Lyons, KE; O'Connell, M; Pahwa, R; Pourcher, E | 1 |
| Heidenreich, WF | 1 |
| Snider, S | 1 |
| Corona-Morales, AA; Hernández, VS; Jáuregui-Huerta, F; Luquín, S; Medina, MP; Ruíz-Velasco, S; Zhang, L | 1 |
| Angrisano, S; Artusi, CA; De Angelis, C; Lopiano, L; Merola, A; Reggio, D; Rizzi, L; Rizzone, M; Zibetti, M | 1 |
| Baumann, CR; Waldvogel, D | 1 |
| Gelfius, CD; Mortimer, D; Potts, MA | 1 |
| Chen, D; Cundy, KC; Hauser, RA; Huff, FJ; LeWitt, PA; Lissin, D; Zomorodi, K | 1 |
| de Beyl, DZ; Dethy, S; Pickut, BA; Van De Maele, H; van der Linden, C | 1 |
| Capone, JG; Contini, E; Golfre-Andreasi, N; Gragnaniello, D; Preda, F; Quatrale, R; Sensi, M; Sette, E; Tola, MR; Trevisani, L; Tugnoli, V | 1 |
| Berg, J; Crooks, K; Evans, J; Fan, Z; Felix, AC; Greenwood, R; Roche, M; Shiloh-Malawsky, Y; Tennison, M; Weck, K; Wilhelmsen, K | 1 |
| Aglan, H; Ahmed, H; Atta, H; Ghazy, M; Salem, A | 1 |
| Ceballos-Baumann, AO; Fietzek, UM; Lehnerer, SM; Messner, M | 1 |
| Chen, CH; Chen, NF; Chen, WF; Feng, CW; Hsiao, CD; Huang, SY; Hung, HC; Wang, HM; Wen, ZH; Yang, SN | 1 |
| Argyris, P; Barla, G; Maltezou, M; Stathis, P; Tzias, V | 1 |
| Epstein, J; Hayes, MT; Lai, L; Madiedo, CJ | 1 |
| Ondo, W | 1 |
| Dillmann, U; Ellenbogen, A; Gupta, S; Hsu, A; Kell, S; Khanna, S; Liang, G; Mahler, A; Rubens, R; Stocchi, F | 1 |
| Merello, M; Rossi, M | 1 |
| Antonini, A; Poewe, W | 1 |
| Chang, MC; Jang, SH; Kwon, YM | 1 |
| Arolt, V; Deckert, J; Dlugos, A; Domschke, K; Gajewska, A; Gieselmann, A; Herrmann, MJ; Jacob, C; Markulin, F; Mühlberger, A; Nienhaus, K; Notzon, S; Pauli, P; Reif, A; Unterecker, S; Warrings, B; Winter, B; Zwanzger, P | 1 |
| Chang, MC; Chun, MH; Kang, CG; Kong, EJ | 1 |
| Benesh, JA; Chatamra, K; Chouinard, S; Dubow, J; Espay, AJ; Fernandez, HH; Fung, VS; Hall, CM; Hauser, RA; Klostermann, F; Lang, AE; Lew, MF; Odin, P; Robieson, WZ; Standaert, DG; Steiger, M; Suchowersky, O; Yakupov, EZ | 1 |
| Chang, FC; Drury, M; Fung, VS; Griffith, JM; Ha, AD; Kim, SD; Mahant, N; Tsui, DS; Wolfe, N | 1 |
| di Biase, L; Di Lazzaro, V; Marano, M; Melgari, JM; Salomone, G; Scrascia, F | 1 |
| Andersen, LM; Gross, J; Joensson, M; Lou, HC; Mouridsen, K; Sandberg, K; Thomsen, KR; Østergaard, L | 1 |
| Fahn, S; Kestenbaum, M | 1 |
| Afshari, D; Azimi, H; Ghadami, MR; Heidarnejadian, J; Razazian, N | 1 |
| Fasano, A; Lang, AE; Liu, LW; Poon, YY | 1 |
| Fung, VS | 1 |
| Chen, C; Cowles, VE; Stover, N; Sweeney, M; Verhagen Metman, L | 1 |
| Gupta, S; Hsu, A; Modi, NB; Yao, HM | 1 |
| Dzyak, L; Gupta, S; Hsu, A; Kell, S; Khanna, S; Nausieda, P; Rudzinska, M; Silver, DE; Spiegel, J; Tsurkalenko, ES; Waters, CH | 1 |
| Barrios-Barrios, A; Bustamante-Balén, M; del-Hoyo-Francisco, J; Martínez-Torres, I; Pons-Beltrán, V; Satorres-Paniagua, C | 1 |
| Johnson, KE | 1 |
| Benedetti, A; Gros, P; Kaminska, M; Kimoff, RJ; Lafontaine, AL; Mery, VP; Robinson, A | 1 |
| Cannas, A; Fasano, A; Lang, AE; Marrosu, F; Marrosu, MG; Mulas, CS; Solla, P | 1 |
| Bellante, F; Dethy, S; Zegers de Beyl, D | 1 |
| Bruno, E; Cicero, CE; Contrafatto, D; Dibilio, V; Giuliano, L; Luca, A; Mostile, G; Nicoletti, A; Pappalardo, I; Raciti, L; Sciacca, G; Sofia, V; Zappia, M | 1 |
| Bonuccelli, U; Ceravolo, R; Frosini, D; Mazzucchi, S | 1 |
| Katunina, EA; Titova, NV | 1 |
| Garg, A; Jha, S; Khanna, A | 1 |
| di Biase, L; Di Lazzaro, V; Marano, M; Melgari, JM; Salomone, G | 1 |
| Kuoppamäki, M; Leinonen, M; Poewe, W | 1 |
| Hattori, N; Ishiguro, Y; Kawajiri, S; Noda, K; Okuma, Y; Tomizawa, Y; Tosaka, Y | 1 |
| Mick, D; Resan, B; Segec, I; Skelac, D; Soldo, SB; Tomic, S | 1 |
| Elmer, L; Gil, RA; Gupta, S; Hsu, A; Kell, S; Khanna, S; Modi, NB; Nausieda, PA; Rubens, R; Singer, C; Spiegel, J | 1 |
| Cannas, A; Marrosu, F; Marrosu, MG; Solla, P | 1 |
| Cordery, P; James, LJ; Maughan, RJ; Peirce, N; Watson, P | 1 |
| Bernardini, A; Cocito, D; Lopiano, L; Merola, A; Romagnolo, A; Zibetti, M | 1 |
| Abou Al-Shaar, H; Al-Ajlan, F; Alkahtani, K; Alkhairallah, T; Bohlega, S; Hasan, N | 1 |
| Mao, ZL; Modi, NB | 1 |
| Greig, SL; McKeage, K | 1 |
| Benesh, JA; Boyd, JT; Chatamra, K; Chouinard, S; Draganov, PV; Dubow, J; Eaton, S; Espay, AJ; Fasano, A; Fernandez, HH; Fung, VS; Klostermann, F; Lang, AE; Lew, MF; Odin, P; Robieson, WZ; Rodriguez, RL; Schmulewitz, N; Slevin, JT; Stein, DA; Zadikoff, C | 1 |
| Băjenaru, O; Buraga, I; Constantinescu, A; Ene, A; Mureşan, DF; Perju-Dumbrava, L; Popescu, BO; Popescu, CD; Sabău, M; Simu, M; Szász, JA | 1 |
| Hattori, N | 1 |
| Dagher, A; Fellows, LK; Simioni, AC | 1 |
| Alonso, V; Anyanwu, EC; Benoit, JL; Ebara, L; Pettit, NN; Wojcik, E | 1 |
| Antonini, A; Benesh, JA; Boyd, JT; Chatamra, K; Eaton, S; Fung, VS; Hall, C; Slevin, JT | 1 |
| Mueller, BK; Muhlack, S; Müller, T; Trommer, I | 1 |
| Cicero, CE; Mostile, G; Nicoletti, A; Zappia, M | 1 |
| Bove, F; Espay, AJ; Espay, KJ; Fasano, A; Krikorian, R; Lena, F; Modugno, N; Poon, YY; Ricciardi, L | 1 |
| Gore, C; Wu, C | 1 |
| Brauer, AF; Ciucci, MR; Kelm-Nelson, CA | 1 |
| Dhall, R; Kreitzman, DL | 1 |
| Silver, DE; Trosch, RM | 1 |
| Benita León, V; Campolongo Perillo, A; Fernández Díez, S; Mariscal Pérez, N; Martínez Castrillo, JC; Puente Périz, V; Santos García, D; Seoane Urgorri, A; Udaeta Baldivieso, B | 1 |
| Friedman, JR | 1 |
| Nyholm, D; Odin, P; Wirdefeldt, K | 2 |
| Almeida, L; Falcão, A; Ferreira, JJ; Nunes, T; Pinto, R; Rocha, JF; Santos, A; Soares-da-Silva, P | 1 |
| Bernardini, A; Espay, AJ; Espay, KJ; Lanotte, M; Lopiano, L; Merola, A; Rizzi, L; Romagnolo, A; Rosso, M; Zibetti, M | 1 |
| Jog, MS; Kumar, N; Rizek, P | 1 |
| Lyons, KE; Pahwa, R | 1 |
| Abreu, L; Bernardo, C; López Gómez, M; Magaz Martínez, M; Martínez Porras, JL; Santiago, J | 1 |
| Mundt-Petersen, U; Odin, P; Timpka, J | 1 |
| Bergmann, L; Dizdar, N; Hauge, T; Holmberg, B; Jansson, R; Johansson, A; Kjellander, S; Linder, J; Marshall, TS; Nyholm, D; Pålhagen, SE; Sydow, O; Widner, H | 1 |
| Amato, MR; De Micco, R; Del Prete, A; Esposito, P; Ferraro, F; Sica, M; Tessitore, A; Zulli, C | 1 |
| Durso, R; McNamara, P; Morgan, J; Smart, K | 1 |
| Cubo, E; Giuffrida, JP; Heldman, DA | 1 |
| Antonini, A; Cannas, A; Costanzo, AM; di Luzio Paparatti, U; Gualberti, G; Gusmaroli, G; Lopiano, L; Mancini, F; Marano, P; Meco, G; Melzi, G; Modugno, N; Quatrale, R; Sensi, M; Tamma, F | 1 |
| Carpenter, MG; Inglis, JT; McKeown, MD; McKeown, MJ; Pasman, EP; Peters, RM | 1 |
| Arbelo, JM; Catalán, MJ; Grandas, F; Mir, P; Parra, JC; Puente, V; Regidor, I; Santos-García, D; Valldeoriola, F | 1 |
| Bloem, BR; Faber, MJ; Nijhuis, FA; Post, B; van Heek, J | 1 |
| Devigili, G; Eleopra, R; Lettieri, C; Rinaldo, S | 1 |
| Lambarth, AT | 1 |
| Avolio, C; De Francesco, V; Lalla, A; Martino, T; Melchionda, D; Specchio, LM; Tonti, P | 1 |
| Bilic, B; Markos, P; Miletic, V; Rustemovic, N | 1 |
| Khatoon, H; Mirza, T; Najam, R; Sikandar, B | 1 |
| Fox, SH; Freitas, ME; Ruiz-Lopez, M | 1 |
| Cataldo, BO; Cury, RG; de Campos Duprat, A; Fonoff, E; Noffs, G; Zarzur, AP | 1 |
| Bojarski, C; Ehlen, F; Klostermann, F; Maier, A; Marzinzik, F; Schindlbeck, KA | 1 |
| Abreu, L; Magaz Martínez, M; Martínez Porras, JL; Oliva, B | 1 |
| Nielsen, EI; Nyholm, D; Senek, M | 3 |
| Borgemeester, R; van Laar, T | 1 |
| Cannas, A; Marrosu, F; Mascia, MM; Meloni, M; Solla, P | 1 |
| Jog, M; Kumar, N | 1 |
| Alonso-Frech, F; Catalán, MJ; Escribano, PM | 1 |
| Modi, NB | 1 |
| Duker, AP; Ellenbogen, A; Farbman, ES; Gupta, S; Hauser, RA; Hsu, A; Kell, S; Khanna, S; Kreitzman, D; Liang, GS; Nausieda, P; Nieves, A; Rubens, R; Tetrud, J | 1 |
| Ács, P; Annus, Á; Aschermann, Z; Dézsi, L; Dibó, G; Harmat, M; Janszky, J; Juhász, A; Karádi, K; Klivényi, P; Komoly, S; Kovács, M; Kovács, N; Makkos, A; Nagy, H; Takáts, A; Tényi, D; Tóth, A; Varannai, L; Vécsei, L; Zádori, D | 1 |
| Debelius, JW; Factor, SA; Hill-Burns, EM; Knight, R; Lewis, MR; Molho, E; Morton, JT; Payami, H; Peddada, SD; Wallen, ZD; Wissemann, WT; Zabetian, CP | 1 |
| Evans, AH; Fung, VSC; Hayes, M; Iansek, R; Kimber, T; O'Sullivan, JD; Sue, CM; Williams, DR | 1 |
| Chatamra, K; Dutta, S; Locke, C; Othman, AA; Rosebraugh, M | 1 |
| Buhmann, C; Hilker, R; Lingor, P; Reichmann, H; Schrader, C; Schwarz, J; Wolz, M | 1 |
| Gupta, S; Mittur, A; Modi, NB | 1 |
| Antonini, A; Cossu, G; Mancini, F; Modugno, N; Pilleri, M; Quatrale, R; Sensi, M; Tamma, F; Zibetti, M | 1 |
| Artusi, CA; Comi, C; Duker, AP; Espay, AJ; Lanotte, M; Lopiano, L; Maule, S; Merola, A; Romagnolo, A; Rosso, M; Zibetti, M | 1 |
| Aquilonius, SM; Nyholm, D | 1 |
| Albo, J; Hellström, M; Nyholm, D; Senek, M; Svenningsson, P | 1 |
| de la Casa, B; Díaz Gómez, A; Díaz Ruiz, R; Fernández Alvárez, C; González Asanza, C; Nogales, Ó | 1 |
| Fasano, A; Naranian, T; Poon, YY; Rohani, M | 1 |
| Angrisano, S; Cicolin, A; Lopiano, L; Merola, A; Montanaro, E; Priano, L; Romagnolo, A; Tribolo, A; Zibetti, M | 1 |
| Aasly, J; Dietrichs, E; Egge, A; Ezat, B; Pihlstrøm, L; Tysnes, OB | 1 |
| Ehm, G; Jeon, B; Kim, A; Kim, HJ; Kim, YE; Lee, WW; Yang, HJ; Yun, JY | 1 |
| Chorbadzhieva, E; Dressler, D; Kleimann, A; Loens, S; Schrader, C | 1 |
| Capone, JG; Golfrè Andreasi, N; Preda, F; Rispoli, V; Sensi, M; Sette, E; Simioni, V; Tugnoli, V | 1 |
| Belagaje, SR; Buetefisch, CM; Haut, MW; Hobbs, G; Kesar, TM; Pergami, P | 1 |
| Bove, F; Di Iorio, R; Fasano, A; Gallicchio, L; Luigetti, M; Petruzzellis, A; Recchia, V; Tamma, F | 1 |
| Durando, M; Kim, JS; Tiu, H | 1 |
| Bentivoglio, AR; Bove, F; Fasano, A; Naranian, T | 1 |
| Eerola-Rautio, J; Kenttämies, A; Kylänpää, L; Lindström, O; Lyytinen, J; Pekkonen, E; Udd, M | 1 |
| Ando, R; Miyaue, N; Nagai, M; Nishikawa, N; Nomoto, M; Tada, S; Yabe, H | 1 |
| Mundt-Petersen, U; Odin, P | 1 |
| Elsea, SH; Hanchard, NA; Kennedy, AD; Magoulas, PL; Pappan, KL; Sun, Q | 1 |
| Abu-Suboh, M; Alvarez-Sabín, J; Armengol, JR; De Fabregues, O; Dot, J; Ferré, A; Gómez, MR; Hernández-Vara, J; Ibarria, M; Puiggros, C; Quintana, M; Raguer, N; Romero, O; Seoane, JL | 1 |
| D'Elia, A; Imbriani, P; Pisani, A; Schirinzi, T | 1 |
| Manno, RA; Maronpot, RR; Nyska, A; Ramot, Y; Sacco, G; Shaltiel-Karyo, R; Tsarfati, Y; Yacoby-Zeevi, O | 1 |
| Baj, R; Chaudhuri, KR; Jalundhwala, YJ; Konwea, H; Lowin, J; Marshall, TS; Sail, K | 1 |
| Dizdar, N; Grenholm, P; Groth, K; Kjellander, S; Larsson, J; Nyholm, D; Permert, J; Schmiauke, U; Urbom, A; Widner, H; Willows, T | 1 |
| Antonini, A; Barch, D; Bergmann, L; Chaudhuri, KR; Jech, R; Odin, P; Onuk, K; Pickut, B; Pirtošek, Z; Poewe, W; Szasz, J; Valldeoriola, F; Winkler, C; Yegin, A | 1 |
| Baastrup, C; Benedetti, F; Grosen, K; Hall, KT; Jensen, TS; Kaptchuk, TJ; Moslemi, K; Petersen, GL; Price, DD; Skyt, I; Svensson, P; Vase, L | 1 |
| Fasano, A; Jog, M; Kumar, N; Murgai, A; Naranian, T | 1 |
| Hoon, M; Petzer, A; Petzer, JP; Viljoen, F | 1 |
| Bopeththa, BVKM; Ralapanawa, U | 1 |
| Compta, Y; Martí, MJ; Muñoz, JE; Ríos, J; Rumià, J; Santacruz, P; Tolosa, E; Valldeoriola, F | 1 |
| Cestari, DM; Eichler, FS; Hunt, AL; Rapalino, O; Swoboda, KJ | 1 |
| Fairchild, A; Hass, S; Marshall, T; Pugh, A | 1 |
| Bartel, T; Blydt-Hansen, I; Connolly, MB; Horvath, GA; Race, S; Ross, CJ; Tarailo-Graovac, M; Van Allen, MI; van Karnebeek, CDM; Wasserman, WW | 1 |
| Challa, JA; Harewood Smith, AN; Silver, MA | 1 |
| Ding, H; Fengsi, -; Liu, H; Sun, C; Zhang, D | 1 |
| Barichella, M; Cassani, E; Cereda, E; Cilia, R; Laguna, J; Pezzoli, G; Raspini, B | 1 |
| Angrisano, S; Artusi, CA; Dematteis, F; Lopiano, L; Merola, A; Romagnolo, A; Zibetti, M | 1 |
| Esqueda-Liquidano, M; García-Gomar, MG; Velasco, AL; Velasco, F | 1 |
| Alhadhrami, A; Alharthi, SS; Alrobaian, MM; Kabel, AM; Omar, MS | 1 |
| Albero Roselló, I; Argente Navarro, P; Gimenez Jimenez, I; Romero García, E | 1 |
| Bendi, VS; Joy, S; Shou, J; Torres-Russotto, D | 1 |
| Bakis, G; Nutt, J; Staisch, J | 1 |
| Antonini, A; Canesi, M; Costanzo, AM; Defazio, G; di Luzio Paparatti, U; Gualberti, G; Latorre, A; Lopiano, L; Marano, P; Melzi, G; Modugno, N; Pontieri, FE; Quatrale, R; Sensi, M; Solla, P; Tambasco, N; Tessitore, A | 1 |
| Kundt, FS; Lex, KM; Lorenzl, S | 1 |
| Arbelo, JM; Catalan, MJ; Cubo, E; Martinez-Martin, P; Mir, P; Molina-Arjona, JA | 1 |
| Eklund, M; Henriksen, T; Nyholm, D; Odin, P; Sahlström, T; Timpka, J | 1 |
| Benesh, J; Boyd, JT; Chatamra, K; Eaton, S; Espay, AJ; Facheris, MF; Fernandez, HH; Fung, VSC; Hall, C; Lew, MF; Robieson, WZ; Rodriguez, RL; Slevin, JT; Standaert, DG; Vanagunas, AD; Zadikoff, C | 1 |
| Andrisani, G; di Biase, L; Di Lazzaro, V; Di Matteo, FM; Di Santo, A; Marano, M; Martino, M; Pandolfi, M; Pizzicannella, M; Rea, R | 1 |
| Ikram, R; Riaz, B; Sikandar, B | 1 |
| Bertram, KL; Hewer, S; Lee, W; Ligtermoet, M; Paul, E; Varley, S; Vijiaratnam, N; Williams, DR | 1 |
| Sue, CM; Vijiaratnam, N | 1 |
| Antonini, A; Bergmann, L; Poewe, W; Robieson, WZ; Yegin, A | 1 |
| Bergquist, F; Ericsson, A; Johansson, A; Johansson, D; Medvedev, A; Nyholm, D; Ohlsson, F; Senek, M; Spira, J; Thomas, I; Westin, J | 1 |
| Fujioka, S; Fukae, J; Hasegawa, S; Hayashi, Y; Mishima, T; Nose, K; Shiwaku, H; Tsuboi, Y; Umemoto, G; Yamashita, K | 1 |
| Culican, SM; Kraus, CL | 1 |
| Aiyappan, V; Tashkent, Y | 1 |
| MacDonald, PA; Seergobin, KN; Vo, A | 1 |
| Ares-Pensado, B; Castro, A; Fernandez-Pajarin, G; Iglesias-Canle, J; Masa-Vazquez, L; Sesar, A | 1 |
| Bingel, U; Gerardi, M; Zunhammer, M | 1 |
| Allone, C; Bonanno, L; Bramanti, P; Ciurleo, R; Corallo, F; Di Lorenzo, G; Lo Buono, V; Marino, S; Palmeri, R; Versaci, R | 1 |
| Cerrone, P; Marchese, M; Marini, C; Pistoia, MA | 1 |
| Antonini, A; Kleinman, LS; Marshall, TS; Odin, PLA; Onuk, K; Sail, KR; Skalicky, AM; Stoessl, AJ | 1 |
| Anang, JBM | 1 |
| Hirozawa, D; Ikenaka, K; Mochizuki, H; Nakano, T; Sasaki, T; Shimamura, M | 1 |
| Memedi, M; Nyholm, D; Thomas, I; Westin, J | 1 |
| Cowie, F; Grosset, DG; Watson-Fargie, T; White, J | 1 |
| den Heijer, T; Groen, J; van der Steen, W | 1 |
| Dinh, P | 1 |
| Goldstein, DS; Holmes, C; Lamotte, G; Sullivan, P | 1 |
| Fabbri, M; Ferreira, JJ; Rosa, MM | 1 |
| Beccaria, L; Fabbri, M; Ferreira, JJ; Lopiano, L; Merola, A; Montanaro, E; Palermo, S; Romagnolo, A; Zibetti, M | 1 |
| Antonini, A; Bergmann, L; Poewe, W; Ray Chaudhuri, K; Robieson, WZ; Sanchez-Soliño, O | 1 |
| Hirata, Y; Ishikawa, H; Kato, N; Matsuura, K; Matsuyama, H; Narita, Y; Niwa, A; Tomimoto, H | 1 |
| Baik, JS; Cho, J; Jeon, B; Kim, HT; Kim, JM; Kim, JW; Koh, SB; Kwon, OD; Lee, HW; Lee, JY; Ma, HI; Yoon, WT | 1 |
| Hamed, M; Lazarescu, A; Shetty, A; Suchowersky, O; Tremain, G | 1 |
| Hirakawa, M; Hirota, T; Ieiri, I; Irie, S; Kashihara, Y; Kimura, M; Kubota, T; Matsuki, S; Terao, Y; Yoda, K | 1 |
| Christie, M; Coss, P; Ondo, W; Pascual, B | 1 |
| Duvvuri, S; Gray, DL; Liu, W; Papapetropoulos, S; Thayer, K | 1 |
| Belsey, J; Kalabina, S; Mohamed, B; Paterson, B; Pivonka, D; Thomas, C | 1 |
| Antonini, A; Bergmann, L; Chaudhuri, KR; Poewe, W | 1 |
| Arbelo, JM; Catalán, MIJ; Grandas, F; Mir, P; Parra, JC; Puente, V; Regidor, I; Santos-García, D; Valldeoriola, F | 1 |
| Cramer, SC; Finklestein, SP; Lin, DJ | 1 |
| Alam, M; Bergquist, F; Johansson, D; Memedi, M; Nyholm, D; Thomas, I; Westin, J | 1 |
| Abd El Fattah, MA; Badawi, GA; El Sayed, MI; Zaki, HF | 1 |
| Sablaban, IM; Sivananthan, M | 1 |
| Lees, AJ; Moro, A; Munhoz, RP; Pessoa, RR; Teive, HAG | 1 |
| Hideshima, M; Hirozawa, D; Ikenaka, K; Ishikura, T; Kitano, T; Konaka, K; Mochizuki, H; Nakano, T; Shimamura, M; Shinzaki, S; Takehara, T | 1 |
| Cabreira, V; Massano, J; Soares-da-Silva, P | 1 |
| Mukai, Y; Murata, M; Nishikawa, N; Takahashi, Y | 1 |
| Benesh, J; Han, JH; Kalluri, HV; Liu, W; Locke, C; Rosebraugh, M; Sidhu, D | 1 |
| Ellenbogen, A; Hauser, RA; Isaacson, SH; Kegler-Ebo, DM; Komjathy, SF; Oh, C; Safirstein, BE; Truong, DD; Zhao, P | 1 |
| Artusi, CA; Fabbri, M; Lopiano, L; Pongmala, C; Rizzone, MG; Romagnolo, A; Zibetti, M | 1 |
| Chen, YC; Ho, PL; Huang, P; Teng, CH; Wu, CC | 1 |
| Di Vico, IA; Novelli, A; Ramat, S; Sorbi, S; Terenzi, F | 1 |
| Januário, C; Morgadinho, A; Reis Carneiro, D; Sousa, M | 1 |
| Centonze, D; Fasano, A; Femiano, C; Lena, F; Modugno, N; Olivola, E; Santilli, M; Varanese, S | 1 |
| Bhakta, BB; Cozens, A; Farrin, AJ; Ford, GA; Hartley, S; Holloway, I; Meads, D; Pearn, J; Ruddock, S; Sackley, CM; Saloniki, EC; Santorelli, G; Walker, MF | 1 |
| Egawa, H; Fukunaga, T; Hatano, T; Hattori, N; Ishibashi, Y; Kaji, S; Kanda, S; Kohira, Y; Oka, S; Oyama, G; Shimo, Y; Yube, Y | 1 |
| Antonini, A; Bentivoglio, A; Eleopra, R; Gualberti, G; Gusmaroli, G; Lopiano, L; Mancini, F; Marano, P; Meco, G; Melzi, G; Modugno, N; Quatrale, R; Sensi, M; Solla, P; Tamma, F; Zangaglia, R | 1 |
| Giladi, N; LeWitt, PA; Navon, N | 1 |
| Abi-Dargham, A; Bailey, V; Brown, PJ; Chen, C; Roose, SP; Rutherford, BR; Slifstein, M; Stern, Y; Valente, E; Vanegas-Arroyave, N; Wall, MW | 1 |
| Duma, S; Fung, VS; Griffith, J; Mahant, N; Martin, A; Morales-Briceño, H; Tsui, D | 1 |
| Bartig, D; Gold, R; Jörges, C; Jost, W; Krogias, C; Richter, D; Stumpe, B; Tönges, L | 1 |
| Amjad, F; Bhatti, D; Davis, TL; Kukreja, P; Metman, LV; Oguh, O; Pahwa, R; Zamudio, J | 1 |
| Antonini, A; Bergmann, L; Kukreja, P; Poewe, W; Robieson, WZ | 1 |
| Zesiewicz, TA | 1 |
| Jinnah, HA | 1 |
| Bancila, I; Ciocîrlan, M; Cotruta, B; Dobru, D; Drug, V; Dumitru, E; Gheorghe, C; Goldis, A; Jinga, M; Manuc, M; Mercea, VA; Pitigoi, D; Saftoiu, A; Seicean, A; Tanțău, M | 1 |
| Almeida, L; Barabas, M; Eisinger, RS; Elkouzi, A; Malaty, IA; Okun, MS; Ramirez-Zamora, A; Zeilman, P | 1 |
| Hoy, SM | 1 |
| Ares-Pensado, B; Castro, A; Fernandez-Pajarin, G; Rivero-de-Aguilar, A; Sesar, A | 1 |
| Fernández García, J; García Hernández, M; Garrido Durán, C; Khorrami Minaei, S; Legarda Ramírez, I; Sendra Rumbeu, P | 1 |
| Guerrero, MF; López, JL; Olaya, MDP; Vergel, NE; Viña, MD | 1 |
| Alam, M; Rönnegård, L; Saqlain, M; Westin, J | 1 |
| Chang, FCF; Fung, VSC; Galea, D; Griffith, J; Ha, AD; Kim, SD; Mahant, N; Morales-Briceño, H; Tsui, D | 1 |
| Artusi, CA; Balestrino, R; Bortolani, S; Fabbri, M; Imbalzano, G; Lopiano, L; Montanaro, E; Tuttobene, S; Zibetti, M | 1 |
| Baille, G; Blaise, AS; Carrière, N; Defebvre, L; Devos, D; Dujardin, K; Grolez, G; Kreisler, A; Kyheng, M; Moreau, C; Mutez, E; Seguy, D | 1 |
| Akbostanci, MC; Bilgiç, B; Bora Tokçaer, A; Çakmur, R; Doğu, O; Elibol, B; Erer Özbek, ÇS; Gültekin, M; Hanağasi, H; İnce Günal, D; Kenangil, G; Mirza, M; Tezcan, S; Ulukan, Ç; Yilmaz Küsbeci, Ö | 1 |
| Arca, R; Cossu, G; di Biase, L; Di Lazzaro, V; Di Santo, A; Fasano, A; Marano, M; Marano, P; Naranian, T; Poon, YY | 1 |
| Ahsan, SA; Briggs, RG; Chendeb, K; Conner, AK; Jacobs, CC; Jones, RG; Nix, CE; Palejwala, AH; Sheets, JR; Sughrue, ME | 1 |
| Jalundhwala, YJ; Lakdawalla, DN; Marshall, TS; Sail, KR; Shih, TM; Sullivan, J; van Eijndhoven, E; Zadikoff, C | 1 |
| Ayala, A; Forjaz, MJ; Harmat, M; Janszky, J; Juhász, A; Kovács, N; Martinez-Martin, P; Pintér, D; Rodriguez-Blazquez, C | 1 |
| McFarthing, K; Prakash, N; Simuni, T | 1 |
| Honsberger, S; Husnain, MG; Su, JS | 1 |
| Belcaro, G; Cesarone, MR; Cotellese, R; Feragalli, B; Hosoi, M; Hu, S; Ledda, A; Maione, C; Scipione, C; Scipione, V | 1 |
| Stocchi, F; Vacca, L | 1 |
| Balogun, CI; Fatoki, AM; Oladimeji, S; Olofinnade, AT; Onaolapo, AY; Onaolapo, OJ; Onaolapo, TM | 1 |
| Gallentine, WB; Mikati, MA; Trau, SP | 1 |
| Armstrong, MJ; Okun, MS | 1 |
| Allen, RS; Bales, KL; Chesler, KC; Feola, AJ; Hendrick, AM; Iuvone, PM; Maa, AY; Mees, LM; Motz, CT; Olson, DE; Pardue, MT; Thule, PM | 1 |
| Chen, HJ; He, JC; Jiang, ZY; Wu, K; Xie, CL; Zhang, XR; Zhang, ZR | 1 |
| Cerroni, R; Imbriani, P; Liguori, C; Mercuri, NB; Pierantozzi, M; Pisani, A; Scalise, S; Stefani, A | 1 |
| Paik, J | 1 |
| Bolia, R; Panda, PK; Sharawat, IK; Shrivastava, Y | 1 |
| Ehlers, C; Honig, H; Odin, P; Timpka, J | 1 |
| Bloem, BR; Nonnekes, J | 1 |
| D'Souza, R; Fisher, S; Hauser, RA; Zeitlin, L | 2 |
| Chaudhuri, KR; Jones, S; Leta, V; Parry, M; Rizos, A; Sauerbier, A; van Wamelen, DJ | 1 |
| Boettcher, L; Edinger, G; Erickson, LO; Gardner, J; Kitzmann, R; Nance, MA; Wichmann, R; Wielinski, CL | 1 |
| Boyd, BM; Christensen, CA; Fagan, TC; Figueroa, AG; Javid, CG; McKay, BS; Snyder, RW | 1 |
| de Bie, RMA; Dijk, JM; Espay, AJ; Katzenschlager, R | 1 |
| Adnan, M; Nyholm, D; Senek, M | 1 |
| Drent, M; Groenendal-Laurensse, JWMJ; Moes, HR; Tissingh, G; van Laar, T | 1 |
| Altiparmak, E; Erdoğan Küçükdağli, F; Köseoğlu, HT; Öztürk, Ö; Saltoğlu, T; Sücüllü Karadağ, Y | 1 |
| Arnold, AC; De Jesus, S; Delnomdedieu, M; Duvvuri, S; Eslinger, PJ; Fernandez-Mendoza, J; Gray, DL; Harrington, W; Huang, X; Kong, L; Lewis, MM; Mahoney, SE; Mailman, RB; Miller, AJ; Snyder, B; Sun, D; Van Scoy, LJ; Wang, X | 1 |
| Farbman, ES; Hauser, RA; Klingler, M; Lee, A; LeWitt, PA; Oh, C; Qian, J; Rudzińska, M; Waters, CH | 1 |
| Adar, L; Case, RJ; Ellenbogen, AL; Espay, AJ; Leinonen, M; Olanow, CW; Oren, S; Orenbach, SF; Poewe, W; Stocchi, F; Yardeni, T | 1 |
| Leucuta, DC; Perju-Dumbrava, L; Popa, LC; Popa, SL; Tohanean, N | 1 |
| Carroll, DG; Halli-Tierney, AD; Luker, J | 1 |
| Gillespie, A; Jones, E; Pappert, E; Pike, J; Thach, A; Wright, J | 1 |
| Guillén Climent, S; Monteagudo, C; Pinazo Canales, MI; Porcar Saura, S | 1 |
| Azandeh, SS; Farbood, Y; Ghasemi Dehcheshmeh, M; Jalali, MS; Mansouri, E; Saki, G; Sarkaki, A | 1 |
| Awad, N; Roy, D; Song, J; Zamudio, P | 1 |
| Athanasakis, E; Avgoustaki, A; Boura, I; Chlouverakis, G; Giakoumakis, E; Giannopoulou, IA; Koulentaki, M; Orfanoudaki, E; Spanaki, C | 1 |
| Barcellos, LJG; de Alcantara Barcellos, HH; de Oliveira, CM; Fagundes, M; Idalencio, R; Kalichak, F; Lopes, TM; Pompermaier, A; Soares, SM | 1 |
| Carr, RA; Enright, BP; Facheris, MF; Jameel, F; Kym, PR; Liu, W; Lou, X; Mayer, PT; Moussa, EM; Rosebraugh, M; Stolarik, D; Voight, EA; Zhang, GGZ | 1 |
| Akiyama, T; Hanaoka, Y; Kaji, R; Kawarai, T; Kobayashi, K; Miyamoto, R; Yoshinaga, H | 1 |
| Ashby, R; Karouta, C; Kelly, T; Morgan, I; Thomson, K | 1 |
| Babu, S; Chang, FC; Dal, S; Fletcher, N; Fung, VSC; Mahant, N; Martin, AJ; Morales-Briceno, H; Nankervis, J; Ong, TL; Robbie, M; Williams, LJ | 1 |
| Khurana, N; Muthuraman, A; Sharma, N; Utreja, P | 1 |
| Benner, J; Jalundhwala, YJ; Lakdawalla, DN; Marshall, TS; Sail, KR; Shih, TM; Sullivan, J; van Eijndhoven, E; Zadikoff, C | 1 |
| Comella, CL; Hauser, RA; LeWitt, PA | 1 |
| Fujioka, S; Fukuchi, T; Furukawa, K; Furune, S; Ikeda, Y; Jin, X; Kato, M; Koike, T; Kubota, E; Murakami, H; Sato, Y; Suzuki, T; Tsuboi, Y; Uehara, T; Yamashita, K; Yamazaki, Y; Yube, Y | 1 |
| Avramovic, V; Blydt-Hansen, I; Drogemoller, B; Friedman, JM; Ghani, A; Horvath, GA; Lee, J; Lehman, A; Matthews, AM; Mwenifumbo, J; Price, M; Ross, CJ; Shyr, C; Stockler, S; Tarailo-Graovac, M; van Karnebeek, CD; Wasserman, WW | 1 |
| Baig, F; Boca, M; Cheminais, L; Collin, N; Mooney, L; Rolinski, M; Selikhova, M; Szewczyk-Krolikowski, K; Whone, A | 1 |
| Ando, R; Hosokawa, Y; Miyaue, N; Nagai, M; Tada, S; Yabe, H; Yamanishi, Y; Yoshida, A | 1 |
| Adar, L; Caraco, Y; Case, R; Djaldetti, R; Giladi, N; Gurevich, T; Leibman-Barak, S; Sasson, N | 1 |
| Berger, SI; Miller, I; Tochen, L | 1 |
| Danoudis, M; Iansek, R; Paul, E; Sung, CB | 1 |
| Aldred, J; Anca-Herschkovitsch, M; Ballina, M; Bergmann, L; Bourgeois, P; Chaudhuri, KR; Cubo, E; Davis, TL; Iansek, R; Jia, J; Kovács, N; Kukreja, P; Ladhani, O; Pontieri, FE; Siddiqui, MS; Simu, M; Standaert, DG | 1 |
71 review(s) available for carbidopa, levodopa drug combination and levodopa
| Article | Year |
|---|---|
An integrated approach to patient management in Parkinson's disease.
Topics: Activities of Daily Living; Antiparkinson Agents; Carbidopa; Dopamine Agents; Drug Combinations; Humans; Levodopa; Parkinson Disease; Selegiline | 1992 |
Clinical studies with and pharmacokinetic considerations of sustained-release levodopa.
Topics: Antiparkinson Agents; Carbidopa; Clinical Trials as Topic; Delayed-Action Preparations; Drug Combinations; Humans; Levodopa | 1992 |
Medical treatment of Parkinson's disease.
Topics: Antiparkinson Agents; Carbidopa; Drug Combinations; Dyskinesia, Drug-Induced; Humans; Levodopa; Parkinson Disease | 1989 |
The promise and limitations of controlled-release oral levodopa administration.
Topics: Carbidopa; Delayed-Action Preparations; Drug Combinations; Humans; Levodopa; Parkinson Disease | 1989 |
Pharmaceutical design and development of a Sinemet controlled-release formulation.
Topics: Antiparkinson Agents; Carbidopa; Chemistry, Pharmaceutical; Delayed-Action Preparations; Drug Combinations; Humans; Levodopa; Tablets | 1989 |
Rationale for continuous dopaminomimetic therapy of Parkinson's disease.
Topics: Antiparkinson Agents; Carbidopa; Drug Combinations; Humans; Levodopa; Parkinson Disease | 1989 |
Parkinson's disease: recent advances in therapy.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Adrenal Medulla; Antiparkinson Agents; Carbidopa; Dopamine; Drug Administration Schedule; Drug Combinations; Humans; Levodopa; Middle Aged; Parkinson Disease; Parkinson Disease, Secondary; Pyridines | 1988 |
Animal models of tardive dyskinesia: their use in the search for new treatment methods.
Topics: Age Factors; Amphetamine; Animals; Antipsychotic Agents; Apomorphine; Carbidopa; Corpus Striatum; Disease Models, Animal; Dopamine; Drug Combinations; Drug Interactions; Dyskinesia, Drug-Induced; Guinea Pigs; Haloperidol; Haplorhini; Humans; Levodopa; Lithium; Male; Parasympatholytics; Rats; Receptors, Dopamine; Stereotyped Behavior | 1983 |
Sinemet and the treatment of Parkinsonism.
Topics: Aromatic Amino Acid Decarboxylase Inhibitors; Carbidopa; Chemical Phenomena; Chemistry; Drug Combinations; Follow-Up Studies; Humans; Levodopa; Parkinson Disease; Prognosis | 1981 |
Hemiatrophy, juvenile-onset exertional alternating leg paresis, hypotonia, and hemidystonia and adult-onset hemiparkinsonism: the spectrum of hemiparkinsonism-hemiatrophy syndrome.
Topics: Antiparkinson Agents; Blood Glucose; Carbidopa; Contrast Media; Deoxyglucose; Dihydroxyphenylalanine; Dominance, Cerebral; Drug Combinations; Female; Fluorodeoxyglucose F18; Functional Laterality; Hemiplegia; Humans; Levodopa; Middle Aged; Muscle Hypotonia; Muscular Atrophy; Neurologic Examination; Parkinson Disease, Secondary; Physical Exertion; Substantia Nigra; Tomography, Emission-Computed | 1995 |
Treatment of Parkinson's disease. From theory to practice.
Topics: Aged; Antiparkinson Agents; Carbidopa; Clinical Trials as Topic; Dopamine; Drug Combinations; Free Radicals; Humans; Levodopa; Oxygen; Parkinson Disease; Selegiline | 1994 |
Pharmacokinetics of continuous-release carbidopa/levodopa.
Topics: Aging; Antiparkinson Agents; Area Under Curve; Blood-Brain Barrier; Carbidopa; Delayed-Action Preparations; Drug Combinations; Gastric Emptying; Humans; Levodopa; Solubility | 1994 |
A preclinical development strategy designed to optimize the use of glial cell line-derived neurotrophic factor in the treatment of Parkinson's disease.
Topics: Animals; Antiparkinson Agents; Carbidopa; Corpus Striatum; Dopamine; Drug Combinations; Drug Evaluation, Preclinical; Drug Therapy, Combination; Glial Cell Line-Derived Neurotrophic Factor; Humans; Levodopa; Nerve Growth Factors; Nerve Regeneration; Nerve Tissue Proteins; Neuroglia; Neuronal Plasticity; Parkinson Disease, Secondary; Substantia Nigra; Tyrosine 3-Monooxygenase | 1998 |
Initiating therapy for Parkinson's disease.
Topics: Activities of Daily Living; Adult; Aged; Amantadine; Antiparkinson Agents; Carbidopa; Cholinergic Antagonists; Delayed-Action Preparations; Dopamine Agonists; Drug Combinations; Drug Therapy, Combination; Female; Humans; Levodopa; Male; Middle Aged; Neurologic Examination; Parkinson Disease; Selegiline | 1998 |
Medical treatment of later-stage motor problems of Parkinson disease.
Topics: Amantadine; Antiparkinson Agents; Benzophenones; Carbidopa; Catechol O-Methyltransferase Inhibitors; Catechols; Cholinergic Antagonists; Dopamine Agonists; Dose-Response Relationship, Drug; Drug Combinations; Dyskinesia, Drug-Induced; Enzyme Inhibitors; Humans; Levodopa; Nitriles; Nitrophenols; Parkinson Disease, Secondary; Propranolol; Randomized Controlled Trials as Topic; Selegiline; Tolcapone | 1999 |
Too many treatments for Parkinson's disease: how should they be used?
Topics: Antiparkinson Agents; Carbidopa; Decision Making; Drug Combinations; Humans; Levodopa; Neurosurgical Procedures; Parkinson Disease; Stereotaxic Techniques | 2000 |
Clinical management of neuroleptic malignant syndrome.
Topics: Bromocriptine; Carbidopa; Dopamine Agonists; Drug Combinations; Electroconvulsive Therapy; Guidelines as Topic; Humans; Levodopa; Neuroleptic Malignant Syndrome; Physical Therapy Specialty | 2001 |
[Serotonin syndrome: report of a fatal case and review of the literature].
Topics: Aged; Antiparkinson Agents; Carbidopa; Depressive Disorder, Major; Drug Combinations; Drug Synergism; Fatal Outcome; Fluoxetine; Humans; Levodopa; Male; Parkinson Disease; Selective Serotonin Reuptake Inhibitors; Selegiline; Serotonin Syndrome | 2002 |
[Prevention and treatment of fluctuations in patients with Parkinson's disease].
Topics: Antiparkinson Agents; Apomorphine; Carbidopa; Catechol O-Methyltransferase Inhibitors; Deep Brain Stimulation; Dopamine Agonists; Drug Administration Routes; Drug Combinations; Dyskinesia, Drug-Induced; Humans; Infusion Pumps, Implantable; Levodopa; Monoamine Oxidase Inhibitors; Neurologic Examination; Parkinson Disease; Treatment Outcome | 2006 |
Levodopa-carbidopa intestinal gel for treatment of advanced Parkinson's disease.
Topics: Antiparkinson Agents; Carbidopa; Drug Combinations; Humans; Levodopa; MEDLINE; Parkinson Disease; Randomized Controlled Trials as Topic | 2011 |
Treatment of advanced Parkinson's disease with levodopa/carbidopa intestinal gel is associated with improvements in Hoehn and Yahr stage.
Topics: Antiparkinson Agents; Carbidopa; Cross-Over Studies; Drug Combinations; Female; Gels; Humans; Levodopa; Male; Outcome Assessment, Health Care; Parkinson Disease; Randomized Controlled Trials as Topic; Severity of Illness Index | 2012 |
IPX066: a novel carbidopa-levodopa extended-release formulation.
Topics: Antiparkinson Agents; Carbidopa; Delayed-Action Preparations; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Combinations; Humans; Levodopa; Parkinson Disease | 2012 |
Clinical inquiry. Which drugs work best for early Parkinson's disease?
Topics: Antiparkinson Agents; Carbidopa; Drug Combinations; Family Practice; Humans; Indoles; Levodopa; Motor Skills; Neurologic Examination; Parkinson Disease | 2012 |
Duodopa® treatment for advanced Parkinson's disease: a review of efficacy and safety.
Topics: Animals; Antiparkinson Agents; Carbidopa; Clinical Trials as Topic; Drug Combinations; Humans; Levodopa; Parkinson Disease; Quality of Life; Severity of Illness Index; Treatment Outcome | 2012 |
Treatment of Parkinson's disease in the advanced stage.
Topics: Antiparkinson Agents; Carbidopa; Dopamine Agonists; Drug Combinations; Dyskinesias; Humans; Levodopa; Parkinson Disease | 2013 |
When the going gets tough: how to select patients with Parkinson's disease for advanced therapies.
Topics: Antiparkinson Agents; Apomorphine; Carbidopa; Deep Brain Stimulation; Drug Combinations; Drug Delivery Systems; Humans; Levodopa; Parkinson Disease; Patient Selection | 2013 |
[Pharmacotherapy of Parkinson's disease: progress or regress?].
Topics: Adenosine A2 Receptor Antagonists; Animals; Antiparkinson Agents; Carbidopa; Corpus Striatum; Dopamine; Dopamine Antagonists; Drug Combinations; Humans; Levodopa; Parkinson Disease; Substantia Nigra | 2013 |
The impact of restless legs syndrome: a familial case study.
Topics: Adult; Analgesics, Opioid; Anticonvulsants; Benzodiazepines; Benzothiazoles; Carbidopa; Dopamine Agonists; Drug Combinations; Family Health; Humans; Incidence; Indoles; Levodopa; Male; Middle Aged; Pramipexole; Prevalence; Restless Legs Syndrome | 2013 |
[The treatment of Parkinson's disease].
Topics: Antiparkinson Agents; Carbidopa; Catechol O-Methyltransferase Inhibitors; Combined Modality Therapy; Deep Brain Stimulation; Dopamine Agonists; Drug Combinations; Humans; Levodopa; Monoamine Oxidase Inhibitors; Neurologic Examination; Parkinson Disease; Physical Therapy Modalities | 2013 |
Parkinson disease treatment in hospitals and nursing facilities: avoiding pitfalls.
Topics: Amantadine; Antiparkinson Agents; Carbidopa; Catechols; Dopamine Agonists; Drug Administration Schedule; Drug Combinations; Hospitalization; Humans; Levodopa; Monoamine Oxidase Inhibitors; Nitriles; Nursing Care; Parkinson Disease | 2014 |
IPX066 , a mixed immediate/sustained-release levodopa preparation for Parkinson's disease.
Topics: Antiparkinson Agents; Carbidopa; Clinical Trials as Topic; Delayed-Action Preparations; Drug Combinations; Humans; Levodopa; Parkinson Disease; Time Factors | 2014 |
Novel formulations and modes of delivery of levodopa.
Topics: Animals; Antiparkinson Agents; Carbidopa; Drug Combinations; Drug Delivery Systems; Humans; Levodopa; Parkinson Disease | 2015 |
Safety of IPX066 , an extended release carbidopa-levodopa formulation, for the treatment of Parkinson's disease.
Topics: Antiparkinson Agents; Carbidopa; Delayed-Action Preparations; Drug Combinations; Dyskinesia, Drug-Induced; Half-Life; Humans; Levodopa; Parkinson Disease | 2015 |
Approach to the patient with Parkinson disease.
Topics: Antiparkinson Agents; Carbidopa; Deep Brain Stimulation; Diagnosis, Differential; Drug Combinations; Humans; Levodopa; Parkinson Disease; Primary Health Care; Risk Factors | 2015 |
Current treatment and future prospects of dopa-induced dyskinesias.
Topics: Amantadine; Antiparkinson Agents; Carbidopa; Delayed-Action Preparations; Dose-Response Relationship, Drug; Drug Combinations; Dyskinesia, Drug-Induced; Humans; Levodopa; Parkinson Disease; Practice Guidelines as Topic; Treatment Outcome | 2015 |
[Current possibilities of quality of life improvement in the late stages of Parkinson's disease].
Topics: Antiparkinson Agents; Carbidopa; Dopamine Agents; Drug Combinations; Gels; Humans; Levodopa; Parkinson Disease; Quality of Life; Severity of Illness Index; Treatment Outcome | 2015 |
Duopa--a carbidopa/levodopa enteral suspension for Parkinson's disease.
Topics: Antiparkinson Agents; Carbidopa; Chemistry, Pharmaceutical; Drug Administration Routes; Drug Combinations; Drug Costs; Humans; Levodopa; Motor Activity; Parkinson Disease; Treatment Outcome | 2015 |
Carbidopa/Levodopa ER Capsules (Rytary(®), Numient™): A Review in Parkinson's Disease.
Topics: Antiparkinson Agents; Carbidopa; Delayed-Action Preparations; Drug Combinations; Drug Interactions; Humans; Levodopa; Parkinson Disease; Randomized Controlled Trials as Topic; Treatment Outcome | 2016 |
Movement disorders: advances in 2015.
Topics: Animals; Antiparkinson Agents; Carbidopa; DNA-Binding Proteins; Drug Combinations; Humans; Levodopa; Mitochondrial Proteins; Movement Disorders; Parkinson Disease; Transcription Factors | 2016 |
Medical Therapies of Amblyopia: Translational Research to Expand Our Treatment Armamentarium.
Topics: Amblyopia; Carbidopa; Cholinesterase Inhibitors; Donepezil; Dopamine Agonists; Drug Combinations; Fluoxetine; Humans; Indans; Levodopa; Neuronal Plasticity; Piperidines; Selective Serotonin Reuptake Inhibitors; Translational Research, Biomedical; Visual Cortex | 2016 |
Advances in levodopa therapy for Parkinson disease: Review of RYTARY (carbidopa and levodopa) clinical efficacy and safety.
Topics: Administration, Oral; Animals; Antiparkinson Agents; Carbidopa; Delayed-Action Preparations; Drug Administration Schedule; Drug Combinations; Dyskinesia, Drug-Induced; Humans; Levodopa; Parkinson Disease; Treatment Outcome | 2016 |
Levodopa-Carbidopa Intestinal Gel in Patients with Parkinson's Disease: A Systematic Review.
Topics: Antiparkinson Agents; Carbidopa; Drug Combinations; Humans; Levodopa; Parkinson Disease; Quality of Life | 2016 |
An update on the diagnosis and treatment of Parkinson disease.
Topics: Age of Onset; Antiparkinson Agents; Carbidopa; Deep Brain Stimulation; Drug Combinations; Dyskinesias; Humans; Levodopa; Life Expectancy; Parkinson Disease; Practice Guidelines as Topic; Risk Assessment | 2016 |
Continuous dopaminergic stimulation therapy for Parkinson's disease - recent advances.
Topics: Administration, Cutaneous; Antiparkinson Agents; Carbidopa; Delayed-Action Preparations; Dopamine Agonists; Drug Combinations; Gels; Humans; Levodopa; Parkinson Disease; Tetrahydronaphthalenes; Thiophenes | 2016 |
Comment on: "Levodopa-Carbidopa Intestinal Gel in Patients with Parkinson's Disease: A Systematic Review".
Topics: Antiparkinson Agents; Carbidopa; Drug Combinations; Gels; Intestines; Levodopa; Parkinson Disease | 2016 |
Novel Levodopa Formulations for Parkinson's Disease.
Topics: Antiparkinson Agents; Carbidopa; Catechols; Chemistry, Pharmaceutical; Drug Combinations; Humans; Levodopa; Nitriles; Parkinson Disease | 2016 |
The need for non-oral therapy in Parkinson's disease; a potential role for apomorphine.
Topics: Animals; Antiparkinson Agents; Apomorphine; Carbidopa; Drug Administration Routes; Drug Combinations; Gels; Humans; Intestines; Levodopa; Parkinson Disease | 2016 |
Application of Pharmacokinetics and Pharmacodynamics in Product Life Cycle Management. A Case Study with a Carbidopa-Levodopa Extended-Release Formulation.
Topics: Antiparkinson Agents; Carbidopa; Delayed-Action Preparations; Drug and Narcotic Control; Drug Combinations; Drug Repositioning; Levodopa; Pharmacokinetics | 2017 |
Practical approaches to commencing device-assisted therapies for Parkinson disease in Australia.
Topics: Antiparkinson Agents; Apomorphine; Australia; Carbidopa; Deep Brain Stimulation; Drug Combinations; Humans; Infusions, Parenteral; Infusions, Subcutaneous; Levodopa; Parkinson Disease | 2017 |
Pharmacokinetics of Rytary
Topics: Animals; Antiparkinson Agents; Capsules; Carbidopa; Delayed-Action Preparations; Dose-Response Relationship, Drug; Drug Combinations; Drug Compounding; Humans; Levodopa; Parkinson Disease | 2017 |
Development of new levodopa treatment strategies in Parkinson's disease-from bedside to bench to bedside.
Topics: Animals; Carbidopa; Central Nervous System; Drug Approval; Drug Combinations; Drug Delivery Systems; Drug Design; European Union; Gels; History, 20th Century; History, 21st Century; Humans; Levodopa; Parkinson Disease; Randomized Controlled Trials as Topic; Tablets | 2017 |
Infusional Therapies, Continuous Dopaminergic Stimulation, and Nonmotor Symptoms.
Topics: Antiparkinson Agents; Apomorphine; Carbidopa; Dopamine; Dopamine Agents; Dopamine Agonists; Drug Combinations; Humans; Infusion Pumps, Implantable; Infusions, Intravenous; Infusions, Subcutaneous; Levodopa; Parkinson Disease; Randomized Controlled Trials as Topic | 2017 |
Using tube feeding and levodopa-carbidopa intestinal gel application in advanced Parkinson's disease.
Topics: Antiparkinson Agents; Carbidopa; Drug Combinations; Enteral Nutrition; Female; Gels; Humans; Intestines; Levodopa; Male; Parkinson Disease; Quality of Life | 2018 |
Levodopa-carbidopa intestinal gel: 'dismantling the road blocks of a journey'.
Topics: Administration, Intranasal; Antiparkinson Agents; Carbidopa; Drug Combinations; Gastrostomy; Humans; Jejunostomy; Jejunum; Levodopa; Parkinson Disease; Patient Compliance | 2018 |
New advances in amblyopia therapy I: binocular therapies and pharmacologic augmentation.
Topics: Amblyopia; Carbidopa; Child; Cytidine Diphosphate Choline; Dopamine Agonists; Drug Combinations; Eyeglasses; Humans; Levodopa; Nootropic Agents; Sensory Deprivation; Vision, Binocular | 2018 |
Adjunctive Therapies in Parkinson's Disease: How to Choose the Best Treatment Strategy Approach.
Topics: Algorithms; Antiparkinson Agents; Carbidopa; Combined Modality Therapy; Deep Brain Stimulation; Drug Combinations; Humans; Levodopa; Parkinson Disease | 2018 |
New Directions in Treatments Targeting Stroke Recovery.
Topics: Brain-Computer Interfaces; Carbidopa; Cell- and Tissue-Based Therapy; Chorionic Gonadotropin; Dopamine Agonists; Drug Combinations; Epoetin Alfa; Humans; Levodopa; Occupational Therapy; Physical Therapy Modalities; Recovery of Function; Robotics; Selective Serotonin Reuptake Inhibitors; Speech Therapy; Stroke; Stroke Rehabilitation; Telerehabilitation; Transcranial Direct Current Stimulation; Transcranial Magnetic Stimulation; Vagus Nerve Stimulation; Virtual Reality | 2018 |
Apomorphine in the treatment of Parkinson's disease: a review.
Topics: Antiparkinson Agents; Apomorphine; Carbidopa; Deep Brain Stimulation; Dopamine Agonists; Drug Combinations; Humans; Levodopa; Parkinson Disease | 2018 |
Contemporary Options for the Management of Motor Complications in Parkinson's Disease: Updated Clinical Review.
Topics: Antiparkinson Agents; Basal Ganglia; Carbidopa; Dopamine Agonists; Drug Carriers; Drug Combinations; Drug Compounding; Drug Liberation; Humans; Levodopa; Parkinson Disease; Receptors, Dopamine; Signal Transduction | 2019 |
Current Practices for Outpatient Initiation of Levodopa-Carbidopa Intestinal Gel for Management of Advanced Parkinson's Disease in the United States.
Topics: Aged; Antiparkinson Agents; Carbidopa; Drug Combinations; Female; Gels; Humans; Infusions, Parenteral; Levodopa; Male; Middle Aged; Observational Studies as Topic; Parkinson Disease; Precision Medicine; Prospective Studies; United States | 2019 |
Parkinson Disease.
Topics: Aged; Antiparkinson Agents; Carbidopa; Drug Combinations; Exercise; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Therapies, Investigational | 2019 |
The Dystonias.
Topics: Acetylcholine Release Inhibitors; Adult; Botulinum Toxins; Carbidopa; Dopamine Agonists; Drug Combinations; Dystonia; Dystonic Disorders; Female; Humans; Levodopa; Middle Aged; Physical Therapy Modalities | 2019 |
Percutaneous Endoscopic Gastrostomy with Jejunal Extension Tube for the Delivery of Levodopa Carbidopa Intestinal Gel: Clinical Practice Guidelines of the Romanian Society of Digestive Endoscopy.
Topics: Antiparkinson Agents; Carbidopa; Consensus; Drug Administration Routes; Drug Combinations; Drug Compounding; Endoscopy, Gastrointestinal; Equipment Design; Gastrostomy; Gels; Humans; Infusion Pumps; Jejunum; Levodopa; Parkinson Disease; Treatment Outcome | 2019 |
Levodopa/Carbidopa Enteral Suspension: A Review in Advanced Parkinson's Disease.
Topics: Antiparkinson Agents; Carbidopa; Drug Combinations; Humans; Levodopa; Parkinson Disease | 2019 |
A systematic review on the clinical experience with melevodopa/carbidopa fixed combination in patients with Parkinson disease.
Topics: Antiparkinson Agents; Carbidopa; Drug Combinations; Humans; Levodopa; Parkinson Disease | 2019 |
Diagnosis and Treatment of Parkinson Disease: A Review.
Topics: Antiparkinson Agents; Carbidopa; Combined Modality Therapy; Deep Brain Stimulation; Diagnosis, Differential; Disease Progression; Dopamine Agonists; Drug Combinations; Humans; Levodopa; Parkinson Disease; Prognosis | 2020 |
The Advantages of Levodopa-Carbidopa Intestinal Gel for Patients with Advanced Parkinson's Disease: A Systematic Review.
Topics: Administration, Oral; Antiparkinson Agents; Carbidopa; Drug Combinations; Gels; Humans; Levodopa; Parkinson Disease | 2020 |
Levodopa Inhalation Powder: A Review in Parkinson's Disease.
Topics: Administration, Inhalation; Antiparkinson Agents; Carbidopa; Drug Combinations; Humans; Levodopa; Parkinson Disease; Powders | 2020 |
The Choice Between Advanced Therapies for Parkinson's Disease Patients: Why, What, and When?
Topics: Antiparkinson Agents; Apomorphine; Carbidopa; Clinical Decision-Making; Deep Brain Stimulation; Dopamine Agents; Drug Combinations; Humans; Infusions, Subcutaneous; Levodopa; Parkinson Disease | 2020 |
On demand therapy for Parkinson's disease patients: Opportunities and choices.
Topics: Antiparkinson Agents; Apomorphine; Carbidopa; Dopamine Agonists; Drug Administration Routes; Drug Combinations; Humans; Levodopa; Parkinson Disease | 2021 |
The Use of Liquid Sinemet in Routine Clinical Practice of Advanced Parkinson's Disease: A Comparison of Available Options.
Topics: Antiparkinson Agents; Carbidopa; Drug Combinations; Humans; Levodopa; Parkinson Disease; Postural Balance; Time and Motion Studies | 2023 |
140 trial(s) available for carbidopa, levodopa drug combination and levodopa
| Article | Year |
|---|---|
A double-blind comparison of levodopa, Madopa, and Sinemet in Parkinson disease.
Topics: Adult; Benserazide; Carbidopa; Clinical Trials as Topic; Double-Blind Method; Drug Combinations; Female; Humans; Hydrazines; Levodopa; Male; Middle Aged; Nausea; Parkinson Disease; Vomiting | 1978 |
Hereditary motor and sensory neuropathy with treatable extrapyramidal features.
Topics: Adult; Aged; Basal Ganglia Diseases; Carbidopa; Drug Combinations; Female; Hereditary Sensory and Motor Neuropathy; Humans; Levodopa; Male; Middle Aged; Peripheral Nervous System Diseases; Placebos | 1992 |
Clinical efficacy of Sinemet CR 50/200 versus Sinemet 25/100 in patients with fluctuating Parkinson's disease. An open, and a double-blind, double-dummy, multicenter treatment evaluation. The Dutch Sinemet CR Study Group.
Topics: Antiparkinson Agents; Carbidopa; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Drug Combinations; Female; Humans; Levodopa; Male; Middle Aged; Neurologic Examination; Parkinson Disease; Patient Satisfaction; Sleep Stages | 1992 |
Objective evidence for tolerance, against a background of improvement, during maintenance therapy with controlled release levodopa/carbidopa.
Topics: Aged; Antiparkinson Agents; Carbidopa; Delayed-Action Preparations; Double-Blind Method; Drug Administration Schedule; Drug Combinations; Gait; Humans; Levodopa; Middle Aged; Parkinson Disease; Tablets | 1992 |
Comparative multiple-dose pharmacokinetics of controlled-release levodopa products.
Topics: Adult; Antiparkinson Agents; Carbidopa; Delayed-Action Preparations; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Combinations; Female; Humans; Levodopa; Male; Metabolic Clearance Rate; Methyldopa; Neurologic Examination; Parkinson Disease | 1992 |
Trial of Sinemet CR4 in patients with Parkinson's disease.
Topics: Aged; Aged, 80 and over; Antiparkinson Agents; Carbidopa; Drug Combinations; Female; Humans; Levodopa; Male; Middle Aged; Movement; Parkinson Disease | 1992 |
Comparative efficacy of two oral sustained-release preparations of L-dopa in fluctuating Parkinson's disease. Preliminary findings in 20 patients.
Topics: Benserazide; Carbidopa; Delayed-Action Preparations; Drug Combinations; Follow-Up Studies; Humans; Levodopa; Parkinson Disease | 1992 |
Long-term evaluation of Sinemet CR in parkinsonian patients with motor fluctuations.
Topics: Aged; Antiparkinson Agents; Carbidopa; Delayed-Action Preparations; Drug Administration Schedule; Drug Combinations; Female; Humans; Levodopa; Male; Movement; Parkinson Disease; Time Factors | 1991 |
L-deprenyl (selegiline) added to Sinemet CR in the management of Parkinson's disease patients with motor response fluctuations.
Topics: Aged; Antiparkinson Agents; Carbidopa; Drug Combinations; Drug Therapy, Combination; Humans; Levodopa; Middle Aged; Movement; Parkinson Disease; Selegiline; Time Factors | 1991 |
Characterisation of the in vivo behaviour of a controlled-release formulation of levodopa (Sinemet CR).
Topics: Adult; Antiparkinson Agents; Carbidopa; Delayed-Action Preparations; Drug Combinations; Food; Gastrointestinal Transit; Humans; Hydrogen-Ion Concentration; Intestinal Absorption; Levodopa; Male; Reference Values; Stomach | 1991 |
Controlled release levodopa/carbidopa (Sinemet CR4) in Parkinson's disease--an open evaluation of efficacy and safety.
Topics: Aged; Aged, 80 and over; Antiparkinson Agents; Carbidopa; Delayed-Action Preparations; Drug Combinations; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease | 1991 |
Sinemet CR in Parkinson's disease.
Topics: Aged; Antiparkinson Agents; Carbidopa; Double-Blind Method; Drug Administration Schedule; Drug Combinations; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Placebos | 1991 |
Standard and controlled-release levodopa/carbidopa in patients with fluctuating Parkinson's disease on a protein redistribution diet. A preliminary report.
Topics: Antiparkinson Agents; Carbidopa; Delayed-Action Preparations; Dietary Proteins; Dose-Response Relationship, Drug; Drug Combinations; Drug Evaluation; Female; Humans; Levodopa; Male; Parkinson Disease | 1991 |
An open multicenter trial of Sinemet CR in levodopa-naive Parkinson's disease patients.
Topics: Aged; Antiparkinson Agents; Carbidopa; Drug Combinations; Drug Tolerance; Female; Humans; Levodopa; Male; Middle Aged; Movement; Parkinson Disease | 1991 |
Results of long-term treatment with controlled-release levodopa/carbidopa (Sinemet CR).
Topics: Antiparkinson Agents; Carbidopa; Delayed-Action Preparations; Double-Blind Method; Drug Administration Schedule; Drug Combinations; Humans; Levodopa; Middle Aged; Parkinson Disease; Prognosis; Statistics as Topic; Time Factors | 1990 |
Diurnal differences in response to oral levodopa.
Topics: Administration, Oral; Aged; Antiparkinson Agents; Carbidopa; Circadian Rhythm; Drug Combinations; Female; Humans; Levodopa; Male; Middle Aged; Motor Skills; Neurologic Examination; Parkinson Disease | 1990 |
Randomized double-blind cross-over study of Sinemet-controlled release (CR4 50/200) versus Sinemet 25/100 in Parkinson's disease.
Topics: Aged; Aged, 80 and over; Carbidopa; Delayed-Action Preparations; Double-Blind Method; Drug Combinations; Drug Interactions; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease | 1990 |
The effect of dietary protein on the efficacy of L-dopa: a double-blind study.
Topics: Antiparkinson Agents; Bromocriptine; Carbidopa; Clinical Trials as Topic; Dietary Proteins; Double-Blind Method; Drug Combinations; Drug Therapy, Combination; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Random Allocation; Selegiline | 1989 |
CV 205-502: safety, tolerance to, and efficacy of increasing doses in patients with Parkinson's disease in a double-blind, placebo crossover study.
Topics: Adult; Aged; Aminoquinolines; Antiparkinson Agents; Carbidopa; Dopamine Agents; Dose-Response Relationship, Drug; Double-Blind Method; Drug Combinations; Drug Evaluation; Drug Therapy, Combination; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease | 1989 |
A double-blind crossover comparison of Sinemet CR4 and standard Sinemet 25/100 in patients with Parkinson's disease and fluctuating motor performance.
Topics: Carbidopa; Clinical Trials as Topic; Delayed-Action Preparations; Dose-Response Relationship, Drug; Double-Blind Method; Drug Combinations; Humans; Levodopa; Middle Aged; Motor Skills; Parkinson Disease; Random Allocation | 1989 |
Comparison of Sinemet CR4 and standard Sinemet: double blind and long-term open trial in parkinsonian patients with fluctuations.
Topics: Aged; Antiparkinson Agents; Carbidopa; Delayed-Action Preparations; Double-Blind Method; Drug Combinations; Humans; Levodopa; Middle Aged; Movement; Parkinson Disease; Randomized Controlled Trials as Topic | 1989 |
An open multicenter long-term treatment evaluation of Sinemet CR. Sinemet CR Multicenter Study Group.
Topics: Aged; Antiparkinson Agents; Carbidopa; Delayed-Action Preparations; Double-Blind Method; Drug Administration Schedule; Drug Combinations; Female; Humans; Levodopa; Male; Multicenter Studies as Topic; Parkinson Disease; Random Allocation; Time Factors | 1989 |
Pharmacokinetics and bioavailability of Sinemet CR: a summary of human studies.
Topics: Adolescent; Adult; Aged; Antiparkinson Agents; Biological Availability; Carbidopa; Clinical Trials as Topic; Delayed-Action Preparations; Drug Combinations; Fasting; Half-Life; Humans; Intestinal Absorption; Levodopa; Middle Aged; Parkinson Disease; Random Allocation; Reference Values; Tablets; Tyrosine | 1989 |
Controlled-release carbidopa/levodopa (Sinemet 50/200 CR4): clinical and pharmacokinetic studies.
Topics: Aged; Antiparkinson Agents; Carbidopa; Clinical Trials as Topic; Delayed-Action Preparations; Double-Blind Method; Drug Combinations; Humans; Levodopa; Middle Aged; Parkinson Disease; Random Allocation; Tyrosine | 1989 |
Gastrointestinal transit of Sinemet CR in healthy volunteers.
Topics: Antiparkinson Agents; Biological Availability; Carbidopa; Clinical Trials as Topic; Delayed-Action Preparations; Double-Blind Method; Drug Combinations; Eating; Gastric Emptying; Gastrointestinal Transit; Humans; Levodopa; Male; Random Allocation; Tablets | 1989 |
Multicenter controlled study of Sinemet CR vs Sinemet (25/100) in advanced Parkinson's disease.
Topics: Aged; Antiparkinson Agents; Carbidopa; Delayed-Action Preparations; Double-Blind Method; Drug Combinations; Female; Humans; Levodopa; Male; Movement Disorders; Multicenter Studies as Topic; Parkinson Disease; Randomized Controlled Trials as Topic | 1989 |
Controlled-release carbidopa/levodopa (CR) in parkinsonian patients with response fluctuations on standard levodopa treatment: clinical and pharmacokinetic observations.
Topics: Aged; Antiparkinson Agents; Carbidopa; Clinical Trials as Topic; Delayed-Action Preparations; Drug Combinations; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Random Allocation | 1989 |
Double-blind comparison of standard Sinemet and Sinemet CR in patients with mild-to-moderate Parkinson's disease.
Topics: Aged; Antiparkinson Agents; Carbidopa; Clinical Trials as Topic; Delayed-Action Preparations; Double-Blind Method; Drug Combinations; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Random Allocation | 1989 |
[Clinical results of using Nakom in diseases of the nervous system].
Topics: Adolescent; Adult; Age Factors; Carbidopa; Catecholamines; Cerebral Palsy; Child; Child, Preschool; Clinical Trials as Topic; Drug Combinations; Dystonia Musculorum Deformans; Humans; Levodopa; Muscle Rigidity; Myasthenia Gravis | 1989 |
Controlled-release Sinemet (CR-4): a double-blind crossover study in patients with fluctuating Parkinson's disease.
Topics: Activities of Daily Living; Adult; Aged; Aged, 80 and over; Antiparkinson Agents; Carbidopa; Clinical Trials as Topic; Consumer Behavior; Delayed-Action Preparations; Dose-Response Relationship, Drug; Double-Blind Method; Drug Combinations; Drug Evaluation; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Random Allocation; Time Factors | 1988 |
Controlled-release carbidopa/levodopa (CR4-Sinemet) in Parkinson's disease patients with and without motor fluctuations.
Topics: Adult; Aged; Antiparkinson Agents; Carbidopa; Clinical Trials as Topic; Delayed-Action Preparations; Double-Blind Method; Drug Combinations; Humans; Levodopa; Middle Aged; Motor Activity; Parkinson Disease | 1988 |
A comparison of bromocriptine (Parlodel) and levodopa-carbidopa (Sinemet) for treatment of "de novo" Parkinson's disease patients.
Topics: Antiparkinson Agents; Bromocriptine; Carbidopa; Clinical Trials as Topic; Double-Blind Method; Drug Combinations; Follow-Up Studies; Humans; Levodopa; Neurologic Examination; Parkinson Disease | 1987 |
A double-blind evaluation of ciladopa in Parkinson's disease.
Topics: Aged; Carbidopa; Clinical Trials as Topic; Dose-Response Relationship, Drug; Double-Blind Method; Drug Combinations; Drug Therapy, Combination; Female; Humans; Levodopa; Male; Middle Aged; Motor Skills; Parkinson Disease; Piperazines; Random Allocation | 1987 |
Clinical significance of the relationship between O-methyldopa levels and levodopa intake.
Topics: Animals; Carbidopa; Corpus Striatum; Delayed-Action Preparations; Drug Combinations; Female; Humans; Levodopa; Parkinson Disease; Rats; Rats, Inbred Strains; Tyrosine | 1988 |
Comparison of controlled-release Sinemet (CR4) and standard Sinemet (25 mg/100 mg) in advanced Parkinson's disease: a double-blind, crossover study.
Topics: Aged; Antiparkinson Agents; Carbidopa; Delayed-Action Preparations; Double-Blind Method; Drug Administration Schedule; Drug Combinations; Drug Evaluation; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease | 1988 |
Treatment of chronic Parkinson's disease with controlled-release carbidopa/levodopa.
Topics: Aged; Carbidopa; Chronic Disease; Delayed-Action Preparations; Disability Evaluation; Drug Combinations; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease | 1988 |
Bromocriptine in the treatment of Parkinson's disease: a double-blind study against L-dopa/carbidopa.
Topics: Aged; Bromocriptine; Carbidopa; Clinical Trials as Topic; Double-Blind Method; Drug Combinations; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Random Allocation | 1987 |
Parallel double-blind study of pergolide in Parkinson's disease.
Topics: Adult; Aged; Antiparkinson Agents; Carbidopa; Clinical Trials as Topic; Double-Blind Method; Drug Combinations; Drug Therapy, Combination; Humans; Levodopa; Middle Aged; Motor Skills; Parkinson Disease; Pergolide; Random Allocation | 1987 |
Double-blind controlled study of pergolide mesylate as an adjunct to Sinemet in the treatment of Parkinson's disease.
Topics: Adult; Aged; Antiparkinson Agents; Carbidopa; Clinical Trials as Topic; Double-Blind Method; Drug Combinations; Drug Therapy, Combination; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Pergolide; Random Allocation | 1987 |
Controlled release levodopa-carbidopa (CR-5) in the management of parkinsonian motor fluctuations.
Topics: Adult; Aged; Antiparkinson Agents; Carbidopa; Delayed-Action Preparations; Drug Combinations; Female; Humans; Levodopa; Male; Middle Aged; Movement; Parkinson Disease; Time Factors | 1987 |
Double-blind trial of pergolide for Parkinson's disease.
Topics: Aged; Carbidopa; Clinical Trials as Topic; Double-Blind Method; Drug Combinations; Ergolines; Female; Follow-Up Studies; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Pergolide | 1985 |
Motor function in the normal aging population: treatment with levodopa.
Topics: Aged; Aging; Carbidopa; Dopamine; Drug Combinations; Humans; Levodopa; Middle Aged; Movement; Movement Disorders; Parkinson Disease | 1985 |
Effortful and automatic memory: effects of dopamine.
Topics: Aged; Carbidopa; Clinical Trials as Topic; Cognition; Double-Blind Method; Drug Combinations; Humans; Levodopa; Memory; Middle Aged | 1984 |
Controlled-release carbidopa/levodopa in the treatment of Parkinsonism.
Topics: Aged; Antiparkinson Agents; Carbidopa; Clinical Trials as Topic; Delayed-Action Preparations; Double-Blind Method; Drug Combinations; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease | 1984 |
Prolactin secretion in Parkinson disease.
Topics: Adult; Aged; Blood-Brain Barrier; Bromocriptine; Carbidopa; Dopamine; Drug Combinations; Female; Humans; Hypothalamus, Anterior; Levodopa; Male; Middle Aged; Parkinson Disease; Pituitary Gland; Placebos; Prolactin; Receptors, Dopamine; Thyrotropin-Releasing Hormone | 1981 |
Behavioral effects of carbidopa/levodopa in hyperactive boys.
Topics: Attention Deficit Disorder with Hyperactivity; Carbidopa; Child; Clinical Trials as Topic; Double-Blind Method; Drug Combinations; Drug Therapy, Combination; Humans; Levodopa; Male | 1982 |
Parkinson's disease: Cogentin with Sinemet, a better response.
Topics: Aged; Antiparkinson Agents; Benztropine; Carbidopa; Double-Blind Method; Drug Combinations; Drug Therapy, Combination; Humans; Levodopa; Middle Aged; Parkinson Disease; Tropanes | 1982 |
The effect of deprenyl and levodopa on the progression of Parkinson's disease.
Topics: Aged; Analysis of Variance; Antiparkinson Agents; Bromocriptine; Carbidopa; Double-Blind Method; Drug Administration Schedule; Drug Combinations; Drug Therapy, Combination; Female; Humans; Least-Squares Analysis; Levodopa; Male; Parkinson Disease; Prospective Studies; Selegiline; Statistics, Nonparametric; Treatment Outcome | 1995 |
Localized proton NMR spectroscopy in the striatum of patients with idiopathic Parkinson's disease: a multicenter pilot study.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Antiparkinson Agents; Aspartic Acid; Carbidopa; Choline; Corpus Striatum; Dopamine Agonists; Drug Combinations; Female; Humans; Levodopa; Magnetic Resonance Spectroscopy; Male; Middle Aged; Parkinson Disease; Pilot Projects; Protons | 1995 |
Comparative study of selegiline plus L-dopa-carbidopa versus L-dopa-carbidopa alone in the treatment of Parkinson's disease.
Topics: Aged; Antiparkinson Agents; Carbidopa; Drug Combinations; Drug Therapy, Combination; Humans; Levodopa; Middle Aged; Parkinson Disease; Selegiline; Treatment Outcome | 1995 |
Fluctuations in plasma levodopa and motor responses with liquid and tablet levodopa/carbidopa.
Topics: Administration, Oral; Aged; Antiparkinson Agents; Biological Availability; Carbidopa; Cross-Over Studies; Double-Blind Method; Drug Combinations; Female; Humans; Levodopa; Male; Middle Aged; Motor Skills; Neurologic Examination; Parkinson Disease; Solutions; Tablets; Therapeutic Equivalency | 1994 |
A multicenter double-blind placebo-controlled trial of pergolide as an adjunct to Sinemet in Parkinson's disease.
Topics: Activities of Daily Living; Adult; Aged; Antiparkinson Agents; Carbidopa; Double-Blind Method; Drug Combinations; Drug Therapy, Combination; Electrocardiography; Female; Humans; Levodopa; Male; Middle Aged; Motor Activity; Motor Skills; Neurologic Examination; Parkinson Disease; Pergolide | 1994 |
Superior clinical efficacy of Sinement CR 50/200 versus Sinemet 25/100 in patients with fluctuating Parkinson's disease. An open and a double-blind, double-dummy, multicenter treatment evaluation. Dutch Sinement CR Study Group.
Topics: Antiparkinson Agents; Carbidopa; Disability Evaluation; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Drug Combinations; Humans; Levodopa; Movement Disorders; Muscle Rigidity; Neurologic Examination; Parkinson Disease | 1993 |
Defining small differences in efficacy between anti-parkinsonian agents using gait analysis: a comparison of two controlled release formulations of levodopa/decarboxylase inhibitor.
Topics: Aged; Analysis of Variance; Antiparkinson Agents; Benserazide; Carbidopa; Carboxy-Lyases; Delayed-Action Preparations; Drug Combinations; Female; Gait; Humans; Levodopa; Male; Middle Aged; Parkinson Disease | 1993 |
[The use of the Sinemet-CR preparation in treating Parkinson's disease].
Topics: Adult; Aged; Antiparkinson Agents; Carbidopa; Delayed-Action Preparations; Drug Combinations; Female; Higher Nervous Activity; Humans; Levodopa; Male; Middle Aged; Neurologic Examination; Parkinson Disease | 1995 |
Effect of entacapone, a COMT inhibitor, on the pharmacokinetics and metabolism of levodopa after administration of controlled-release levodopa-carbidopa in volunteers.
Topics: Adult; Carbidopa; Catechols; Dopamine Agonists; Dose-Response Relationship, Drug; Drug Combinations; Enzyme Inhibitors; Humans; Levodopa; Male; Nitriles; Reference Values | 1995 |
Objective measurement of activation of rigidity: diagnostic, pathogenetic and therapeutic implications in parkinsonism.
Topics: Adult; Aged; Antiparkinson Agents; Carbidopa; Delayed-Action Preparations; Drug Combinations; Female; Hand Strength; Humans; Isometric Contraction; Levodopa; Male; Muscle Rigidity; Parkinson Disease; Physical Exertion; Reproducibility of Results; Sensitivity and Specificity; Torque; Trihexyphenidyl | 1996 |
Pharmacokinetic comparison of Sinemet and Atamet (generic carbidopa/levodopa): a single-dose study.
Topics: Administration, Oral; Aged; Antiparkinson Agents; Biological Availability; Carbidopa; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Combinations; Female; Humans; Levodopa; Male; Metabolic Clearance Rate; Motor Skills; Neurologic Examination; Parkinson Disease; Therapeutic Equivalency | 1996 |
International (NL-UK) double-blind study of Sinemet CR and standard Sinemet (25/100) in 170 patients with fluctuating Parkinson's disease.
Topics: Adult; Aged; Antiparkinson Agents; Carbidopa; Delayed-Action Preparations; Double-Blind Method; Drug Combinations; Humans; International Cooperation; Levodopa; Middle Aged; Parkinson Disease | 1996 |
Comparison of immediate-release and controlled release carbidopa/levodopa in Parkinson's disease. A multicenter 5-year study. The CR First Study Group.
Topics: Activities of Daily Living; Aged; Antiparkinson Agents; Carbidopa; Delayed-Action Preparations; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Combinations; Female; Humans; Levodopa; Male; Middle Aged; Neurologic Examination; Parkinson Disease | 1997 |
Controlled release levodopa/carbidopa 25/100 (Sinemet CR 25/100): pharmacokinetics and clinical efficacy in untreated parkinsonian patients.
Topics: Absorption; Antiparkinson Agents; Biological Availability; Carbidopa; Delayed-Action Preparations; Drug Combinations; Humans; Levodopa; Parkinson Disease | 1994 |
Endurance performance in humans: the effect of a dopamine precursor or a specific serotonin (5-HT2A/2C) antagonist.
Topics: Adult; Analysis of Variance; Blood Chemical Analysis; Carbidopa; Cross-Over Studies; Dopamine Agonists; Double-Blind Method; Drug Combinations; Energy Metabolism; Exercise Test; Humans; Levodopa; Male; Physical Endurance; Ritanserin; Serotonin Antagonists; Statistics, Nonparametric | 1997 |
Quality of life in patients with Parkinson's disease who transfer from standard levodopa to Sinemet CR: the STAR Study. The STAR Multicenter Study Group.
Topics: Activities of Daily Living; Antiparkinson Agents; Carbidopa; Delayed-Action Preparations; Drug Combinations; Humans; Levodopa; Parkinson Disease; Quality of Life; Treatment Outcome | 1998 |
Implications of the 5-year CR FIRST trial. Sinemet CR Five-Year International Response Fluctuation Study.
Topics: Activities of Daily Living; Aged; Antiparkinson Agents; Carbidopa; Delayed-Action Preparations; Dose-Response Relationship, Drug; Drug Combinations; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Male; Middle Aged; Neurologic Examination; Parkinson Disease | 1998 |
Pharmacoeconomic analysis of using Sinemet CR over standard Sinemet in parkinsonian patients with motor fluctuations.
Topics: Adult; Aged; Aged, 80 and over; Antiparkinson Agents; Carbidopa; Cost-Benefit Analysis; Delayed-Action Preparations; Drug Combinations; Female; Humans; Levodopa; Male; Middle Aged; Movement Disorders; Parkinson Disease; Prospective Studies | 1998 |
COMT inhibition with tolcapone does not affect carbidopa pharmacokinetics in parkinsonian patients in levodopa/carbidopa (Sinemet).
Topics: Aged; Antiparkinson Agents; Benzophenones; Carbidopa; Catechol O-Methyltransferase; Catechol O-Methyltransferase Inhibitors; Drug Combinations; Drug Interactions; Enzyme Inhibitors; Female; Humans; Levodopa; Male; Middle Aged; Nitrophenols; Parkinson Disease; Tolcapone | 1999 |
The effect of dopamine agonist therapy on dopamine transporter imaging in Parkinson's disease.
Topics: Aged; Brain; Brain Mapping; Carbidopa; Carrier Proteins; Cocaine; Corpus Striatum; Dopamine Agonists; Dopamine Plasma Membrane Transport Proteins; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Combinations; Drug Therapy, Combination; Female; Humans; Iodine Radioisotopes; Levodopa; Male; Membrane Glycoproteins; Membrane Transport Proteins; Middle Aged; Motor Skills; Nerve Tissue Proteins; Parkinson Disease; Pergolide; Putamen; Tomography, Emission-Computed, Single-Photon | 1999 |
Occlusion and levodopa-carbidopa treatment for childhood amblyopia.
Topics: Administration, Oral; Amblyopia; Carbidopa; Child; Contrast Sensitivity; Dopamine Agonists; Drug Combinations; Female; Humans; Levodopa; Male; Patient Compliance; Sensory Deprivation; Treatment Outcome; Vision Tests; Visual Acuity | 1998 |
Levodopa may improve vision loss in recent-onset, nonarteritic anterior ischemic optic neuropathy.
Topics: Aged; Arteritis; Carbidopa; Dopamine Agonists; Drug Combinations; Female; Humans; Levodopa; Male; Optic Neuropathy, Ischemic; Time Factors; Vision Disorders; Visual Acuity; Visual Fields | 2000 |
The catechol-O-methyltransferase (COMT) inhibitor entacapone enhances the pharmacokinetic and clinical response to Sinemet CR in Parkinson's disease.
Topics: Adult; Aged; Antiparkinson Agents; Biological Availability; Carbidopa; Catechol O-Methyltransferase Inhibitors; Catechols; Cross-Over Studies; Delayed-Action Preparations; Double-Blind Method; Drug Combinations; Enzyme Inhibitors; Female; Humans; Levodopa; Male; Middle Aged; Nitriles; Parkinson Disease | 2000 |
Oral solution of levodopa ethylester for treatment of response fluctuations in patients with advanced Parkinson's disease.
Topics: Administration, Oral; Adult; Aged; Antiparkinson Agents; Biological Availability; Carbidopa; Double-Blind Method; Drug Combinations; Female; Humans; Levodopa; Male; Middle Aged; Neurologic Examination; Treatment Outcome | 2002 |
Randomized trial of pallidotomy versus medical therapy for Parkinson's disease.
Topics: Antiparkinson Agents; Atrophy; Brain; Carbidopa; Depressive Disorder, Major; Diagnostic and Statistical Manual of Mental Disorders; Drug Combinations; Dyskinesia, Drug-Induced; Female; Follow-Up Studies; Globus Pallidus; Humans; Hypokinesia; Levodopa; Magnetic Resonance Imaging; Male; Middle Aged; Muscle Rigidity; Neurosurgical Procedures; Parkinson Disease; Severity of Illness Index; Treatment Outcome; Tremor | 2003 |
[Pharmacokinetic comparison of Sinemet and Grifoparkin (levodopa/carbidopa 250/25 mg) in Parkinson s disease: a single dose study].
Topics: Antiparkinson Agents; Biological Availability; Carbidopa; Double-Blind Method; Drug Combinations; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease | 2003 |
Quality of life in early Parkinson's disease: impact of dyskinesias and motor fluctuations.
Topics: Aged; Antiparkinson Agents; Benzothiazoles; Carbidopa; Double-Blind Method; Drug Combinations; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Male; Middle Aged; Neurologic Examination; Pain Measurement; Parkinson Disease; Pramipexole; Quality of Life; Thiazoles | 2004 |
Effect of monoamine reuptake inhibitor NS 2330 in advanced Parkinson's disease.
Topics: Aged; Antiparkinson Agents; Benzothiazoles; Carbidopa; Dopamine Plasma Membrane Transport Proteins; Dopamine Uptake Inhibitors; Double-Blind Method; Drug Combinations; Drug Therapy, Combination; Female; Humans; Indoles; Levodopa; Male; Membrane Glycoproteins; Membrane Transport Proteins; Middle Aged; Nerve Tissue Proteins; Parkinson Disease; Pilot Projects; Pramipexole; Thiazoles | 2004 |
Mood-elevating effects of d-amphetamine and incentive salience: the effect of acute dopamine precursor depletion.
Topics: Adult; Affect; Attention; Carbidopa; Central Nervous System Stimulants; Dextroamphetamine; Dopamine; Double-Blind Method; Drug Combinations; Humans; Levodopa; Male; Motivation; Neuropsychological Tests; Pain Measurement; Phenylalanine; Reaction Time; Tyrosine | 2007 |
Bilateral impairments of skilled reach-to-eat in early Parkinson's disease patients presenting with unilateral or asymmetrical symptoms.
Topics: Adult; Aged; Aged, 80 and over; Antiparkinson Agents; Carbidopa; Disability Evaluation; Double-Blind Method; Drug Combinations; Feeding Behavior; Female; Follow-Up Studies; Functional Laterality; Humans; Levodopa; Male; Middle Aged; Motor Skills Disorders; Parkinson Disease; Prospective Studies; Severity of Illness Index | 2008 |
Single-dose administration of MK-0657, an NR2B-selective NMDA antagonist, does not result in clinically meaningful improvement in motor function in patients with moderate Parkinson's disease.
Topics: Aged; Antiparkinson Agents; Carbidopa; Drug Combinations; Female; Humans; Hypertension; Levodopa; Male; Middle Aged; Motor Activity; Parkinson Disease; Piperidines; Pyrimidines; Receptors, N-Methyl-D-Aspartate | 2009 |
Pharmacokinetic-pharmacodynamic modeling of levodopa in patients with advanced Parkinson disease.
Topics: Age of Onset; Aged; Antiparkinson Agents; Aromatic Amino Acid Decarboxylase Inhibitors; Benserazide; Benzophenones; Carbidopa; Catechol O-Methyltransferase Inhibitors; Drug Combinations; Drug Therapy, Combination; Dyskinesias; Enzyme Inhibitors; Female; Half-Life; Humans; Levodopa; Male; Metabolic Clearance Rate; Middle Aged; Models, Biological; Nitrophenols; Parkinson Disease; Severity of Illness Index; Tolcapone; Tyrosine | 2010 |
Replacing a dopamine agonist by the COMT-inhibitor tolcapone as an adjunct to L-dopa in the treatment of Parkinson's disease: a randomized, multicenter, open-label, parallel-group study.
Topics: Aged; Ambulatory Care Facilities; Aromatic Amino Acid Decarboxylase Inhibitors; Benserazide; Benzophenones; Carbidopa; Catechol O-Methyltransferase Inhibitors; Dopamine Agonists; Drug Combinations; Drug Therapy, Combination; Dyskinesias; Enzyme Inhibitors; Feasibility Studies; Female; Humans; Levodopa; Male; Middle Aged; Nitrophenols; Parkinson Disease; Severity of Illness Index; Time Factors; Tolcapone; Treatment Outcome | 2010 |
Effect of controlled-release levodopa on the microstructure of sleep in Parkinson's disease.
Topics: Aged; Aged, 80 and over; Carbidopa; Delayed-Action Preparations; Dopamine Agonists; Drug Combinations; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Polysomnography; Sleep; Sleep Wake Disorders | 2011 |
Night-time bioavailability of levodopa/carbidopa/entacapone is higher compared to controlled-release levodopa/carbidopa.
Topics: Adolescent; Adult; Antiparkinson Agents; Area Under Curve; Biological Availability; Carbidopa; Catechols; Cross-Over Studies; Delayed-Action Preparations; Drug Administration Schedule; Drug Combinations; Female; Half-Life; Humans; Levodopa; Male; Nitriles; Time Factors; Young Adult | 2010 |
Elevation of total homocysteine levels in patients with Parkinson's disease treated with duodenal levodopa/carbidopa gel.
Topics: Aged; Antiparkinson Agents; Carbidopa; Drug Combinations; Duodenum; Female; Gels; Homocysteine; Humans; Hyperhomocysteinemia; Levodopa; Male; Methyldopa; Middle Aged; Parkinson Disease | 2011 |
Inhibition of catechol-O-methyltransferase modifies acute homocysteine rise during repeated levodopa application in patients with Parkinson's disease.
Topics: Aged; Antiparkinson Agents; Aromatic Amino Acid Decarboxylase Inhibitors; Biological Availability; Carbidopa; Catechol O-Methyltransferase Inhibitors; Catechols; Drug Combinations; Drug Therapy, Combination; Female; Half-Life; Homocysteine; Humans; Levodopa; Male; Middle Aged; Nitriles; Parkinson Disease; Tyrosine | 2011 |
Pharmacokinetics of levodopa/carbidopa delivered from gastric-retentive extended-release formulations in patients with Parkinson's disease.
Topics: Aged; Antiparkinson Agents; Area Under Curve; Carbidopa; Cross-Over Studies; Delayed-Action Preparations; Drug Combinations; Female; Humans; Levodopa; Male; Middle Aged; Models, Biological; Parkinson Disease; Tablets; Time Factors | 2012 |
[Levodopa medications in the treatment of Parkinson's disease].
Topics: Aged; Antiparkinson Agents; Carbidopa; Drug Combinations; Drugs, Generic; Female; Humans; Levodopa; Male; Parkinson Disease; Severity of Illness Index; Treatment Outcome | 2011 |
Crossover comparison of IPX066 and a standard levodopa formulation in advanced Parkinson's disease.
Topics: Aged; Aged, 80 and over; Analysis of Variance; Antiparkinson Agents; Carbidopa; Cross-Over Studies; Delayed-Action Preparations; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Combinations; Female; Humans; Levodopa; Male; Middle Aged; Movement; Parkinson Disease; Time Factors | 2011 |
Dopaminergic drug-induced modulation of the expression of the dopamine transporter in peripheral blood lymphocytes in Parkinson's disease.
Topics: Aged; Antiparkinson Agents; Benzothiazoles; Carbidopa; Dopamine Agonists; Dopamine Plasma Membrane Transport Proteins; Drug Combinations; Female; Flow Cytometry; Gene Expression Regulation; Humans; Indoles; Levodopa; Lymphocytes; Male; Middle Aged; Parkinson Disease; Pramipexole | 2011 |
Dynamic, adaptive changes in MAO-A binding after alterations in substrate availability: an in vivo [(11)C]-harmine positron emission tomography study.
Topics: Carbidopa; Carbon Radioisotopes; Corpus Striatum; Dopamine; Dopamine Agonists; Drug Combinations; Harmine; Humans; Levodopa; Monoamine Oxidase; Parkinson Disease; Positron-Emission Tomography; Prefrontal Cortex; Protein Binding; Serotonin; Substrate Specificity; Time Factors; Tryptophan | 2012 |
Dopamine and performance in a reinforcement learning task: evidence from Parkinson's disease.
Topics: Adult; Aged; Aged, 80 and over; Association Learning; Carbidopa; Choice Behavior; Dopamine Agents; Dose-Response Relationship, Drug; Drug Combinations; Female; Generalization, Psychological; Humans; Image Processing, Computer-Assisted; Levodopa; Magnetic Resonance Imaging; Male; Middle Aged; Nucleus Accumbens; Oxygen; Parkinson Disease; Photic Stimulation; Prefrontal Cortex; Psychomotor Performance; Reinforcement, Psychology | 2012 |
Interim analysis of long-term intraduodenal levodopa infusion in advanced Parkinson disease.
Topics: Antiparkinson Agents; Carbidopa; Drug Administration Routes; Drug Combinations; Female; Humans; Infusions, Parenteral; Levodopa; Male; Middle Aged; Parkinson Disease; Quality of Life; Treatment Outcome | 2012 |
Levodopa/carbidopa to improve motor function subsequent to brain tumor excision.
Topics: Adult; Brain Neoplasms; Carbidopa; Combined Modality Therapy; Dopamine Agonists; Drug Combinations; Exercise Therapy; Female; Humans; Levodopa; Magnetic Resonance Imaging; Motor Skills; Paresis; Postoperative Complications | 2013 |
[The optimization of using levodopa in patients with Parkinson's disease: results of the OPTIMA study].
Topics: Aged; Antiparkinson Agents; Carbidopa; Drug Administration Schedule; Drug Combinations; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Treatment Outcome | 2012 |
Levodopa-carbidopa intestinal gel in advanced Parkinson's disease open-label study: interim results.
Topics: Aged; Antiparkinson Agents; Carbidopa; Drug Combinations; Female; Gels; Humans; Infusion Pumps; Jejunum; Levodopa; Male; Middle Aged; Parkinson Disease | 2013 |
Ropinirole does not affect plasma arginine vasopressin levels in patients with advanced Parkinson's disease.
Topics: Aged; Arginine Vasopressin; Carbidopa; Catechols; Dopamine Agonists; Dose-Response Relationship, Drug; Drug Combinations; Drug Therapy, Combination; Female; Humans; Inappropriate ADH Syndrome; Indoles; Levodopa; Male; Middle Aged; Nitriles; Parkinson Disease | 2012 |
Population pharmacodynamics of IPX066: an oral extended-release capsule formulation of carbidopa-levodopa, and immediate-release carbidopa-levodopa in patients with advanced Parkinson's disease.
Topics: Antiparkinson Agents; Carbidopa; Cross-Over Studies; Delayed-Action Preparations; Drug Combinations; Dyskinesias; Female; Humans; Levodopa; Male; Models, Biological; Parkinson Disease | 2013 |
Extended-release carbidopa-levodopa (IPX066) compared with immediate-release carbidopa-levodopa in patients with Parkinson's disease and motor fluctuations: a phase 3 randomised, double-blind trial.
Topics: Aged; Carbidopa; Chemistry, Pharmaceutical; Delayed-Action Preparations; Double-Blind Method; Drug Combinations; Female; Humans; Levodopa; Male; Middle Aged; Motor Skills Disorders; Parkinson Disease; Treatment Outcome | 2013 |
Prospective assessment of peripheral neuropathy in Duodopa-treated parkinsonian patients.
Topics: Action Potentials; Aged; Antiparkinson Agents; Carbidopa; Drug Combinations; Female; Follow-Up Studies; Gels; Humans; Intestinal Absorption; Levodopa; Male; Middle Aged; Neural Conduction; Parkinsonian Disorders; Peripheral Nervous System Diseases; Prospective Studies; Reaction Time; Vitamin B 12; Vitamin B 12 Deficiency | 2014 |
Randomized trial of IPX066, carbidopa/levodopa extended release, in early Parkinson's disease.
Topics: Aged; Antiparkinson Agents; Carbidopa; Dose-Response Relationship, Drug; Double-Blind Method; Drug Combinations; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Treatment Outcome | 2014 |
Double-blind study of the actively transported levodopa prodrug XP21279 in Parkinson's disease.
Topics: Antiparkinson Agents; Carbidopa; Cross-Over Studies; Double-Blind Method; Drug Combinations; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Prodrugs; Treatment Outcome | 2014 |
Comparison of IPX066 with carbidopa-levodopa plus entacapone in advanced PD patients.
Topics: Aged; Antiparkinson Agents; Carbidopa; Catechols; Cross-Over Studies; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Drug Combinations; Female; Humans; Levodopa; Male; Middle Aged; Nitriles; Parkinson Disease; Treatment Outcome; Walking | 2014 |
Multilevel impact of the dopamine system on the emotion-potentiated startle reflex.
Topics: Adult; Alleles; Anxiety; Arousal; Carbidopa; Catechol O-Methyltransferase; Dopamine; Double-Blind Method; Drug Combinations; Emotions; Female; Genotype; Humans; Levodopa; Male; Polymorphism, Genetic; Reflex, Startle | 2015 |
Levodopa-carbidopa intestinal gel in advanced Parkinson's disease: final 12-month, open-label results.
Topics: Adult; Aged; Antiparkinson Agents; Carbidopa; Drug Combinations; Female; Gels; Humans; Intestines; Levodopa; Male; Middle Aged; Parkinson Disease; Prospective Studies; Severity of Illness Index; Treatment Outcome | 2015 |
Gabapentin versus levodopa-c for the treatment of restless legs syndrome in hemodialysis patients: a randomized clinical trial.
Topics: Adult; Aged; Amines; Carbidopa; Cyclohexanecarboxylic Acids; Drug Combinations; Gabapentin; gamma-Aminobutyric Acid; Humans; Iran; Levodopa; Male; Middle Aged; Motor Activity; Renal Dialysis; Restless Legs Syndrome; Sleep; Surveys and Questionnaires; Time Factors; Treatment Outcome | 2015 |
Gastroretentive carbidopa/levodopa, DM-1992, for the treatment of advanced Parkinson's disease.
Topics: Adult; Aged; Aged, 80 and over; Antiparkinson Agents; Carbidopa; Cross-Over Studies; Drug Combinations; Drug Delivery Systems; Female; Follow-Up Studies; Gastrointestinal Tract; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Severity of Illness Index; Time Factors; Treatment Outcome | 2015 |
Comparison of the pharmacokinetics of an oral extended-release capsule formulation of carbidopa-levodopa (IPX066) with immediate-release carbidopa-levodopa (Sinemet(®)), sustained-release carbidopa-levodopa (Sinemet(®) CR), and carbidopa-levodopa-entacapo
Topics: Adolescent; Adult; Antiparkinson Agents; Carbidopa; Catechols; Cross-Over Studies; Delayed-Action Preparations; Drug Combinations; Female; Humans; Levodopa; Male; Young Adult | 2015 |
Long-Term Treatment with Extended-Release Carbidopa-Levodopa (IPX066) in Early and Advanced Parkinson's Disease: A 9-Month Open-Label Extension Trial.
Topics: Adult; Aged; Aged, 80 and over; Antiparkinson Agents; Carbidopa; Cross-Over Studies; Delayed-Action Preparations; Double-Blind Method; Drug Administration Schedule; Drug Combinations; Female; Humans; Levodopa; Long-Term Care; Male; Middle Aged; Parkinson Disease; Severity of Illness Index | 2015 |
Obstructive sleep apnea in Parkinson's disease patients: effect of Sinemet CR taken at bedtime.
Topics: Aged; Arousal; Carbidopa; Drug Administration Schedule; Drug Combinations; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Polysomnography; Sleep Apnea, Obstructive; Wakefulness | 2016 |
Efficacy and safety of entacapone in levodopa/carbidopa versus levodopa/benserazide treated Parkinson's disease patients with wearing-off.
Topics: Antiparkinson Agents; Benserazide; Carbidopa; Catechol O-Methyltransferase Inhibitors; Catechols; Data Interpretation, Statistical; Double-Blind Method; Drug Combinations; Drug Therapy, Combination; Female; Humans; Levodopa; Male; Middle Aged; Nitriles; Parkinson Disease; Retrospective Studies; Treatment Outcome | 2015 |
Conversion to IPX066 from Standard Levodopa Formulations in Advanced Parkinson's Disease: Experience in Clinical Trials.
Topics: Aged; Antiparkinson Agents; Carbidopa; Catechols; Cross-Over Studies; Double-Blind Method; Drug Administration Schedule; Drug Combinations; Female; Humans; Levodopa; Male; Middle Aged; Nitriles; Outcome Assessment, Health Care; Parkinson Disease; Treatment Outcome | 2015 |
A Catecholamine Precursor Does Not Influence Exercise Performance in Warm Conditions.
Topics: Adult; Athletic Performance; Bicycling; Body Temperature; Carbidopa; Cross-Over Studies; Drug Combinations; Exercise Test; Heart Rate; Hot Temperature; Humans; Levodopa; Male; Prolactin; Single-Blind Method; Skin Temperature; Young Adult | 2016 |
Dose-Response Analysis of the Effect of Carbidopa-Levodopa Extended-Release Capsules (IPX066) in Levodopa-Naive Patients With Parkinson Disease.
Topics: Aged; Antiparkinson Agents; Capsules; Carbidopa; Cohort Studies; Delayed-Action Preparations; Dose-Response Relationship, Drug; Double-Blind Method; Drug Combinations; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Treatment Outcome | 2016 |
Effect of levodopa-carbidopa intestinal gel on dyskinesia in advanced Parkinson's disease patients.
Topics: Administration, Mucosal; Aged; Antiparkinson Agents; Carbidopa; Double-Blind Method; Drug Combinations; Dyskinesia, Drug-Induced; Female; Gels; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Treatment Outcome | 2016 |
Levodopa increases oxidative stress and repulsive guidance molecule A levels: a pilot study in patients with Parkinson's disease.
Topics: Aged; Antiparkinson Agents; Carbidopa; Chromatography, High Pressure Liquid; Cysteine; Dipeptides; Drug Combinations; Female; GPI-Linked Proteins; Humans; Levodopa; Male; Middle Aged; Nerve Tissue Proteins; Oxidative Stress; Parkinson Disease; Pilot Projects | 2016 |
Effect of 3 Single-Dose Regimens of Opicapone on Levodopa Pharmacokinetics, Catechol-O-Methyltransferase Activity and Motor Response in Patients With Parkinson Disease.
Topics: Adult; Aged; Antiparkinson Agents; Benserazide; Carbidopa; Catechol O-Methyltransferase; Catechol O-Methyltransferase Inhibitors; Cross-Over Studies; Dose-Response Relationship, Drug; Double-Blind Method; Drug Combinations; Drug Interactions; Female; Humans; Levodopa; Male; Middle Aged; Oxadiazoles; Parkinson Disease | 2016 |
Effect of Levodopa + Carbidopa on the Laryngeal Electromyographic Pattern in Parkinson Disease.
Topics: Aged; Antiparkinson Agents; Brazil; Carbidopa; Drug Administration Schedule; Drug Combinations; Electromyography; Female; Humans; Laryngeal Muscles; Levodopa; Male; Middle Aged; Parkinson Disease; Phonation; Predictive Value of Tests; Prospective Studies; Time Factors; Treatment Outcome; Voice Quality | 2017 |
Levodopa-entacapone-carbidopa intestinal gel in Parkinson's disease: A randomized crossover study.
Topics: Aged; Antiparkinson Agents; Carbidopa; Catechols; Cross-Over Studies; Drug Combinations; Female; Humans; Infusions, Parenteral; Levodopa; Male; Nitriles; Parkinson Disease; Treatment Outcome | 2017 |
Conversion to carbidopa and levodopa extended-release (IPX066) followed by its extended use in patients previously taking controlled-release carbidopa-levodopa for advanced Parkinson's disease.
Topics: Aged; Aged, 80 and over; Antiparkinson Agents; Carbidopa; Delayed-Action Preparations; Drug Administration Schedule; Drug Combinations; Drug Substitution; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Severity of Illness Index; Treatment Outcome | 2017 |
Levodopa-Carbidopa Intestinal Gel Pharmacokinetics: Lower Variability than Oral Levodopa-Carbidopa.
Topics: Administration, Oral; Antiparkinson Agents; Carbidopa; Double-Blind Method; Drug Combinations; Drug Delivery Systems; Gels; Humans; Levodopa; Parkinson Disease | 2017 |
Effects of monoaminergic drugs on training-induced motor cortex plasticity in older adults.
Topics: Aged; Biogenic Monoamines; Biomechanical Phenomena; Carbidopa; Cross-Over Studies; Dextroamphetamine; Double-Blind Method; Drug Combinations; Electromyography; Evoked Potentials, Motor; Female; Humans; Levodopa; Male; Methylphenidate; Middle Aged; Motor Cortex; Motor Skills; Movement; Muscle, Skeletal; Neuronal Plasticity; Transcranial Magnetic Stimulation; Wrist | 2017 |
Daily intake of Mucuna pruriens in advanced Parkinson's disease: A 16-week, noninferiority, randomized, crossover, pilot study.
Topics: Aged; Antiparkinson Agents; Carbidopa; Cross-Over Studies; Double-Blind Method; Drug Combinations; Female; Humans; Levodopa; Male; Middle Aged; Mucuna; Outcome Assessment, Health Care; Parkinson Disease; Phytotherapy; Pilot Projects; Plant Preparations; Seeds | 2018 |
Long-term safety and efficacy of levodopa-carbidopa intestinal gel in advanced Parkinson's disease.
Topics: Adult; Aged; Aged, 80 and over; Antiparkinson Agents; Carbidopa; Compulsive Behavior; Double-Blind Method; Drug Combinations; Female; Gels; Humans; International Cooperation; Intestines; Levodopa; Longitudinal Studies; Male; Middle Aged; Outcome Assessment, Health Care; Parkinson Disease; Polyneuropathies; Weight Loss | 2018 |
The effect of dopamine on conditioned placebo analgesia in healthy individuals: a double-blind randomized trial.
Topics: Adult; Analgesia; Carbidopa; Conditioning, Psychological; Dopamine; Double-Blind Method; Drug Combinations; Female; Humans; Learning; Levodopa; Male; Pain; Pain Measurement; Placebo Effect; Reward | 2018 |
A Transitional Probability Model for Parkinson's Disease Motor States With Applications to Missing Data.
Topics: Aged; Antiparkinson Agents; Carbidopa; Delayed-Action Preparations; Dopamine Agonists; Double-Blind Method; Drug Combinations; Dyskinesias; Female; Humans; Levodopa; Male; Markov Chains; Middle Aged; Models, Statistical; Movement; Parkinson Disease | 2019 |
Behavioural and trait changes in parkinsonian patients with impulse control disorder after switching from dopamine agonist to levodopa therapy: results of REIN-PD trial.
Topics: Adult; Aged; Aged, 80 and over; Antiparkinson Agents; Carbidopa; Disruptive, Impulse Control, and Conduct Disorders; Dopamine Agonists; Drug Combinations; Drug Substitution; Female; Humans; Indoles; Levodopa; Male; Middle Aged; Parkinson Disease; Pramipexole | 2019 |
Effects of magnesium oxide on pharmacokinetics of L-dopa/carbidopa and assessment of pharmacodynamic changes by a model-based simulation.
Topics: Administration, Oral; Adult; Animals; Antiparkinson Agents; Carbidopa; Computer Simulation; Drug Combinations; Drug Interactions; Drug Stability; Female; Healthy Volunteers; Humans; Injections, Intravenous; Levodopa; Magnesium Oxide; Male; Models, Biological; Rats, Wistar; Young Adult | 2019 |
Levodopa-carbidopa intestinal gel high concentration formulation is clinically bioequivalent to commercial formulation.
Topics: Adult; Antiparkinson Agents; Carbidopa; Cross-Over Studies; Drug Combinations; Drug Liberation; Female; Gels; Humans; Levodopa; Male; Middle Aged; Therapeutic Equivalency | 2019 |
Orally inhaled levodopa (CVT-301) for early morning OFF periods in Parkinson's disease.
Topics: Administration, Inhalation; Aged; Antiparkinson Agents; Carbidopa; Cross-Over Studies; Double-Blind Method; Drug Combinations; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease | 2019 |
Safety and efficacy of co-careldopa as an add-on therapy to occupational and physical therapy in patients after stroke (DARS): a randomised, double-blind, placebo-controlled trial.
Topics: Adult; Aged; Aged, 80 and over; Brain Ischemia; Carbidopa; Dopamine Agents; Double-Blind Method; Drug Combinations; Female; Humans; Intracranial Hemorrhages; Levodopa; Male; Middle Aged; Mobility Limitation; Occupational Therapy; Physical Therapy Modalities; Prospective Studies; Stroke; Stroke Rehabilitation; Treatment Outcome | 2019 |
Pharmacokinetics and efficacy of a novel formulation of carbidopa-levodopa (Accordion Pill
Topics: Aged; Antiparkinson Agents; Carbidopa; Cohort Studies; Cross-Over Studies; Drug Combinations; Drug Compounding; Drug Delivery Systems; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Pilot Projects; Proof of Concept Study; Treatment Outcome | 2019 |
Effects of L-DOPA Monotherapy on Psychomotor Speed and [
Topics: Aged; Aged, 80 and over; Carbidopa; Corpus Striatum; Depressive Disorder, Major; Dopamine; Dopamine Antagonists; Drug Combinations; Female; Humans; Levodopa; Magnetic Resonance Imaging; Male; Middle Aged; New York; Positron-Emission Tomography; Raclopride; Receptors, Dopamine D2; Walking Speed | 2019 |
The effect of functional status impairment on nursing home admission risk among patients with advanced Parkinson's disease.
Topics: Activities of Daily Living; Aged; Aged, 80 and over; Antiparkinson Agents; Carbidopa; Double-Blind Method; Drug Combinations; Female; Gels; Homes for the Aged; Humans; Levodopa; Male; Medicare; Monte Carlo Method; Nursing Homes; Parkinson Disease; Physical Functional Performance; Severity of Illness Index; United States | 2020 |
Novel Detection and Restorative Levodopa Treatment for Preclinical Diabetic Retinopathy.
Topics: Adult; Aged; Carbidopa; Diabetic Retinopathy; Drug Combinations; Electroretinography; Female; Humans; Levodopa; Male; Middle Aged | 2020 |
The D1/D5 Dopamine Partial Agonist PF-06412562 in Advanced-Stage Parkinson's Disease: A Feasibility Study.
Topics: Aged; Carbidopa; Cross-Over Studies; Dopamine Agonists; Double-Blind Method; Drug Combinations; Feasibility Studies; Female; Humans; Levodopa; Male; Middle Aged; Outcome Assessment, Health Care; Parkinson Disease; Receptors, Dopamine D1; Receptors, Dopamine D5; Severity of Illness Index | 2020 |
Population pharmacokinetics of levodopa gel infusion in Parkinson's disease: effects of entacapone infusion and genetic polymorphism.
Topics: Carbidopa; Catechol O-Methyltransferase; Catechols; Cross-Over Studies; Dopa Decarboxylase; Double-Blind Method; Drug Combinations; Drug Delivery Systems; Female; Gels; Genotype; Humans; Levodopa; Male; Models, Biological; Nitriles; Parkinson Disease; Polymorphism, Genetic | 2020 |
A 12-month, dose-level blinded safety and efficacy study of levodopa inhalation powder (CVT-301, Inbrija) in patients with Parkinson's disease.
Topics: Administration, Inhalation; Aged; Carbidopa; Dopamine Agonists; Drug Combinations; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Levodopa; Male; Middle Aged; Outcome Assessment, Health Care; Powders; Single-Blind Method; Spirometry | 2020 |
Continuous Subcutaneous Levodopa Delivery for Parkinson's Disease: A Randomized Study.
Topics: Aged; Antiparkinson Agents; Carbidopa; Drug Combinations; Dyskinesia, Drug-Induced; Feasibility Studies; Female; Humans; Infusions, Parenteral; Levodopa; Male; Middle Aged; Outcome Assessment, Health Care; Parkinson Disease; Severity of Illness Index; Single-Blind Method | 2021 |
Duration of benefit per Dose: Carbidopa-Levodopa immediate release vs. extended release capsules (Rytary®).
Topics: Aged; Carbidopa; Delayed-Action Preparations; Dopamine Agonists; Dose-Response Relationship, Drug; Double-Blind Method; Drug Combinations; Female; Humans; Levodopa; Male; Middle Aged; Outcome Assessment, Health Care; Parkinson Disease; Time Factors | 2021 |
Fasting state is one of the factors associated with plasma levodopa fluctuations during levodopa‒carbidopa intestinal gel treatment.
Topics: Aged; Antiparkinson Agents; Carbidopa; Drug Combinations; Eating; Fasting; Female; Gels; Humans; Intestines; Levodopa; Lunch; Male; Motor Activity; Parkinson Disease | 2021 |
ND0612 (levodopa/carbidopa for subcutaneous infusion) in patients with Parkinson's disease and motor response fluctuations: A randomized, placebo-controlled phase 2 study.
Topics: Administration, Oral; Aged; Antiparkinson Agents; Carbidopa; Catechols; Double-Blind Method; Drug Combinations; Drug Therapy, Combination; Female; Humans; Infusions, Subcutaneous; Levodopa; Male; Middle Aged; Motor Activity; Nitriles; Parkinson Disease; Proof of Concept Study; Treatment Outcome | 2021 |
472 other study(ies) available for carbidopa, levodopa drug combination and levodopa
| Article | Year |
|---|---|
Effect of dopamine agonist (Lergotrile mesylate) therapy on twenty-four hour secretion of prolactin in treated Parkinson's disease.
Topics: Adult; Aged; Carbidopa; Circadian Rhythm; Drug Combinations; Drug Therapy, Combination; Ergolines; Female; Growth Hormone; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Prolactin; Sleep | 1978 |
[Therapy of rigidity and hypokinesis in old age using Sinemet].
Topics: Aged; Carbidopa; Drug Combinations; Female; Humans; Hydrazines; Levodopa; Male; Movement Disorders; Muscle Rigidity; Parkinson Disease, Postencephalitic; Trihexyphenidyl | 1979 |
[Modulation of the immune response of HSIAH strain rats with the preparations Nakom and L-dopa. Hereditary stress-induced arterial hypertension].
Topics: Adjuvants, Immunologic; Animals; Carbidopa; Drug Combinations; Female; Hypertension; Iliac Artery; Levodopa; Lymph Nodes; Male; Rats; Rats, Inbred Strains; Stress, Physiological | 1992 |
Dopaminergic responsivity during cocaine abstinence: a pilot study.
Topics: Adult; Carbidopa; Cocaine; Dopamine Agents; Drug Combinations; Growth Hormone; Homovanillic Acid; Humans; Levodopa; Male; Methoxyhydroxyphenylglycol; Middle Aged; Prolactin; Receptors, Dopamine; Substance Withdrawal Syndrome; Substance-Related Disorders | 1992 |
Clozapine for the treatment of levodopa-induced psychosis in Parkinson's disease.
Topics: Antiparkinson Agents; Carbidopa; Clozapine; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Combinations; Humans; Levodopa; Male; Middle Aged; Paranoid Disorders; Parkinson Disease; Psychoses, Substance-Induced | 1992 |
Lack of changes in ventricular cerebrospinal fluid concentrations of homovanillic acid following acute challenge with levodopa.
Topics: Aged; Carbidopa; Cerebral Ventricles; Drug Combinations; Female; Homovanillic Acid; Humans; Hydrocephalus, Normal Pressure; Levodopa; Male; Middle Aged; Parkinson Disease | 1992 |
Sensorimotor disinhibition in Parkinson's disease: effects of levodopa.
Topics: Carbidopa; Drug Combinations; Hand; Humans; Levodopa; Male; Motor Activity; Parkinson Disease; Psychomotor Performance; Reaction Time | 1992 |
The use of Sinemet CR in the management of mild to moderate Parkinson's disease.
Topics: Carbidopa; Drug Administration Schedule; Drug Combinations; Dyskinesia, Drug-Induced; Humans; Levodopa; Movement; Parkinson Disease; Patient Compliance; Patient Education as Topic; Tissue Distribution | 1992 |
Hemiballism and chorea in a patient with parkinsonism due to a multisystem degeneration.
Topics: Aged; Antiparkinson Agents; Atrophy; Brain; Carbidopa; Central Nervous System Diseases; Chorea; Diagnosis, Differential; Drug Combinations; Female; Humans; Levodopa; Movement Disorders; Nerve Degeneration; Parkinson Disease; Spinal Cord | 1992 |
Dopamine agonist treatment of fluctuating parkinsonism. D-2 (controlled-release MK-458) vs combined D-1 and D-2 (pergolide)
Topics: Adult; Aged; Antiparkinson Agents; Carbidopa; Dose-Response Relationship, Drug; Drug Combinations; Female; Humans; Lactose; Levodopa; Male; Methylcellulose; Middle Aged; Oxazines; Parkinson Disease; Pergolide | 1992 |
Unforeseen beneficial effects of controlled-release levodopa-carbidopa (Sinemet CR)
Topics: Aged; Antiparkinson Agents; Carbidopa; Delayed-Action Preparations; Depressive Disorder; Drug Administration Schedule; Drug Combinations; Humans; Levodopa; Male; Neurologic Examination; Parkinson Disease | 1992 |
Protein redistribution diet remains effective in patients with fluctuating parkinsonism.
Topics: Adult; Aged; Amino Acids; Antiparkinson Agents; Brain; Carbidopa; Dietary Proteins; Drug Combinations; Humans; Levodopa; Middle Aged; Parkinson Disease | 1992 |
Levodopa-associated hemifacial dystonia.
Topics: Aged; Antiparkinson Agents; Carbidopa; Drug Combinations; Dystonia; Facial Muscles; Female; Humans; Levodopa; Parkinson Disease; Putamen | 1991 |
Autologous adrenal medullary transplants in advanced Parkinson's disease with particular attention to the selective improvement in symptoms.
Topics: Adrenal Medulla; Adult; Antiparkinson Agents; Carbidopa; Caudate Nucleus; Combined Modality Therapy; Drug Combinations; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Prognosis; Time Factors; Tomography, X-Ray Computed; Transplantation, Heterotopic | 1991 |
Sinemet (CR4): an open-label study in moderately severe Parkinson's disease.
Topics: Aged; Antiparkinson Agents; Carbidopa; Delayed-Action Preparations; Drug Combinations; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease | 1991 |
Dopaminergic induced changes in cognitive and motor processing in Parkinson's disease: an electrophysiological investigation.
Topics: Adult; Aged; Antiparkinson Agents; Carbidopa; Cerebral Cortex; Cognition Disorders; Dopamine; Dose-Response Relationship, Drug; Drug Combinations; Electroencephalography; Evoked Potentials; Female; Humans; Levodopa; Male; Middle Aged; Neurologic Examination; Parkinson Disease; Psychomotor Performance; Reaction Time; Receptors, Dopamine | 1991 |
Sinemet CR for Parkinson's disease.
Topics: Carbidopa; Delayed-Action Preparations; Drug Combinations; Humans; Levodopa; Parkinson Disease | 1991 |
Treating the progressive stages of Parkinson's disease.
Topics: Amantadine; Antiparkinson Agents; Bromocriptine; Carbidopa; Drug Combinations; Electroconvulsive Therapy; Humans; Levodopa; Parasympatholytics; Parkinson Disease; Pergolide; Selegiline | 1991 |
Dopamine sulfate in ventricular cerebrospinal fluid and motor function in Parkinson's disease.
Topics: Carbidopa; Cerebral Ventricles; Dopamine; Drug Combinations; Female; Humans; Levodopa; Male; Middle Aged; Motor Activity; Movement; Parkinson Disease; Sulfates | 1991 |
Sustained-release (+)-PHNO [MK-458 (HPMC)] in the treatment of Parkinson's disease: evidence for tolerance to a selective D2-receptor agonist administered as a long-acting formulation.
Topics: Activities of Daily Living; Antiparkinson Agents; Brain; Carbidopa; Delayed-Action Preparations; Dopamine Agents; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Combinations; Humans; Levodopa; Oxazines; Parkinson Disease; Receptors, Dopamine; Receptors, Dopamine D2 | 1990 |
Off-period screaming accompanying motor fluctuations in Parkinson's disease.
Topics: Antiparkinson Agents; Carbidopa; Crying; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Combinations; Female; Hallucinations; Humans; Levodopa; Middle Aged; Parkinson Disease; Receptors, Dopamine | 1991 |
Oral levodopa dose-response study in MPTP-induced hemiparkinsonian monkeys: assessment with a new rating scale for monkey parkinsonism.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Administration, Oral; Animals; Antiparkinson Agents; Carbidopa; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Combinations; Levodopa; Macaca mulatta; Neurologic Examination; Parkinson Disease, Secondary; Stereotyped Behavior | 1991 |
New drugs for Parkinson's disease.
Topics: Aged; Antiparkinson Agents; Carbidopa; Drug Combinations; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Phenethylamines; Quality of Life; Selegiline | 1990 |
Utilization of unilateral and bilateral stereotactically placed adrenomedullary-striatal autografts in parkinsonian humans: rationale, techniques, and observations.
Topics: Adrenal Medulla; Adult; Aged; Antiparkinson Agents; Carbidopa; Corpus Striatum; Dose-Response Relationship, Drug; Drug Combinations; Female; Humans; Levodopa; Male; Middle Aged; Neurosurgery; Parkinson Disease; Postoperative Complications; Stereotaxic Techniques; Tomography, X-Ray Computed | 1990 |
A view from inside.
Topics: Accidental Falls; Antiparkinson Agents; Bromocriptine; Carbidopa; Dentists; Drug Combinations; Humans; Levodopa; Male; Northern Ireland; Parkinson Disease | 1990 |
Recovery from vegetative state of six months' duration associated with Sinemet (levodopa/carbidopa).
Topics: Activities of Daily Living; Adult; Antiparkinson Agents; Brain Injuries; Carbidopa; Cognition; Coma; Drug Combinations; Humans; Levodopa; Male | 1990 |
Neuroleptic malignant syndrome without neuroleptics.
Topics: Aged; Aged, 80 and over; Antiparkinson Agents; Carbidopa; Depressive Disorder; Drug Combinations; Drug Therapy, Combination; Female; Humans; Levodopa; Neuroleptic Malignant Syndrome; Parkinson Disease; Substance Withdrawal Syndrome; Tranylcypromine; Tryptophan | 1990 |
Sinemet-ferrous sulphate interaction in patients with Parkinson's disease.
Topics: Adult; Aged; Antiparkinson Agents; Biological Availability; Carbidopa; Drug Combinations; Drug Interactions; Female; Ferrous Compounds; Humans; Levodopa; Male; Middle Aged; Oxygen; Parkinson Disease | 1990 |
Pharmacodynamic modeling of concentration-effect relationships after controlled-release carbidopa/levodopa (Sinemet CR4) in Parkinson's disease.
Topics: Adult; Aged; Antiparkinson Agents; Carbidopa; Delayed-Action Preparations; Drug Combinations; Female; Humans; Levodopa; Linear Models; Male; Middle Aged; Models, Biological; Parkinson Disease | 1990 |
Treatment of Parkinson's disease.
Topics: Antiparkinson Agents; Carbidopa; Drug Combinations; Drug Therapy, Combination; Ergolines; Humans; Levodopa; Lisuride; Parkinson Disease | 1990 |
Severity of Parkinson's disease is a risk factor for peak-dose dyskinesia.
Topics: Aged; Antiparkinson Agents; Benserazide; Carbidopa; Carboxy-Lyases; Dose-Response Relationship, Drug; Drug Combinations; Dyskinesia, Drug-Induced; Humans; Hydrazines; Levodopa; Middle Aged; Motor Skills; Neurologic Examination; Parkinson Disease | 1990 |
Steady plasma levodopa concentrations required for good clinical response to CR-4 in patients with 'on-off'.
Topics: Aged; Antiparkinson Agents; Carbidopa; Delayed-Action Preparations; Dose-Response Relationship, Drug; Drug Combinations; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease | 1990 |
Marijuana for parkinsonian tremor.
Topics: Antiparkinson Agents; Apomorphine; Carbidopa; Diazepam; Drug Combinations; Humans; Levodopa; Marijuana Smoking; Parkinson Disease; Tremor | 1990 |
Dystonia with marked diurnal variation associated with biopterin deficiency.
Topics: Adolescent; Adult; Biopterins; Carbidopa; Child; Child, Preschool; Circadian Rhythm; Drug Combinations; Dystonia; Female; Homovanillic Acid; Humans; Hydroxyindoleacetic Acid; Levodopa; Male; Neopterin; Sibling Relations | 1988 |
Selegiline in the treatment of Parkinson's disease--long term experience.
Topics: Antiparkinson Agents; Carbidopa; Drug Combinations; Drug Therapy, Combination; Female; Humans; Levodopa; Male; Parkinson Disease; Phenethylamines; Selegiline | 1989 |
Dopamine and memory function in Parkinson's disease.
Topics: Aged; Attention; Brain; Carbidopa; Dopamine; Drug Combinations; Female; Humans; Levodopa; Male; Memory; Mental Recall; Middle Aged; Motor Skills; Neuropsychological Tests; Parkinson Disease; Pattern Recognition, Visual; Receptors, Dopamine; Synaptic Transmission; Verbal Learning | 1989 |
Clinical and pharmacokinetic evaluation of controlled-release levodopa/carbidopa (CR-4) in parkinsonian patients with severe motor fluctuations: a six month follow-up study.
Topics: Adult; Aged; Carbidopa; Delayed-Action Preparations; Dose-Response Relationship, Drug; Drug Combinations; Female; Follow-Up Studies; Humans; Levodopa; Male; Middle Aged; Movement Disorders; Parkinson Disease | 1989 |
[Dopamine deficiency syndrome in children with specific reaction to the treatment with levodopa preparations].
Topics: Adolescent; Aphasia; Carbidopa; Child; Dopamine; Dose-Response Relationship, Drug; Drug Combinations; Dystonia Musculorum Deformans; Enzyme Activation; Female; Humans; Levodopa; Male; Tyrosine 3-Monooxygenase | 1989 |
New strategies in dopaminergic therapy of Parkinson's disease: the use of a controlled-release formulation. London, England, April 28 and 29, 1989. Proceedings.
Topics: Antiparkinson Agents; Carbidopa; Delayed-Action Preparations; Drug Combinations; Humans; Levodopa; Parkinson Disease | 1989 |
A pharmacokinetic and pharmacodynamic comparison of Sinemet CR (50/200) and standard Sinemet (25/100).
Topics: Antiparkinson Agents; Carbidopa; Drug Combinations; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Tyrosine | 1989 |
Development and progression of motor fluctuations and side effects in Parkinson's disease: comparison of Sinemet CR versus carbidopa/levodopa.
Topics: Antiparkinson Agents; Carbidopa; Delayed-Action Preparations; Drug Combinations; Humans; Levodopa; Middle Aged; Movement Disorders; Parkinson Disease; Psychomotor Performance | 1989 |
Effect of controlled-release carbidopa/levodopa on motor performance in advanced Parkinson's disease.
Topics: Administration, Oral; Aged; Antiparkinson Agents; Carbidopa; Delayed-Action Preparations; Drug Combinations; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Psychomotor Performance; Tablets | 1989 |
Treatment of early Parkinson's disease with controlled-release levodopa preparations.
Topics: Aged; Antiparkinson Agents; Benserazide; Carbidopa; Delayed-Action Preparations; Drug Combinations; Female; Humans; Hydrazines; Levodopa; Male; Parkinson Disease | 1989 |
Sinemet CR in the treatment of patients with Parkinson's disease already on long-term treatment with levodopa.
Topics: Aged; Aged, 80 and over; Antiparkinson Agents; Carbidopa; Delayed-Action Preparations; Drug Combinations; Female; Hallucinations; Humans; Levodopa; Male; Middle Aged; Parkinson Disease | 1989 |
Experiences with Sinemet CR in the Paracelsus-Elena-Klinik.
Topics: Adult; Aged; Antiparkinson Agents; Carbidopa; Delayed-Action Preparations; Drug Combinations; Humans; Levodopa; Middle Aged; Parkinson Disease | 1989 |
Long-term clinical efficacy of Sinemet CR in patients with Parkinson's disease.
Topics: Aged; Antiparkinson Agents; Carbidopa; Delayed-Action Preparations; Drug Combinations; Follow-Up Studies; Humans; Levodopa; Middle Aged; Movement Disorders; Parkinson Disease | 1989 |
Adrenal medullary autograft transplantation into the striatum of patients with Parkinson's disease.
Topics: Adrenal Medulla; Adult; Carbidopa; Caudate Nucleus; Drug Combinations; Dyskinesia, Drug-Induced; Follow-Up Studies; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Postoperative Complications; Stereotaxic Techniques | 1989 |
Correlates of memory in Parkinson's disease.
Topics: Adult; Aged; Aged, 80 and over; Amantadine; Carbidopa; Drug Combinations; Female; Humans; Levodopa; Male; Memory; Memory Disorders; Middle Aged; Movement Disorders; Neuropsychological Tests; Parkinson Disease | 1989 |
Efficacy of sinemet CR4 in subgroups of patients with Parkinson's disease.
Topics: Activities of Daily Living; Adult; Aged; Biological Availability; Carbidopa; Corpus Striatum; Delayed-Action Preparations; Drug Combinations; Female; Humans; Levodopa; Male; Middle Aged; Motor Skills; Parkinson Disease | 1989 |
Disability profiles and objective quantitative assessment in Parkinson's disease.
Topics: Adult; Aged; Benserazide; Carbidopa; Disability Evaluation; Drug Combinations; Female; Humans; Levodopa; Locomotion; Male; Middle Aged; Parkinson Disease; Posture; Psychomotor Performance; Reaction Time | 1989 |
Pharmacokinetic and pharmacodynamic modeling of L-dopa plasma concentrations and clinical effects in Parkinson's disease after Sinemet.
Topics: Adult; Aged; Carbidopa; Drug Combinations; Female; Humans; Levodopa; Male; Mathematics; Middle Aged; Models, Theoretical; Parkinson Disease | 1989 |
Motor abnormalities during sleep in patients with childhood hereditary progressive dystonia, and their unaffected family members.
Topics: Adolescent; Adult; Aged; Antiparkinson Agents; Basal Ganglia; Carbidopa; Child; Child, Preschool; Drug Combinations; Dystonia; Female; Genetic Carrier Screening; Humans; Levodopa; Male; Middle Aged; Motor Activity; Sleep Stages; Sleep Wake Disorders; Sleep, REM | 1989 |
An open trial of controlled release carbidopa/L-dopa (sinemet CR) for the treatment of mild-to-moderate Parkinson's disease.
Topics: Aged; Carbidopa; Delayed-Action Preparations; Drug Combinations; Drug Evaluation; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease | 1989 |
Black cartilage associated with levodopa.
Topics: Aged; Antiparkinson Agents; Carbidopa; Cartilage Diseases; Drug Combinations; Female; Humans; Levodopa; Pigmentation Disorders; Ribs | 1986 |
(+)-4-Propyl-9-hydroxynaphthoxazine in Parkinson's disease.
Topics: Animals; Callithrix; Carbidopa; Domperidone; Dose-Response Relationship, Drug; Drug Combinations; Drug Therapy, Combination; Humans; Levodopa; Oxazines; Parkinson Disease; Time Factors | 1986 |
Painful Parkinson's disease.
Topics: Acute Disease; Adult; Aged; Antiparkinson Agents; Benserazide; Carbidopa; Drug Administration Schedule; Drug Combinations; Dyskinesia, Drug-Induced; Dystonia; Female; Humans; Levodopa; Male; Middle Aged; Motor Activity; Pain; Parkinson Disease; Time Factors | 1986 |
Antiparkinsonian activity of a single oral dose of PHNO.
Topics: Administration, Oral; Adult; Aged; Carbidopa; Dopamine Agents; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Combinations; Female; Humans; Levodopa; Male; Middle Aged; Oxazines; Parkinson Disease, Secondary; Reaction Time | 1987 |
Parkinson's disease, depression, and the on-off phenomenon.
Topics: Bromocriptine; Carbidopa; Depressive Disorder; Drug Combinations; Drug Therapy, Combination; Humans; Levodopa; Male; Middle Aged; Motor Skills; Parkinson Disease | 1989 |
Dose-dependent memory impairment in Parkinson's disease.
Topics: Carbidopa; Dopamine; Drug Combinations; Humans; Levodopa; Memory Disorders; Parkinson Disease | 1989 |
Comprehensive care of the patient with Parkinson's disease.
Topics: Aged; Amantadine; Bromocriptine; Carbidopa; Drug Combinations; Humans; Levodopa; Male; Muscle Rigidity; Parasympatholytics; Parkinson Disease; Patient Care Planning; Patient Care Team; Tremor | 1986 |
Carbidopa plus L-dopa pretreatment inhibits the prolactin (PRL) response to thyrotropin-releasing hormone and thus cannot distinguish central from pituitary sites of prolactin stimulation.
Topics: Adult; Brain; Carbidopa; Drug Combinations; Humans; Levodopa; Male; Pituitary Gland, Anterior; Prolactin; Thyrotropin-Releasing Hormone | 1986 |
[Therapeutic strategies and tactics in parkinsonism].
Topics: Amantadine; Antidepressive Agents; Antiparkinson Agents; Benserazide; Carbidopa; Depressive Disorder; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Combinations; Drug Therapy, Combination; Humans; Levodopa; Lisuride; Motor Skills; Parkinson Disease; Selegiline; Sleep Initiation and Maintenance Disorders | 1986 |
Drugs for parkinsonism.
Topics: Amantadine; Bromocriptine; Carbidopa; Drug Combinations; Humans; Levodopa; Parasympatholytics; Parkinson Disease; Selegiline | 1988 |
[A model of Parkinson's disease: effect of L-dopa therapy on movement parameters and electromyographic activity in monkeys treated with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)].
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Behavior, Animal; Carbidopa; Disease Models, Animal; Drug Combinations; Electromyography; Levodopa; Macaca mulatta; Movement Disorders; Parkinson Disease, Secondary; Pyridines | 1985 |
A new syndrome of axial muscle rigidity associated with etretinate therapy.
Topics: Adult; Antiparkinson Agents; Back; Carbidopa; Drug Combinations; Etretinate; Humans; Levodopa; Male; Middle Aged; Muscle Rigidity; Neck Muscles; Psoriasis; Syndrome | 1988 |
Drug-induced alzheimerism.
Topics: Aged; Alzheimer Disease; Biperiden; Carbidopa; Drug Combinations; Humans; Levodopa; Male; Parkinson Disease; Piperidines | 1988 |
Controlled-release levodopa/carbidopa. III: Sinemet CR5 treatment of response fluctuations in Parkinson's disease.
Topics: Aged; Antiparkinson Agents; Biological Availability; Carbidopa; Delayed-Action Preparations; Drug Combinations; Drug Evaluation; Humans; Levodopa; Parkinson Disease | 1988 |
False positive diagnosis of phaeochromocytoma in a patient with Parkinson's disease receiving levodopa.
Topics: Adrenal Gland Neoplasms; Aged; Carbidopa; Diagnostic Errors; Drug Combinations; Female; Humans; Levodopa; Parkinson Disease; Pheochromocytoma; Vanilmandelic Acid | 1988 |
[Cholestasis caused by Nakom].
Topics: Antiparkinson Agents; Carbidopa; Cholestasis; Diagnosis, Differential; Drug Combinations; Humans; Levodopa; Male; Middle Aged; Parkinson Disease | 1988 |
Mood swings associated with the 'on-off' phenomenon in Parkinson's disease.
Topics: Adult; Aged; Antiparkinson Agents; Carbidopa; Depressive Disorder; Drug Combinations; Female; Humans; Levodopa; Male; Middle Aged; Mood Disorders; Parkinson Disease; Parkinson Disease, Secondary | 1987 |
Effect of increasing regimens of levodopa on chronic MPTP-induced parkinsonism in monkey; mechanographic and electromyographic data.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Carbidopa; Dose-Response Relationship, Drug; Drug Combinations; Electromyography; Levodopa; Macaca mulatta; Parkinson Disease, Secondary; Pyridines | 1986 |
Preservation of the substantia nigra and locus coeruleus in a patient receiving levodopa (2 kg) plus decarboxylase inhibitor over a four-year period.
Topics: Aged; Carbidopa; Drug Combinations; Humans; Levodopa; Locus Coeruleus; Male; Parkinson Disease; Substantia Nigra | 1986 |
Sudden onset of confusion with severe exacerbation of parkinsonism during levodopa therapy.
Topics: Aged; Carbidopa; Cognition Disorders; Confusion; Dose-Response Relationship, Drug; Drug Combinations; Humans; Levodopa; Male; Parkinson Disease, Secondary | 1986 |
Parkinsonism induced by high-dose cytosine arabinoside.
Topics: Carbidopa; Cytarabine; Dose-Response Relationship, Drug; Drug Combinations; Female; Humans; Leukemia, Myelomonocytic, Acute; Levodopa; Middle Aged; Parkinson Disease, Secondary | 1987 |
Controlled release levodopa treatment of motor fluctuations in Parkinson's disease.
Topics: Adult; Aged; Antiparkinson Agents; Carbidopa; Delayed-Action Preparations; Drug Combinations; Drug Therapy, Combination; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Psychomotor Performance | 1987 |
A case of normal pressure hydrocephalus presenting as levodopa responsive parkinsonism.
Topics: Antiparkinson Agents; Carbidopa; Drug Combinations; Female; Humans; Hydrocephalus; Hydrocephalus, Normal Pressure; Levodopa; Middle Aged; Parkinson Disease | 1987 |
Parkinson's disease and motor fluctuations: long-acting carbidopa/levodopa (CR-4-Sinemet).
Topics: Adult; Aged; Carbidopa; Drug Combinations; Female; Humans; Levodopa; Male; Middle Aged; Movement; Parkinson Disease | 1987 |
Excessive yawning and progressive supranuclear palsy.
Topics: Aged; Bromocriptine; Carbidopa; Drug Combinations; Humans; Levodopa; Middle Aged; Supranuclear Palsy, Progressive; Yawning | 1987 |
Stridor during dystonic phases of Parkinson's disease.
Topics: Adult; Carbidopa; Drug Combinations; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Respiratory Sounds | 1987 |
Controlled-release Sinemet.
Topics: Carbidopa; Delayed-Action Preparations; Drug Combinations; Humans; Levodopa; Parkinson Disease | 1987 |
L-dopa in uremic patients with the restless legs syndrome.
Topics: Aged; Carbidopa; Drug Combinations; Female; Humans; Levodopa; Male; Middle Aged; Restless Legs Syndrome; Uremia | 1987 |
Controlled-release levodopa/carbidopa. II. Sinemet CR4 treatment of response fluctuations in Parkinson's disease.
Topics: Carbidopa; Delayed-Action Preparations; Drug Administration Schedule; Drug Combinations; Humans; Levodopa; Paranoid Disorders; Parkinson Disease; Patient Acceptance of Health Care; Time Factors | 1987 |
[Phenomenon of inverted rotation in spastic torticollis].
Topics: Adult; Brain; Carbidopa; Drug Combinations; Female; Humans; Levodopa; Muscle Spasticity; Receptors, Dopamine; Rotation; Substance Withdrawal Syndrome; Torticollis | 1986 |
Sinemet in Parkinson's disease: efficacy with and without food.
Topics: Administration, Oral; Aged; Antiparkinson Agents; Carbidopa; Diet; Drug Administration Schedule; Drug Combinations; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease | 1986 |
Pharmacotherapy: problems and practices.
Topics: Amantadine; Bromocriptine; Carbidopa; Drug Combinations; Humans; Levodopa; Parasympatholytics; Parkinson Disease | 1986 |
L-dopa induced "serotonin syndrome" in a parkinsonian patient on bromocriptine.
Topics: Aged; Bromocriptine; Carbidopa; Drug Combinations; Drug Interactions; Humans; Levodopa; Male; Myoclonus; Parkinson Disease; Serotonin | 1986 |
Drugs for parkinsonism.
Topics: Amantadine; Antiparkinson Agents; Bromocriptine; Carbidopa; Drug Combinations; Drug Therapy, Combination; Humans; Levodopa; Parasympatholytics; Parkinson Disease | 1986 |
Management of Parkinson's disease in general practice.
Topics: Aged; Benserazide; Bromocriptine; Carbidopa; Drug Combinations; Family Practice; Humans; Levodopa; Medical Audit; Parkinson Disease | 1986 |
Clinical and biochemical studies with controlled-release levodopa/carbidopa.
Topics: Aged; Carbidopa; Drug Combinations; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease | 1986 |
[Neurologic and electromyographic findings in chronic manganese encephalopathy].
Topics: Adult; Brain Diseases; Carbidopa; Chronic Disease; Drug Combinations; Electromyography; Humans; Levodopa; Male; Manganese Poisoning; Metallurgy; Middle Aged; Occupational Diseases | 1986 |
Controlled-release levodopa/carbidopa. I. Sinemet CR3 treatment of response fluctuations in Parkinson's disease.
Topics: Adult; Aged; Antiparkinson Agents; Biological Availability; Carbidopa; Delayed-Action Preparations; Dose-Response Relationship, Drug; Drug Combinations; Female; Humans; Levodopa; Male; Middle Aged; Nervous System Diseases; Parkinson Disease | 1987 |
Alleviation of severe emotional symptoms by carbidopa-levodopa, MSD, in a Parkinson's patient: a personal report.
Topics: Affective Symptoms; Aged; Carbidopa; Dopamine; Drug Combinations; Emotions; Humans; Levodopa; Male; Parkinson Disease | 1987 |
Low-dosage treatment in de novo patients with Parkinson's disease: a prospective study.
Topics: Aged; Bromocriptine; Carbidopa; Disability Evaluation; Dose-Response Relationship, Drug; Drug Combinations; Drug Therapy, Combination; Female; Humans; Levodopa; Male; Middle Aged; Orphenadrine; Parkinson Disease | 1987 |
Permanent human parkinsonism due to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP): seven cases.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Acute Disease; Adult; Carbidopa; Chronic Disease; Drug Combinations; Female; Humans; Levodopa; Male; Parkinson Disease; Pyridines; Substance-Related Disorders; Substantia Nigra | 1985 |
[Effect of the test with the drug Nakom on the dynamics of excretion of catecholamines and DOPA in children with Duchenne's progressive muscular dystrophy].
Topics: Adolescent; Carbidopa; Catecholamines; Child; Child, Preschool; Circadian Rhythm; Dihydroxyphenylalanine; Drug Combinations; Humans; Levodopa; Muscular Dystrophies | 1985 |
Pharmacologic treatment of parkinsonian tremor.
Topics: Amantadine; Carbidopa; Drug Combinations; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Tremor; Trihexyphenidyl | 1986 |
Hyperthermia after discontinuance of levodopa and bromocriptine therapy: impaired dopamine receptors a possible cause.
Topics: Body Temperature Regulation; Bromocriptine; Carbidopa; Drug Combinations; Female; Fever; Humans; Levodopa; Malignant Hyperthermia; Middle Aged; Neuroleptic Malignant Syndrome; Parkinson Disease; Receptors, Dopamine | 1985 |
Unsuccessful treatment of severe pain from bone metastases with Sinemet 25/100.
Topics: Analgesics; Bone Neoplasms; Carbidopa; Drug Combinations; Humans; Levodopa; Pain, Intractable; Pilot Projects | 1985 |
Reversal of sleep disturbance in Parkinson's disease by antiparkinsonian therapy: a preliminary study.
Topics: Aged; Carbidopa; Drug Combinations; Ergolines; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Pergolide; Receptors, Dopamine; Sleep Wake Disorders; Sleep, REM | 1985 |
Monoamine oxidase inhibitors and Sinemet in Shy-Drager syndrome.
Topics: Autonomic Nervous System Diseases; Carbidopa; Drug Combinations; Female; Humans; Hypotension, Orthostatic; Levodopa; Middle Aged; Monoamine Oxidase Inhibitors; Shy-Drager Syndrome | 1985 |
Sinemet "abusers".
Topics: Antiparkinson Agents; Carbidopa; Drug Combinations; Humans; Levodopa; Male; Middle Aged; Self Administration; Substance-Related Disorders | 1985 |
[Drug therapy of Parkinson's disease].
Topics: Adult; Aged; Antiparkinson Agents; Benserazide; Carbidopa; Drug Combinations; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease | 1985 |
[Clinical significance of cramps of the lower extremities in patients with parkinsonism].
Topics: Aged; Antiparkinson Agents; Benserazide; Carbidopa; Drug Combinations; Female; Humans; Hydrazines; Leg; Levodopa; Male; Middle Aged; Muscle Cramp; Parkinson Disease | 1985 |
[Value of the test with Nakom for assessing the state of the sympathoadrenal system in patients with different forms of progressive muscular dystrophy].
Topics: Adolescent; Adult; Carbidopa; Catecholamines; Child; Child, Preschool; Drug Combinations; Humans; Levodopa; Male; Muscular Atrophy; Muscular Dystrophies | 1984 |
Complicated response fluctuations in Parkinson's disease: response to intravenous infusion of levodopa.
Topics: Administration, Oral; Carbidopa; Dopamine; Drug Combinations; Humans; Infusions, Parenteral; Kinetics; Levodopa; Male; Middle Aged; Parkinson Disease; Receptors, Adrenergic; Time Factors | 1982 |
Cholinergic and dopaminergic mechanisms in Parkinson's disease after long term levodopa administration.
Topics: Carbidopa; Drug Combinations; Humans; Levodopa; Parkinson Disease; Receptors, Cholinergic; Receptors, Dopamine; Time Factors | 1982 |
Dopamine agonists in clinical research for new tardive dyskinesia treatments.
Topics: Adult; Aged; Antipsychotic Agents; Apomorphine; Benserazide; Carbidopa; Dopamine; Drug Combinations; Dyskinesia, Drug-Induced; Humans; Hydrazines; Levodopa; Middle Aged; Synaptic Transmission | 1983 |
False diagnosis of phaeochromocytoma in patients on Sinemet.
Topics: Adrenal Gland Neoplasms; Aged; Antiparkinson Agents; Carbidopa; Drug Combinations; False Positive Reactions; Female; Humans; Levodopa; Male; Middle Aged; Pheochromocytoma; Vanilmandelic Acid | 1984 |
Skin rash associated with Sinemet 25/100.
Topics: Antiparkinson Agents; Carbidopa; Drug Combinations; Drug Eruptions; Humans; Levodopa | 1983 |
[Circadian rhythm of catecholamine excretion, effect of L-DOPA and Nacom in various diseases of the nervous system].
Topics: Adult; Aged; Carbidopa; Catecholamines; Drug Combinations; Dystonia Musculorum Deformans; Female; Humans; Huntington Disease; Levodopa; Male; Middle Aged; Muscular Dystrophies; Nervous System Diseases; Neurotic Disorders; Parkinson Disease | 1983 |
Sinemet skin rash.
Topics: Aged; Carbidopa; Coloring Agents; Drug Combinations; Drug Eruptions; Female; Humans; Levodopa | 1984 |
Urinary homovanillic acid and c-AMP in drug-free Parkinson patients: effect of L-dopa treatment.
Topics: Aged; Carbidopa; Cyclic AMP; Drug Combinations; Female; Homovanillic Acid; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Phenylacetates | 1981 |
Severity of Parkinson's disease and the dosage of bromocriptine.
Topics: Adult; Aged; Bromocriptine; Carbidopa; Drug Combinations; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Retrospective Studies | 1984 |
One-year trial of pergolide as an adjunct to Sinemet in treatment of Parkinson's disease.
Topics: Athetosis; Carbidopa; Chorea; Drug Combinations; Drug Evaluation; Drug Therapy, Combination; Ergolines; Humans; Hypotension; Levodopa; Male; Middle Aged; Parkinson Disease; Pergolide | 1984 |
Response to Sinemet 25/100 in Parkinson's disease.
Topics: Aged; Benserazide; Body Weight; Carbidopa; Drug Combinations; Drug Therapy, Combination; Female; Humans; Hydrazines; Levodopa; Male; Middle Aged; Parkinson Disease; Sex Factors | 1984 |
What to do when Sinemet fails: Part one.
Topics: Antiparkinson Agents; Carbidopa; Dementia; Drug Administration Schedule; Drug Combinations; Dyskinesia, Drug-Induced; Humans; Levodopa; Parkinson Disease; Psychoses, Substance-Induced | 1984 |
[Treatment of patients with vascular parkinsonism with the preparations nakom and madopar].
Topics: Adult; Aged; Antiparkinson Agents; Benserazide; Carbidopa; Drug Combinations; Humans; Hydrazines; Levodopa; Middle Aged; Parkinson Disease, Secondary | 1984 |
Behavioral control of L-dopa induced dyskinesia in Parkinsonism.
Topics: Adult; Antiparkinson Agents; Biofeedback, Psychology; Carbidopa; Drug Combinations; Dyskinesia, Drug-Induced; Electromyography; Humans; Levodopa; Male; Relaxation Therapy | 1982 |
Metabolism of (-) deprenyl to amphetamine and methamphetamine may be responsible for deprenyl's therapeutic benefit: a biochemical assessment.
Topics: 3,4-Dihydroxyphenylacetic Acid; Adult; Amphetamines; Biogenic Amines; Carbidopa; Depression; Drug Combinations; Female; Humans; Levodopa; Male; Methamphetamine; Middle Aged; Monoamine Oxidase; Parkinson Disease; Phenethylamines; Selegiline; Tyramine | 1982 |
Thyrotrophin and prolactin responses to thyrotrophin-releasing hormone in patients with Parkinson's disease.
Topics: Adult; Aged; Antiparkinson Agents; Benserazide; Carbidopa; Drug Combinations; Female; Humans; Hydrazines; Levodopa; Male; Middle Aged; Parkinson Disease; Prolactin; Thyrotropin; Thyrotropin-Releasing Hormone; Thyroxine; Triiodothyronine | 1982 |
Pergolide mesylate and idiopathic Parkinson disease.
Topics: Adolescent; Adult; Carbidopa; Child; Child, Preschool; Drug Combinations; Drug Therapy, Combination; Ergolines; Female; Humans; Levodopa; Male; Parkinson Disease; Pergolide | 1982 |
Further studies with pergolide in Parkinson disease.
Topics: Adult; Aged; Carbidopa; Confusion; Drug Combinations; Drug Therapy, Combination; Ergolines; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Pergolide | 1982 |
Prolactin response to acute administration of different L-dopa plus decarboxylase inhibitors in Parkinson's disease.
Topics: Aged; Animals; Benserazide; Carbidopa; Dose-Response Relationship, Drug; Drug Combinations; Drug Therapy, Combination; Humans; Hydrazines; Levodopa; Male; Middle Aged; Parkinson Disease; Prolactin; Rats | 1982 |
Adverse interaction of levodopa with tricyclic antidepressants.
Topics: Aged; Amitriptyline; Carbidopa; Drug Combinations; Drug Interactions; Female; Humans; Imipramine; Levodopa; Parkinson Disease | 1982 |
Drug-induced asterixis in Parkinson disease.
Topics: Aged; Carbidopa; Drug Combinations; Female; Humans; Levodopa; Middle Aged; Muscle Contraction; Muscular Diseases; Parkinson Disease; Posture | 1982 |
Sinemet - 25/100.
Topics: Carbidopa; Drug Combinations; Humans; Levodopa; Parkinson Disease | 1980 |
The effect of levodopa with carbidopa (Sinemet R) on the metabolic response to semistarvation.
Topics: Adaptation, Physiological; Aromatic Amino Acid Decarboxylase Inhibitors; Basal Metabolism; Carbidopa; Diet, Reducing; Drug Combinations; Energy Intake; Female; Humans; Levodopa; Middle Aged; Obesity; Triiodothyronine | 1980 |
Sinemet and brain injury: functional versus statistical change and suggestions for future research designs.
Topics: Aged; Brain Damage, Chronic; Carbidopa; Dopamine Agonists; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Combinations; Female; Follow-Up Studies; Glasgow Coma Scale; Head Injuries, Closed; Humans; Levodopa; Neurologic Examination; Neuropsychological Tests | 1995 |
Parkinsonism and bipolar affective disorder.
Topics: Aged; Antiparkinson Agents; Bipolar Disorder; Carbidopa; Clonazepam; Dopamine; Drug Combinations; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Humans; Levodopa; Lithium Carbonate; Male; Parkinson Disease, Secondary | 1995 |
Adverse reactions to Sinemet CR.
Topics: Aged; Antiparkinson Agents; Carbidopa; Confusion; Delayed-Action Preparations; Drug Combinations; Dyskinesia, Drug-Induced; Hallucinations; Humans; Levodopa | 1995 |
Use of Sinemet in locked-in syndrome: a report of two cases.
Topics: Adult; Carbidopa; Child; Dopamine Agonists; Drug Combinations; Humans; Levodopa; Male; Quadriplegia | 1995 |
Contemporaneous bilateral postero-ventral pallidotomy for early onset "juvenile type" Parkinson's disease. Case report.
Topics: Antiparkinson Agents; Brain Mapping; Carbidopa; Combined Modality Therapy; Drug Combinations; Drug Therapy, Combination; Globus Pallidus; Humans; Levodopa; Male; Middle Aged; Neurologic Examination; Parkinson Disease; Postoperative Complications | 1994 |
Adverse reactions to controlled release levodopa/carbidopa in older persons: case reports.
Topics: Aged; Aged, 80 and over; Antiparkinson Agents; Carbidopa; Delayed-Action Preparations; Dopamine Agonists; Drug Combinations; Frail Elderly; Hallucinations; Humans; Levodopa; Male; Mental Status Schedule; Parkinson Disease; Severity of Illness Index | 1995 |
Anticholinergics and dyskinesia.
Topics: Aged; Biperiden; Carbidopa; Drug Combinations; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Neurologic Examination; Parkinson Disease; Tremor; Trihexyphenidyl | 1994 |
Parkinson's disease: reorganization of the reach to grasp movement in response to perturbation of the distal motor patterning.
Topics: Aged; Antiparkinson Agents; Attention; Carbidopa; Drug Combinations; Female; Hand Strength; Humans; Kinesthesis; Levodopa; Male; Middle Aged; Motor Skills; Neurologic Examination; Orientation; Parkinson Disease; Psychomotor Performance; Reaction Time; Selegiline; Size Perception | 1994 |
Portable device for quantifying parkinsonian wrist rigidity.
Topics: Adult; Aged; Antiparkinson Agents; Antipsychotic Agents; Carbidopa; Drug Combinations; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Male; Middle Aged; Muscle Rigidity; Muscle Tonus; Neurologic Examination; Parkinson Disease; Parkinson Disease, Secondary; Psychotic Disorders; Risk Factors; Transducers | 1994 |
Hyponatraemia and dopaminergic agents.
Topics: Aged; Antiparkinson Agents; Carbidopa; Dopamine Agents; Drug Combinations; Female; Humans; Hyponatremia; Levodopa | 1994 |
A 6-hydroxydopamine-induced selective parkinsonian rat model: further biochemical and behavioral characterization.
Topics: Amphetamine; Animals; Brain; Carbidopa; Caudate Nucleus; Corpus Striatum; Dopamine; Drug Combinations; Functional Laterality; Immunohistochemistry; Levodopa; Male; Mesencephalon; Models, Neurological; Motor Activity; Nucleus Accumbens; Oxidopamine; Parkinson Disease, Secondary; Rats; Rats, Sprague-Dawley; Rotation; Tyrosine 3-Monooxygenase | 1994 |
Parkinson's disease: making the diagnosis, selecting drug therapies.
Topics: Aged; Antiparkinson Agents; Carbidopa; Cholinergic Antagonists; Diagnosis, Differential; Dopamine Agonists; Drug Combinations; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease | 1994 |
[Catecholamines and the dopamine-beta-hydroxylase activity of the blood plasma in motor pathology in children: the role of central and peripheral mechanisms].
Topics: Adolescent; Carbidopa; Catecholamines; Child; Chromatography, High Pressure Liquid; Dopamine Agonists; Dopamine beta-Hydroxylase; Drug Combinations; Female; Humans; Levodopa; Male; Movement Disorders; Spectrophotometry | 1994 |
First emergence of "delayed-on" and "dose failure" phenomena in a patient with Parkinson's disease following vagotomy.
Topics: Antiparkinson Agents; Carbidopa; Drug Combinations; Duodenal Ulcer; Female; Gastric Emptying; Gastrointestinal Transit; Humans; Levodopa; Middle Aged; Parkinson Disease; Postoperative Complications; Vagotomy; Vagus Nerve | 1994 |
Role of selective D1 and D2 agonists in inducing dyskinesia in drug-naive MPTP monkeys.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Brain Mapping; Carbidopa; Corpus Striatum; Dopamine Agents; Dose-Response Relationship, Drug; Down-Regulation; Drug Combinations; Dyskinesia, Drug-Induced; Female; Levodopa; Locomotion; Macaca fascicularis; Parkinson Disease, Secondary; Psychomotor Performance; Receptors, Dopamine D1; Receptors, Dopamine D2 | 1993 |
Dopaminergic treatment of restless legs and rebound phenomenon.
Topics: Aged; Carbidopa; Dopamine Agents; Drug Combinations; Female; Humans; Levodopa; Male; Middle Aged; Prospective Studies; Restless Legs Syndrome; Substance Withdrawal Syndrome | 1993 |
Drugs for Parkinson's disease.
Topics: Carbidopa; Dopamine Agents; Drug Combinations; Humans; Levodopa; Parasympatholytics; Parkinson Disease; Selegiline | 1993 |
Management of neuroleptic malignant syndrome--a series of eight cases.
Topics: Adolescent; Adult; Bromocriptine; Carbidopa; Dantrolene; Dopamine Agents; Drug Combinations; Female; Humans; India; Levodopa; Male; Muscular Diseases; Neuroleptic Malignant Syndrome | 1993 |
Hyponatraemia due to amantadine hydrochloride and L-dopa/carbidopa.
Topics: Aged; Amantadine; Antiparkinson Agents; Carbidopa; Dopamine Agents; Drug Combinations; Humans; Hyponatremia; Levodopa; Male | 1993 |
Individualizing therapy in patients with disabling Parkinson's disease symptoms.
Topics: Aged; Aged, 80 and over; Carbidopa; Drug Combinations; Female; Humans; Levodopa; Middle Aged; Parkinson Disease | 1994 |
Severe evening dyskinesias in advanced Parkinson's disease: clinical description, relation to plasma levodopa, and treatment.
Topics: Aged; Antiparkinson Agents; Bromocriptine; Carbidopa; Chorea; Circadian Rhythm; Delayed-Action Preparations; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Combinations; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Dystonia; Female; Humans; Levodopa; Male; Middle Aged; Neurologic Examination; Parkinson Disease | 1994 |
Antiparkinsonian effects of remacemide hydrochloride, a glutamate antagonist, in rodent and primate models of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Acetamides; Analysis of Variance; Animals; Anticonvulsants; Antiparkinson Agents; Brain; Carbidopa; Dizocilpine Maleate; Dose-Response Relationship, Drug; Drug Combinations; Levodopa; Macaca mulatta; Male; Motor Activity; Parkinson Disease, Secondary; Rats; Rats, Sprague-Dawley; Reserpine; Time Factors | 1994 |
The influence of a standard meal on Sinemet CR absorption in patients with Parkinson's disease.
Topics: Aged; Antiparkinson Agents; Carbidopa; Delayed-Action Preparations; Dietary Proteins; Drug Administration Schedule; Drug Combinations; Eating; Female; Humans; Intestinal Absorption; Levodopa; Male; Metabolic Clearance Rate; Middle Aged; Neurologic Examination; Parkinson Disease | 1993 |
Continuous duodenal infusions of levodopa.
Topics: Activities of Daily Living; Adult; Aged; Antiparkinson Agents; Carbidopa; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Combinations; Duodenum; Female; Humans; Intubation, Gastrointestinal; Levodopa; Male; Middle Aged; Neurologic Examination; Parkinson Disease; Patient Education as Topic | 1993 |
Levodopa pharmacodynamics.
Topics: Carbidopa; Drug Combinations; Drugs, Generic; Humans; Levodopa; Parkinson Disease; United States; United States Food and Drug Administration | 1994 |
Suppression of dyskinesias in advanced Parkinson's disease. I. Continuous intravenous levodopa shifts dose response for production of dyskinesias but not for relief of parkinsonism in patients with advanced Parkinson's disease.
Topics: Aged; Antiparkinson Agents; Carbidopa; Dihydroxyphenylalanine; Dose-Response Relationship, Drug; Drug Combinations; Female; Humans; Infusions, Intravenous; Levodopa; Male; Middle Aged; Movement Disorders; Parkinson Disease; Tyrosine | 1993 |
Risk factors for motor response complications in L-dopa-treated parkinsonian patients.
Topics: Adult; Age Factors; Aged; Antiparkinson Agents; Carbidopa; Drug Combinations; Dyskinesia, Drug-Induced; Female; Follow-Up Studies; Humans; Levodopa; Long-Term Care; Male; Middle Aged; Motor Activity; Neurologic Examination; Parkinson Disease; Risk Factors | 1993 |
Treatment of drug-induced psychosis in Parkinson's disease with clozapine.
Topics: Aged; Antiparkinson Agents; Carbidopa; Clozapine; Dementia; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Combinations; Female; Humans; Levodopa; Male; Middle Aged; Neurologic Examination; Parkinson Disease; Psychoses, Substance-Induced | 1993 |
Plasma levels of levodopa and its main metabolites in parkinsonian patients after conventional and controlled-release levodopa-carbidopa associations.
Topics: 3,4-Dihydroxyphenylacetic Acid; Aged; Antiparkinson Agents; Blood-Brain Barrier; Carbidopa; Delayed-Action Preparations; Dopamine; Dose-Response Relationship, Drug; Drug Combinations; Female; Homovanillic Acid; Humans; Levodopa; Male; Middle Aged; Neurologic Examination; Parkinson Disease; Tyrosine | 1993 |
Clinical experience with controlled-release carbidopa/levodopa in Parkinson's disease.
Topics: Adult; Aged; Aged, 80 and over; Antiparkinson Agents; Carbidopa; Delayed-Action Preparations; Drug Combinations; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Patient Satisfaction; Treatment Outcome | 1993 |
Determination of tetrahydropapaveroline in the urine of parkinsonian patients receiving L-dopa-carbidopa (Sinemet) therapy by high-performance liquid chromatography.
Topics: Adsorption; Aluminum Oxide; Antiparkinson Agents; Carbidopa; Cation Exchange Resins; Chromatography, High Pressure Liquid; Chromatography, Ion Exchange; Drug Combinations; Electrochemistry; Humans; Levodopa; Parkinson Disease; Resins, Synthetic; Silanes; Tetrahydropapaveroline | 1993 |
Worsening of postural tremor in patients with levodopa-induced dyskinesia: a quantitative analysis.
Topics: Aged; Aged, 80 and over; Antiparkinson Agents; Carbidopa; Drug Combinations; Dyskinesia, Drug-Induced; Humans; Levodopa; Male; Middle Aged; Posture; Tremor | 1993 |
[Changes in the indices of standing and walking in patients with infantile cerebral palsy under the influence of low doses of Nakom].
Topics: Adolescent; Antiparkinson Agents; Carbidopa; Cerebral Palsy; Child; Dose-Response Relationship, Drug; Drug Combinations; Female; Gait; Humans; Levodopa; Male; Posture; Walking | 1995 |
Sinemet in locked-in syndrome.
Topics: Carbidopa; Dopamine Agonists; Drug Combinations; Humans; Levodopa; Male; Quadriplegia; Terminology as Topic | 1996 |
[The prolactin and thyrotropic hormone content of the blood plasma in neostriatal dysfunction].
Topics: Basal Ganglia Diseases; Carbidopa; Dopamine Agonists; Dopamine Antagonists; Drug Combinations; Haloperidol; Humans; Immunoenzyme Techniques; Levodopa; Neostriatum; Prolactin; Thyrotropin; Time Factors | 1995 |
Levodopa stability in solution: time course, environmental effects, and practical recommendations for clinical use.
Topics: Antiparkinson Agents; Ascorbic Acid; Carbidopa; Drug Combinations; Drug Stability; Drug Storage; Humans; Levodopa; Light; Parkinson Disease; Temperature; Time Factors | 1996 |
Slow increase of homovanillic acid in cerebrospinal fluid after levodopa administration.
Topics: 3,4-Dihydroxyphenylacetic Acid; Aged; Antiparkinson Agents; Carbidopa; Drug Administration Schedule; Drug Combinations; Female; Homovanillic Acid; Humans; Hydrocephalus; Levodopa; Male; Middle Aged | 1996 |
Amantadine-induced "vocal" myoclonus.
Topics: Aged; Amantadine; Antiparkinson Agents; Carbidopa; Dose-Response Relationship, Drug; Drug Combinations; Drug Therapy, Combination; Dysarthria; Female; Humans; Levodopa; Myoclonus; Neurologic Examination; Parkinson Disease; Verbal Behavior | 1996 |
Levodopa in pregnancy.
Topics: Adverse Drug Reaction Reporting Systems; Antiparkinson Agents; Carbidopa; Drug Combinations; Female; Humans; Infant, Newborn; Levodopa; Parkinson Disease; Pregnancy; Pregnancy Complications; Risk Factors | 1996 |
[The brain catecholaminergic system during the long-term correction of hereditary arterial hypertension].
Topics: Animals; Brain; Brain Chemistry; Carbidopa; Dopamine; Dopamine Agents; Drug Combinations; Drug Evaluation, Preclinical; Hypertension; Levodopa; Male; Norepinephrine; Rats; Rats, Inbred SHR; Receptors, Catecholamine; Time Factors | 1996 |
Supplement: treatment for Parkinson's disease.
Topics: Algorithms; Antiparkinson Agents; Carbidopa; Drug Combinations; Humans; Levodopa; Middle Aged; Parkinson Disease | 1995 |
Familial akathisia and depression treated with nefazodone.
Topics: Adult; Akathisia, Drug-Induced; Antidepressive Agents, Second-Generation; Antiparkinson Agents; Carbidopa; Depressive Disorder; Drug Combinations; Drug Therapy, Combination; Humans; Levodopa; Male; Piperazines; Restless Legs Syndrome; Selective Serotonin Reuptake Inhibitors; Triazoles | 1996 |
Intrafamilial variability in Machado-Joseph disease.
Topics: Adult; Antiparkinson Agents; Carbidopa; Drug Combinations; Female; Genes, Dominant; Humans; Levodopa; Machado-Joseph Disease; Male; Neurologic Examination; Phenotype | 1996 |
[Brain catecholamines and the hypothalamo-hypophyseal-adrenocortical system in hereditary arterial hypertension].
Topics: Aging; Animals; Blood Pressure; Brain; Brain Chemistry; Carbidopa; Catecholamines; Dopamine Agonists; Drug Combinations; Female; Hypertension; Hypothalamo-Hypophyseal System; Levodopa; Male; Pituitary-Adrenal System; Rats; Rats, Inbred SHR; Rats, Wistar; Stress, Psychological | 1996 |
Triphasic waves in serotonin syndrome.
Topics: 1-Naphthylamine; Aged; Amantadine; Antiparkinson Agents; Brain Diseases; Carbidopa; Drug Combinations; Drug Therapy, Combination; Electroencephalography; Hallucinations; Humans; Levodopa; Male; Myoclonus; Parkinson Disease; Selective Serotonin Reuptake Inhibitors; Sertraline; Syndrome | 1997 |
Comparison of utilization of Sinemet and Parkinson's disease mortality as surrogate indicators of Parkinson's disease in the United States.
Topics: Antiparkinson Agents; Carbidopa; Demography; Drug Combinations; Drug Utilization; Humans; Levodopa; Linear Models; Parkinson Disease; United States | 1997 |
The nurse's role in clinical trials.
Topics: Antiparkinson Agents; Carbidopa; Clinical Trials, Phase IV as Topic; Drug Combinations; Humans; Job Description; Levodopa; Nursing Care; Parkinson Disease | 1996 |
Rats with partial striatal dopamine depletions exhibit robust and long-lasting behavioral deficits in a simple fixed-ratio bar-pressing task.
Topics: Animals; Antiparkinson Agents; Appetitive Behavior; Brain Mapping; Carbidopa; Corpus Striatum; Dominance, Cerebral; Dopamine; Drug Combinations; Levodopa; Male; Mental Recall; Motor Skills; Oxidopamine; Psychomotor Performance; Rats; Rats, Sprague-Dawley; Reinforcement Schedule | 1997 |
Henoch-Schönlein syndrome induced by carbidopa/levodopa.
Topics: Aged; Antiparkinson Agents; Carbidopa; Drug Combinations; Humans; IgA Vasculitis; Levodopa; Male | 1997 |
Validation of a rodent model of Parkinson's Disease: evidence of a therapeutic window for oral Sinemet.
Topics: Administration, Oral; Animals; Antiparkinson Agents; Carbidopa; Dose-Response Relationship, Drug; Drug Combinations; Drug Evaluation, Preclinical; Dyskinesia, Drug-Induced; Levodopa; Male; Parkinson Disease, Secondary; Rats; Rats, Sprague-Dawley; Reproducibility of Results; Stereotyped Behavior | 1996 |
Somatic delivery of catecholamines in the striatum attenuate parkinsonian symptoms and widen the therapeutic window of oral sinemet in rats.
Topics: Administration, Oral; Animals; Antiparkinson Agents; Apomorphine; Behavior, Animal; Carbidopa; Cell Transplantation; Disease Models, Animal; Dopamine; Drug Combinations; Drug Synergism; Levodopa; Male; Movement Disorders; Neostriatum; Parkinson Disease, Secondary; PC12 Cells; Rats; Rats, Sprague-Dawley; Rotation | 1997 |
Glial cell line-derived neurotrophic factor-levodopa interactions and reduction of side effects in parkinsonian monkeys.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Carbidopa; Cerebral Ventricles; Dose-Response Relationship, Drug; Drug Combinations; Drug Interactions; Female; Glial Cell Line-Derived Neurotrophic Factor; Injections, Intraventricular; Levodopa; Macaca mulatta; Motor Activity; Nerve Growth Factors; Nerve Tissue Proteins; Neuroprotective Agents; Parkinson Disease, Secondary; Stereotyped Behavior | 1997 |
[The effect of low doses of nakom on the hormonal secretion of the hypothalamo-hypophyseal-adrenal system in patients with infantile cerebral palsy].
Topics: Adolescent; Adrenal Cortex Hormones; Carbidopa; Cerebral Palsy; Child; Dopamine Agonists; Dose-Response Relationship, Drug; Drug Combinations; Female; Humans; Hypothalamic Hormones; Hypothalamo-Hypophyseal System; Levodopa; Male; Pituitary Hormones; Pituitary-Adrenal System | 1996 |
Clinical implications of sustained dopaminergic stimulation.
Topics: Aged; Benserazide; Carbidopa; Delayed-Action Preparations; Dopamine Agonists; Drug Combinations; Dyskinesia, Drug-Induced; Follow-Up Studies; Humans; Levodopa; Lisuride; Parkinson Disease; Reaction Time | 1994 |
Treatment with AC pulsed electromagnetic fields improves the response to levodopa in Parkinson's disease.
Topics: Antiparkinson Agents; Carbidopa; Circadian Rhythm; Combined Modality Therapy; Drug Combinations; Electromagnetic Fields; Humans; Levodopa; Male; Middle Aged; Parkinson Disease | 1997 |
Square-wave action dystonia in Parkinson's disease.
Topics: Antiparkinson Agents; Carbidopa; Dominance, Cerebral; Drug Combinations; Dystonia; Globus Pallidus; Humans; Levodopa; Male; Middle Aged; Neurologic Examination; Parkinson Disease | 1998 |
Hyperprolactinemia, a tool in treatment control of tetrahydrobiopterin deficiency: endocrine studies in an affected girl.
Topics: Adolescent; Biopterins; Carbidopa; Delayed-Action Preparations; Drug Combinations; Female; Follicle Stimulating Hormone; Human Growth Hormone; Humans; Hydrocortisone; Hyperprolactinemia; Insulin; Levodopa; Luteinizing Hormone; Melatonin; Phenylketonurias; Phosphorus-Oxygen Lyases; Prolactin | 1998 |
The co-ordination and phasing of a bilateral prehension task. The influence of Parkinson's disease.
Topics: Aged; Antiparkinson Agents; Carbidopa; Drug Combinations; Female; Functional Laterality; Hand Strength; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Psychomotor Performance; Reaction Time; Reference Values | 1998 |
Highlights of the North American and European experiences.
Topics: Antiparkinson Agents; Benserazide; Benzophenones; Carbidopa; Catechol O-Methyltransferase Inhibitors; Dopamine Agents; Double-Blind Method; Drug Combinations; Drug Therapy, Combination; Enzyme Inhibitors; Europe; Humans; Levodopa; Nitrophenols; North America; Parkinson Disease; Randomized Controlled Trials as Topic; Tolcapone | 1998 |
[Vascular parkinsonism].
Topics: Antiparkinson Agents; Brain Ischemia; Carbidopa; Drug Combinations; Electroencephalography; Female; Follow-Up Studies; Humans; Levodopa; Magnetic Resonance Imaging; Middle Aged; Parkinson Disease, Secondary; Ultrasonography, Doppler, Transcranial | 1998 |
Quality of life and Parkinson's disease: the CR FIRST Study.
Topics: Antiparkinson Agents; Carbidopa; Delayed-Action Preparations; Drug Combinations; Emotions; Humans; Levodopa; Parkinson Disease; Quality of Life; Social Isolation; Treatment Outcome | 1998 |
Levodopa in human breast milk: clinical implications.
Topics: Adult; Antiparkinson Agents; Carbidopa; Drug Combinations; Female; Humans; Lactation; Levodopa; Milk, Human; Osmolar Concentration; Parkinson Disease | 1998 |
Orthostatic tremor: an electrophysiological analysis.
Topics: Aged; Antiparkinson Agents; Carbidopa; Central Nervous System Diseases; Clonazepam; Drug Combinations; Electroencephalography; Electromyography; Evoked Potentials; Female; Follow-Up Studies; Humans; Levodopa; Male; Middle Aged; Motor Neurons; Muscle, Skeletal; Neural Conduction; Posture; Treatment Outcome; Tremor | 1998 |
Effects of tolcapone, a catechol-O-methyltransferase inhibitor, and Sinemet on intestinal electrolyte and fluid transport in conscious dogs.
Topics: Animals; Benzophenones; Biological Transport; Carbidopa; Catechol O-Methyltransferase Inhibitors; Dogs; Dose-Response Relationship, Drug; Drug Combinations; Electrolytes; Enzyme Inhibitors; Female; Intestinal Mucosa; Intestinal Secretions; Intestines; Levodopa; Nitrophenols; Tolcapone | 1998 |
[Amoxapine-induced pseudopheochromocytoma. Apropos of a case].
Topics: Adrenal Gland Neoplasms; Adrenergic Uptake Inhibitors; Aged; Amoxapine; Antidepressive Agents, Second-Generation; Antiparkinson Agents; Carbidopa; Diagnosis, Differential; Drug Combinations; Drug Interactions; Epinephrine; Female; Humans; Levodopa; Norepinephrine; Pheochromocytoma | 1998 |
My doctor prescribed Sinemet for my restless legs and it was a catastrophe. Why did you recommend it in a recent article?
Topics: Carbidopa; Dopamine Agonists; Drug Combinations; Humans; Levodopa; Restless Legs Syndrome | 1998 |
Early-occurrence of manual motor blocks in Parkinson's disease: a quantitative assessment.
Topics: Aged; Antiparkinson Agents; Carbidopa; Drug Combinations; Female; Gait; Humans; Levodopa; Male; Middle Aged; Motor Skills; Neurologic Examination; Parkinson Disease; Psychomotor Disorders; Treatment Outcome | 1999 |
Internal globus pallidus discharge is nearly suppressed during levodopa-induced dyskinesias.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Carbidopa; Drug Combinations; Dyskinesia, Drug-Induced; Dyskinesias; Electrophysiology; Eye Movements; Globus Pallidus; Levodopa; Macaca mulatta; Motor Activity; Neurons; Parkinsonian Disorders | 1999 |
Successful orchestration of antiparkinsonian pharmacotherapy.
Topics: Aged; Aged, 80 and over; Antiparkinson Agents; Carbidopa; Comorbidity; Disease Progression; Drug Combinations; Dyskinesias; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Pharmacists | 1999 |
Neuroendocrine responses to levodopa in multiple system atrophy (MSA).
Topics: Adult; Aged; Antiparkinson Agents; Blood Glucose; Carbidopa; Dopamine; Drug Combinations; Female; Growth Hormone-Releasing Hormone; Human Growth Hormone; Humans; Hypothalamo-Hypophyseal System; Insulin-Like Growth Factor I; Levodopa; Male; Middle Aged; Multiple System Atrophy; Reference Values; Thyrotropin | 1999 |
Striatal D2 dopamine receptor status in Parkinson's disease: an [18F]dopa and [11C]raclopride PET study.
Topics: Adult; Aged; Antiparkinson Agents; Brain Mapping; Carbidopa; Carbon Radioisotopes; Corpus Striatum; Dihydroxyphenylalanine; Drug Combinations; Female; Fluorine Radioisotopes; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Raclopride; Receptors, Dopamine D2; Tomography, Emission-Computed | 1999 |
The reach-to-grasp movement in Parkinson's disease before and after dopaminergic medication.
Topics: Adult; Aged; Antiparkinson Agents; Basal Ganglia; Benserazide; Carbidopa; Drug Combinations; Female; Humans; Levodopa; Male; Middle Aged; Neuropsychological Tests; Parkinson Disease; Psychomotor Performance; Reaction Time; Receptors, Dopamine | 2000 |
The effect of pregnancy in Parkinson's disease.
Topics: Adult; Antiparkinson Agents; Carbidopa; Disease Progression; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Combinations; Female; Follow-Up Studies; Humans; Infant, Newborn; Levodopa; Neurologic Examination; Parkinson Disease; Pregnancy; Pregnancy Complications; Quality of Life | 2000 |
Convection-enhanced delivery of AAV vector in parkinsonian monkeys; in vivo detection of gene expression and restoration of dopaminergic function using pro-drug approach.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Aromatic-L-Amino-Acid Decarboxylases; Carbidopa; Catheterization; Caudate Nucleus; Cell Line; Dependovirus; Dopamine; Drug Administration Routes; Drug Combinations; Fluorine Radioisotopes; Genetic Therapy; Genetic Vectors; Levodopa; Macaca mulatta; Magnetic Resonance Imaging; Neurons; Parkinson Disease, Secondary; Prodrugs; Putamen; Tomography, Emission-Computed; Tyrosine; Tyrosine 3-Monooxygenase | 2000 |
Atypical presentation of dopa-responsive dystonia: generalized hypotonia and proximal weakness.
Topics: Carbidopa; Child; Chromosome Aberrations; Chromosome Disorders; Circadian Rhythm; Drug Combinations; Dystonic Disorders; Gait; Genes, Dominant; GTP Cyclohydrolase; Humans; Levodopa; Male; Muscle Hypotonia; Muscle Weakness; Neurologic Examination; Point Mutation; Treatment Outcome | 2001 |
Periodic limb movement disorder : a clinical and polysomnographic study.
Topics: Adult; Aged; Anticonvulsants; Carbamazepine; Carbidopa; Clonazepam; Drug Combinations; Drug Therapy, Combination; Humans; Levodopa; Male; Middle Aged; Nocturnal Myoclonus Syndrome; Polysomnography; Retreatment | 2001 |
Entacapone in restless legs syndrome.
Topics: Antiparkinson Agents; Carbidopa; Catechols; Delayed-Action Preparations; Drug Combinations; Drug Therapy, Combination; Female; Humans; Levodopa; Middle Aged; Neurologic Examination; Nitriles; Restless Legs Syndrome | 2002 |
Acute dopaminergic challenge tests to assess postural/kinetic tremor of different origin: a case report.
Topics: Aged; Antiparkinson Agents; Apomorphine; Carbidopa; Dose-Response Relationship, Drug; Drug Combinations; Electromyography; Essential Tremor; Female; Humans; Levodopa; Neurologic Examination; Parkinson Disease; Posture; Receptors, Dopamine | 2002 |
[The use of amantadine sulfate in combined therapy of Parkinson's disease].
Topics: Aged; Amantadine; Carbidopa; Dopamine Agents; Drug Combinations; Drug Therapy, Combination; Electromyography; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease | 2002 |
Effect of promoters on cellular immune response induced by recombinant fowlpox virus expressing multi-epitope polypeptides from HIV-1.
Topics: Animals; Carbidopa; CD8-Positive T-Lymphocytes; Cell Line; Chickens; Drug Combinations; Epitopes; Epitopes, T-Lymphocyte; Female; Fowlpox virus; Gene Expression Regulation, Viral; HIV Antigens; Immunity, Cellular; Levodopa; Mice; Peptides; Promoter Regions, Genetic; Recombinant Fusion Proteins; Recombination, Genetic; T-Lymphocytes, Cytotoxic; Vaccinia virus | 2002 |
Levodopa but not ropinirole induces an internalization of D1 dopamine receptors in parkinsonian rats.
Topics: Animals; Antiparkinson Agents; Carbidopa; Corpus Striatum; Cytoplasm; Drug Combinations; Indoles; Levodopa; Male; Microscopy, Immunoelectron; Neurons; Oxidopamine; Parkinsonian Disorders; Rats; Rats, Sprague-Dawley; Receptors, Dopamine D1; Synaptic Membranes; Tyrosine 3-Monooxygenase | 2002 |
Clozapine withdrawal symptoms in a Parkinson's disease patient.
Topics: Aged; Antipsychotic Agents; Carbidopa; Clozapine; Dose-Response Relationship, Drug; Drug Combinations; Drug Interactions; Drug Therapy, Combination; Hallucinations; Humans; Levodopa; Male; Neurologic Examination; Parkinson Disease; Parkinson Disease, Secondary; Substance Withdrawal Syndrome | 2002 |
Leg muscle strength is reduced in Parkinson's disease and relates to the ability to rise from a chair.
Topics: Antiparkinson Agents; Carbidopa; Disability Evaluation; Drug Combinations; Female; Hip; Humans; Knee; Levodopa; Lower Extremity; Male; Middle Aged; Muscle Weakness; Muscle, Skeletal; Parkinson Disease; Posture; Random Allocation; Severity of Illness Index | 2003 |
Parkinsonian speech disfluencies: effects of L-dopa-related fluctuations.
Topics: Aged; Aged, 80 and over; Antiparkinson Agents; Basal Ganglia; Carbidopa; Dopamine; Drug Combinations; Female; Humans; Levodopa; Male; Middle Aged; Neurologic Examination; Parkinson Disease; Reading; Speech Production Measurement; Stuttering | 2003 |
L-DOPA biotransformation: correlations of dosage, erythrocyte catechol O-methyltransferase and platelet SULT1A3 activities with metabolic pathways in Parkinsonian patients.
Topics: Adenosine Diphosphate; Aged; Arylsulfotransferase; Biotransformation; Blood Platelets; Carbidopa; Catechol O-Methyltransferase; Dose-Response Relationship, Drug; Drug Combinations; Erythrocytes; Female; Humans; Levodopa; Male; Methylation; Middle Aged; Parkinson Disease; S-Adenosylmethionine; Sulfates | 2003 |
Split spinal cord malformation in an elderly patient: case report.
Topics: Aged; Anticonvulsants; Antiparkinson Agents; Carbidopa; Clonazepam; Drug Combinations; Drug Therapy, Combination; Female; Humans; Levodopa; Low Back Pain; Magnetic Resonance Imaging; Movement Disorders; Spinal Dysraphism; Tomography, X-Ray Computed | 2004 |
Exercise-induced dystonia as a preceding symptom of familial Parkinson's disease.
Topics: Aged; Antiparkinson Agents; Carbidopa; Disease Progression; DNA Mutational Analysis; Drug Combinations; Dystonic Disorders; Exercise; Female; Genotype; Humans; Levodopa; Male; Middle Aged; Neurologic Examination; Parkinsonian Disorders; Phenotype; Semen; Ubiquitin-Protein Ligases; Videotape Recording | 2004 |
Drug adherence in Parkinson's disease.
Topics: Aged; Antiparkinson Agents; Carbidopa; Chronic Disease; Drug Administration Schedule; Drug Combinations; Drug Monitoring; Female; Humans; Levodopa; Male; Medication Systems; Parkinson Disease; Patient Compliance; Surveys and Questionnaires | 2004 |
Severe multivalvular heart disease: a new complication of the ergot derivative dopamine agonists.
Topics: Adult; Aged; Cabergoline; Carbidopa; Dopamine Agonists; Drug Combinations; Echocardiography, Transesophageal; Ergolines; Ergot Alkaloids; Female; Heart Valve Diseases; Humans; Levodopa; Male; Parkinson Disease; Pergolide | 2004 |
Markedly asymmetrical parkinsonism as a leading feature of adult-onset Huntington's disease.
Topics: Adult; Alleles; Antiparkinson Agents; Carbidopa; Cognition Disorders; Diagnosis, Differential; Drug Combinations; Humans; Huntington Disease; Levodopa; Male; Neuropsychological Tests; Parkinsonian Disorders; Pedigree; Severity of Illness Index | 2004 |
An intermittent, controlled-rate, slow progressive degeneration model of Parkinson's disease: antiparkinson effects of Sinemet and protective effects of methylphenidate.
Topics: Animals; Antiparkinson Agents; Behavior, Animal; Carbidopa; Cell Count; Differential Threshold; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Combinations; Drug Interactions; Drug Therapy, Combination; Immunohistochemistry; Levodopa; Male; Methylphenidate; Motor Activity; Movement; Nerve Degeneration; Neurons; Oxidopamine; Parkinson Disease; Parkinson Disease, Secondary; Rats; Rats, Long-Evans; Rotarod Performance Test; Substantia Nigra; Tyrosine 3-Monooxygenase | 2005 |
[18F]FDOPA PET and clinical features in parkinsonism due to manganism.
Topics: Adult; Antiparkinson Agents; Brain; Carbidopa; Drug Combinations; Female; Fluorodeoxyglucose F18; Gait; Humans; Levodopa; Magnetic Resonance Imaging; Manganese Poisoning; Middle Aged; Parkinson Disease; Positron-Emission Tomography; Radiopharmaceuticals | 2005 |
Parcopa: a rapidly dissolving formulation of carbidopa/levodopa.
Topics: Administration, Oral; Antiparkinson Agents; Carbidopa; Dose-Response Relationship, Drug; Drug Combinations; Fees, Pharmaceutical; Humans; Levodopa; Parkinson Disease | 2005 |
Signal transduction pathways of nitric oxide release in primary microglial culture challenged with gram-positive bacterial constituent, lipoteichoic acid.
Topics: Animals; Antibodies; Blotting, Western; Carbidopa; Cells, Cultured; Dose-Response Relationship, Drug; Drug Combinations; Eye Proteins; Fluorescent Antibody Technique; gamma-Synuclein; Gene Expression Regulation; I-kappa B Proteins; Indoles; Lectins; Levodopa; Lipopolysaccharide Receptors; Lipopolysaccharides; Microglia; Nerve Tissue Proteins; Nitric Oxide; Nitric Oxide Synthase; Nitric Oxide Synthase Type II; Nitrites; p38 Mitogen-Activated Protein Kinases; Rats; Rats, Wistar; Signal Transduction; Teichoic Acids; Time Factors | 2005 |
Psychiatric sequelae of Parkinson disease: a case report.
Topics: Antiparkinson Agents; Cabergoline; Carbidopa; Compulsive Behavior; Drug Combinations; Ergolines; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Selective Serotonin Reuptake Inhibitors; Severity of Illness Index; Sex Offenses | 2006 |
Inhibition of catechol-O-methyltransferase contributes to more stable levodopa plasma levels.
Topics: Adult; Aged; Antiparkinson Agents; Carbidopa; Catechol O-Methyltransferase Inhibitors; Catechols; Dopamine Agonists; Drug Combinations; Drug Therapy, Combination; Female; Humans; Levodopa; Male; Middle Aged; Nitriles; Parkinson Disease | 2006 |
Augmentation of artistic productivity in Parkinson's disease.
Topics: Antiparkinson Agents; Art; Carbidopa; Creativity; Dopamine Agents; Dose-Response Relationship, Drug; Drug Combinations; Drug Therapy, Combination; Frontal Lobe; Humans; Indoles; Levodopa; Male; Middle Aged; Parkinson Disease; Poetry as Topic | 2006 |
[Dopamine receptors agonists (mirapex) in the treatment of Parkinson's disease].
Topics: Anxiety; Benzothiazoles; Carbidopa; Delayed-Action Preparations; Depression; Dopamine Agonists; Drug Combinations; Drug Therapy, Combination; Follow-Up Studies; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Pramipexole; Receptors, Dopamine D1; Thiazoles; Treatment Outcome | 2006 |
Levodopa can worsen tremor associated with dystonia.
Topics: Aged; Antiparkinson Agents; Carbidopa; Diagnostic Errors; Drug Combinations; Dystonia; Female; Humans; Levodopa; Neurologic Examination; Parkinsonian Disorders; Psychomotor Performance; Tremor | 2006 |
The effect of levodopa or levodopa-carbidopa (sinemet) on fracture healing.
Topics: Animals; Carbidopa; Drug Combinations; Female; Fracture Healing; Levodopa; Rats; Rats, Sprague-Dawley | 2006 |
Skin rash associated with Sinemet does not equal levodopa allergy.
Topics: Aged; Antiparkinson Agents; Carbidopa; Coloring Agents; Drug Combinations; Drug Eruptions; Drug Hypersensitivity; Drug Therapy, Combination; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Skin; Withholding Treatment | 2007 |
I couldn't sleep at all last night.
Topics: Antiparkinson Agents; Carbidopa; Drug Combinations; Female; Humans; Levodopa; Middle Aged; Restless Legs Syndrome; Sleep Initiation and Maintenance Disorders; Treatment Outcome | 2005 |
Acute overdose with controlled-release levodopa-carbidopa.
Topics: Antiparkinson Agents; Carbidopa; Delayed-Action Preparations; Dopamine; Drug Combinations; Drug Overdose; Epinephrine; Humans; Kinetics; Levodopa; Male; Middle Aged; Norepinephrine; Psychomotor Agitation; Psychoses, Substance-Induced; Tachycardia | 2008 |
Dopa-responsive dystonia presenting as delayed and awkward gait.
Topics: Carbidopa; Child, Preschool; Dopamine Agonists; Drug Combinations; Dystonic Disorders; Gait Disorders, Neurologic; GTP Cyclohydrolase; Humans; Levodopa; Male; Mutation; Pedigree | 2008 |
Sildenafil induced choreoathetosis in men with Parkinson's disease.
Topics: Antiparkinson Agents; Athetosis; Carbidopa; Chorea; Drug Combinations; Drug Interactions; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Phosphodiesterase Inhibitors; Piperazines; Purines; Sildenafil Citrate; Sulfones | 2010 |
Levodopa-responsive parkinsonism after aneurysmal subarachnoid hemorrhage.
Topics: Adult; Carbidopa; Drug Combinations; Female; Humans; Levodopa; Parkinson Disease; Subarachnoid Hemorrhage; Substantia Nigra | 2010 |
Effect of S-COMT deficiency on behavior and extracellular brain dopamine concentrations in mice.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Behavior, Animal; Brain; Carbidopa; Catechol O-Methyltransferase; Dopamine; Drug Combinations; Extracellular Space; Female; Levodopa; Male; Methylation; Mice; Mice, Inbred C57BL; Mice, Knockout; Microdialysis; Mutation; Phenotype; Sensory Gating; Sex Factors; Social Dominance | 2010 |
Simultaneous voltammetric determination of levodopa, carbidopa and benserazide in pharmaceuticals using multivariate calibration.
Topics: Algorithms; Benserazide; Calibration; Carbidopa; Dopamine Agents; Drug Combinations; Electrochemical Techniques; Electrodes; Excipients; Levodopa | 2010 |
Clinical and biochemical characterization of patients with early infantile onset of autosomal recessive GTP cyclohydrolase I deficiency without hyperphenylalaninemia.
Topics: Antiparkinson Agents; Carbidopa; Child, Preschool; Deficiency Diseases; Drug Combinations; Female; Follow-Up Studies; GTP Cyclohydrolase; Humans; Infant; Levodopa; Male; Mutation; Neurotransmitter Agents; Phenylketonurias | 2011 |
Delayed-onset parkinsonian tremor following a mesencephalic lesion.
Topics: Antiparkinson Agents; Carbidopa; Dopamine; Drug Combinations; Electromyography; Female; Humans; Levodopa; Magnetic Resonance Imaging; Mesencephalon; Middle Aged; Neurologic Examination; Parkinson Disease; Tegmentum Mesencephali; Tremor | 2011 |
Transfusion of defibrinated blood in P.O.W. camps at Chungkai and Nakom Paton, Thailand.
Topics: Blood Transfusion; Carbidopa; Drug Combinations; Humans; Levodopa; Military Medicine; Military Personnel; Prisoners; Prisoners of War; Thailand; Warfare | 1946 |
Reducing uncertainty in value-based pricing using evidence development agreements: the case of continuous intraduodenal infusion of levodopa/carbidopa (Duodopa®) in Sweden.
Topics: Antiparkinson Agents; Carbidopa; Drug Administration Routes; Drug Combinations; Drug Costs; Duodenum; Government Agencies; Humans; Levodopa; Models, Economic; Parkinson Disease; Reimbursement Mechanisms; Sweden; Treatment Outcome | 2010 |
Parkinson disease: adjunctive entacapone therapy increases risk of dyskinesia.
Topics: Antiparkinson Agents; Carbidopa; Catechols; Corpus Striatum; Dopamine; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Combinations; Drug Therapy, Combination; Humans; Levodopa; Neurologic Examination; Nitriles; Parkinson Disease; Randomized Controlled Trials as Topic; Receptors, Dopamine | 2010 |
A tale of two tauopathies.
Topics: Aged; Carbidopa; Dopamine Agonists; Drug Combinations; Humans; Levodopa; Magnetic Resonance Imaging; Male; Tauopathies | 2011 |
Hemiparkinsonism-hemiatrophy syndrome.
Topics: Adult; Antiparkinson Agents; Atrophy; Benzothiazoles; Biperiden; Carbidopa; Cerebral Cortex; Cerebral Ventricles; Dopamine Agonists; Drug Combinations; Humans; Indans; Levodopa; Magnetic Resonance Imaging; Male; Monoamine Oxidase Inhibitors; Parkinson Disease, Secondary; Pramipexole; Tomography, X-Ray Computed | 2011 |
Deletion in the tyrosine hydroxylase gene in a patient with a mild phenotype.
Topics: Antiparkinson Agents; Carbidopa; DNA Mutational Analysis; Drug Combinations; Female; Homovanillic Acid; Humans; Infant; Levodopa; Movement Disorders; Phenotype; Sequence Deletion; Tyrosine 3-Monooxygenase; Video Recording | 2011 |
Comparison of subthalamic nucleus deep brain stimulation and Duodopa in the treatment of advanced Parkinson's disease.
Topics: Aged; Antiparkinson Agents; Carbidopa; Deep Brain Stimulation; Disability Evaluation; Drug Combinations; Female; Follow-Up Studies; Humans; Levodopa; Male; Middle Aged; Neuropsychological Tests; Parkinson Disease; Retrospective Studies; Severity of Illness Index; Statistics, Nonparametric; Subthalamic Nucleus; Treatment Outcome | 2011 |
Severe weight loss in a young Parkinson's disease patient: a multidisciplinary approach to diagnosis and treatment.
Topics: Antiparkinson Agents; Carbidopa; Caregivers; Disease Progression; Domestic Violence; Drug Combinations; Eating; Female; Humans; Hypertrichosis; Levodopa; Middle Aged; Nutritional Status; Parkinson Disease; Weight Loss | 2011 |
Levodopa-induced breathing, cognitive and behavioral changes in Parkinson's disease.
Topics: Aged; Antiparkinson Agents; Carbidopa; Cognition Disorders; Drug Combinations; Humans; Levodopa; Male; Mental Disorders; Parkinson Disease; Respiration Disorders | 2011 |
Clinical vignettes in Parkinson's disease: a collection of unusual medication-induced hallucinations, delusions, and compulsive behaviours.
Topics: Adult; Aged; Aged, 80 and over; Antiparkinson Agents; Carbidopa; Compulsive Behavior; Delusions; Drug Combinations; Female; Hallucinations; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Psychiatric Status Rating Scales | 2011 |
Executive control in Parkinson's disease: effects of dopaminergic medication and deep brain stimulation on anti-cue keypress performance.
Topics: Aged; Benserazide; Benzothiazoles; Carbidopa; Cues; Deep Brain Stimulation; Dopamine Agents; Drug Combinations; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Pergolide; Pramipexole; Psychomotor Performance; Reaction Time; Subthalamic Nucleus | 2011 |
Parkinsonism and dropped head: dystonia, myopathy or both?
Topics: Aged; Carbidopa; Drug Combinations; Dystonic Disorders; Electromyography; Female; Head Movements; Humans; Levodopa; Male; Middle Aged; Multiple System Atrophy; Muscular Diseases; Parkinsonian Disorders; Retrospective Studies | 2012 |
Duodopa infusion treatment: a point of view from the gastroenterologist.
Topics: Adult; Aged; Antiparkinson Agents; Carbidopa; Drug Combinations; Female; Gastroenterology; Gels; Humans; Infusions, Intravenous; Levodopa; Male; Middle Aged; Parkinson Disease | 2011 |
Lees' syndrome: a case series.
Topics: Adult; Aged; Antiparkinson Agents; Carbidopa; Dopamine; Dopamine Agents; Drug Combinations; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Syndrome | 2011 |
Parkinson's disease patients cannot get their dopamine replacement: the 8-Sinemet limit.
Topics: Carbidopa; Dopamine; Dopamine Agonists; Drug Combinations; Humans; Levodopa; Parkinson Disease | 2012 |
Nasogastric medication for perioperative Parkinson's rigidity during anaesthesia emergence.
Topics: Amantadine; Anesthesia; Anesthesia Recovery Period; Anesthesia, General; Antiparkinson Agents; Carbidopa; Drug Combinations; Fracture Fixation, Internal; Fractures, Bone; Humans; Humerus; Intraoperative Awareness; Intubation, Gastrointestinal; Levodopa; Male; Middle Aged; Muscle Rigidity; Parkinson Disease; Perioperative Care | 2011 |
Duodenal levodopa/carbidopa infusion therapy in patients with advanced Parkinson's disease leads to improvement in caregivers' stress and burden.
Topics: Activities of Daily Living; Adult; Aged; Antiparkinson Agents; Carbidopa; Caregivers; Drug Combinations; Duodenostomy; Female; Humans; Infusion Pumps; Levodopa; Male; Middle Aged; Parkinson Disease; Prospective Studies; Quality of Life; Spouses; Stress, Psychological; Surveys and Questionnaires | 2012 |
Burning mouth syndrome in Parkinson's disease: dopamine as cure or cause?
Topics: Aged; Antiparkinson Agents; Benzothiazoles; Burning Mouth Syndrome; Carbidopa; Dopamine; Dopamine Agonists; Drug Combinations; Female; Humans; Levodopa; Parkinson Disease; Pramipexole | 2012 |
Levodopa/carbidopa intestinal gel infusion long-term therapy in advanced Parkinson's disease.
Topics: Antiparkinson Agents; Carbidopa; Drug Combinations; Female; Gels; Humans; Infusions, Parenteral; Intestines; Levodopa; Male; Middle Aged; Parkinson Disease; Retrospective Studies | 2012 |
Finasteride attenuates pathological gambling in patients with Parkinson disease.
Topics: 5-alpha Reductase Inhibitors; Aged; Antiparkinson Agents; Benzothiazoles; Cabergoline; Carbidopa; Catechols; Drug Combinations; Drug Monitoring; Drug Therapy, Combination; Ergolines; Finasteride; Gambling; Humans; Levodopa; Male; Middle Aged; Nitriles; Parkinson Disease; Pramipexole; Treatment Outcome; Video Games | 2012 |
A clinically silent, but severe, duodenal complication of duodopa infusion.
Topics: Aged; Bezoars; Carbidopa; Drug Combinations; Duodenum; Humans; Infusion Pumps, Implantable; Levodopa; Male | 2012 |
Dopamine dysregulation syndrome including mania related to coadministration of droxidopa.
Topics: Aggression; Antiparkinson Agents; Behavior, Addictive; Benzothiazoles; Bipolar Disorder; Carbidopa; Droxidopa; Drug Combinations; Drug Monitoring; Drug Therapy, Combination; Humans; Levodopa; Male; Middle Aged; Neurotoxicity Syndromes; Parkinson Disease; Pramipexole; Treatment Outcome | 2012 |
Cysteine decrease following acute Levodopa intake in patients with Parkinson's disease.
Topics: Administration, Oral; Antiparkinson Agents; Aromatic Amino Acid Decarboxylase Inhibitors; Carbidopa; Cysteine; Drug Combinations; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease | 2012 |
'You never told me I would turn into a gambler': a first person account of dopamine agonist--induced gambling addiction in a patient with restless legs syndrome.
Topics: Cabergoline; Carbidopa; Cognitive Behavioral Therapy; Dopamine Agonists; Drug Combinations; Ergolines; Gambling; Humans; Indoles; Levodopa; Male; Middle Aged; Restless Legs Syndrome; Tetrahydronaphthalenes; Thiophenes | 2011 |
Drugs for treating Parkinson disease.
Topics: Antiparkinson Agents; Apomorphine; Carbidopa; Catechols; Drug Combinations; Drugs, Generic; Humans; Indans; Levodopa; Nitriles; Parkinson Disease | 2012 |
Long-term duodenal levodopa infusion in Parkinson's disease: a 3-year motor and cognitive follow-up study.
Topics: Adult; Aged; Antiparkinson Agents; Carbidopa; Cognition Disorders; Disability Evaluation; Drug Combinations; Duodenum; Female; Humans; Infusions, Parenteral; Levodopa; Longitudinal Studies; Male; Middle Aged; Motor Activity; Neuropsychological Tests; Parkinson Disease; Quality of Life; Statistics, Nonparametric | 2013 |
Refractory epileptic seizures due to vitamin B6 deficiency in a patient with Parkinson's disease under duodopa® therapy.
Topics: Aged; Carbidopa; Drug Combinations; Female; Humans; Levodopa; Parkinson Disease; Seizures; Treatment Outcome; Vitamin B 6; Vitamin B 6 Deficiency | 2013 |
DYT16: the original cases.
Topics: Adolescent; Adult; Age of Onset; Anti-Dyskinesia Agents; Antiparkinson Agents; Baclofen; Biperiden; Botulinum Toxins; Carbidopa; Child; Child, Preschool; Cholinergic Antagonists; Drug Combinations; Drug Resistance; Dystonia; Dystonic Disorders; Female; Humans; Levodopa; Male; Middle Aged; Muscle Relaxants, Central; Mutation; Parkinsonian Disorders; Pedigree; Phenotype; RNA-Binding Proteins; Speech Disorders; Trihexyphenidyl; Young Adult | 2012 |
Valproate as a treatment for dopamine dysregulation syndrome (DDS) in Parkinson's disease.
Topics: Aged; Aged, 80 and over; Akathisia, Drug-Induced; Anticonvulsants; Carbidopa; Disruptive, Impulse Control, and Conduct Disorders; Dopamine Agents; Drug Combinations; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Valproic Acid | 2013 |
Isolated extra pontine myelinolysis presenting as acute onset parkinsonism.
Topics: Acute Disease; Antiparkinson Agents; Carbidopa; Drug Combinations; Female; Humans; Hyponatremia; Levodopa; Magnetic Resonance Imaging; Middle Aged; Myelinolysis, Central Pontine; Parkinson Disease, Secondary; Saline Solution, Hypertonic | 2012 |
Assuring the quality of next-generation sequencing in clinical laboratory practice.
Topics: Carbidopa; Chromosome Mapping; Drug Combinations; Levodopa; Practice Guidelines as Topic; Quality Assurance, Health Care; Sequence Analysis, DNA; United States | 2012 |
Severe gastrointestinal complications in patients with levodopa/carbidopa intestinal gel infusion.
Topics: Aged; Antiparkinson Agents; Carbidopa; Drug Combinations; Female; Gastrointestinal Diseases; Humans; Infusions, Parenteral; Levodopa; Male; Middle Aged; Parkinson Disease | 2012 |
Pharmacokinetics of levodopa, carbidopa, and 3-O-methyldopa following 16-hour jejunal infusion of levodopa-carbidopa intestinal gel in advanced Parkinson's disease patients.
Topics: Aged; Antiparkinson Agents; Biotransformation; Carbidopa; Chemistry, Pharmaceutical; Drug Combinations; Female; Gels; Germany; Humans; Infusion Pumps; Intestinal Absorption; Intubation, Gastrointestinal; Jejunum; Levodopa; Male; Middle Aged; Parkinson Disease; Sweden; Tyrosine | 2013 |
Perioperative medication withholding in patients with Parkinson's disease: a retrospective electronic health records review.
Topics: Aged; Antiparkinson Agents; Carbidopa; Comorbidity; Drug Combinations; Electronic Health Records; Female; Half-Life; Humans; Levodopa; Male; Parkinson Disease; Retrospective Studies; Surgical Procedures, Operative | 2013 |
Extended-release carbidopa-levodopa in Parkinson's disease.
Topics: Carbidopa; Drug Combinations; Female; Humans; Levodopa; Male; Motor Skills Disorders; Parkinson Disease | 2013 |
Mydriasis in a Parkinson disease patient on low-dose carbidopa/levodopa.
Topics: Antiparkinson Agents; Carbidopa; Drug Combinations; Female; Humans; Levodopa; Middle Aged; Mydriasis; Parkinson Disease | 2013 |
Heterotopic ossification following distal radius fractures in a patient with Parkinson disease treated with levodopa-carbidopa.
Topics: Antiparkinson Agents; Carbidopa; Causality; Drug Combinations; Fracture Fixation, Internal; Humans; Levodopa; Male; Middle Aged; Ossification, Heterotopic; Parkinson Disease; Radiography; Radius Fractures | 2013 |
Guillain-Barre/CIDP-like neuropathy in two parkinsonian patients following intestinal levodopa/carbidopa treatment.
Topics: Aged; Antiparkinson Agents; Carbidopa; Drug Combinations; Female; Guillain-Barre Syndrome; Humans; Levodopa; Parkinson Disease; Polyradiculoneuropathy, Chronic Inflammatory Demyelinating | 2014 |
Brief case report: dopa-responsive dystonia.
Topics: Adult; Carbidopa; Dopamine Agonists; Drug Combinations; Dystonia; Female; Humans; Insurance, Life; Levodopa | 2013 |
Drugs for Parkinson's disease.
Topics: Antiparkinson Agents; Carbidopa; Catechol O-Methyltransferase Inhibitors; Cholinergic Antagonists; Deep Brain Stimulation; Dopamine Agonists; Drug Combinations; Drug Therapy, Combination; Humans; Levodopa; Parkinson Disease | 2013 |
Dopamine receptor dysregulation in hippocampus of aged rats underlies chronic pulsatile L-Dopa treatment induced cognitive and emotional alterations.
Topics: Age Factors; Anhedonia; Animals; Antiparkinson Agents; Behavior, Animal; Carbidopa; Cognition Disorders; Drug Combinations; Emotions; Hippocampus; Levodopa; Male; Mental Disorders; Motor Activity; Neurons; Rats, Wistar; Receptors, Dopamine; Receptors, Dopamine D2; Receptors, Dopamine D3; Receptors, Dopamine D5; Spatial Learning | 2014 |
Levodopa/carbidopa intestinal gel infusion in advanced Parkinson's disease: a 7-year experience.
Topics: Aged; Aged, 80 and over; Antiparkinson Agents; Carbidopa; Drug Combinations; Female; Gels; Humans; Infusions, Parenteral; Levodopa; Male; Middle Aged; Parkinson Disease; Treatment Outcome | 2014 |
Deleterious cognitive and motoric effects of haloperidol in an adolescent with cerebral palsy: a case report.
Topics: Adolescent; Amantadine; Carbidopa; Cerebral Palsy; Cognition Disorders; Dopamine Agonists; Dopamine Antagonists; Drug Combinations; Haloperidol; Humans; Levodopa; Male; Psychomotor Disorders | 2013 |
Intestinal levodopa infusion: the Belgian experience.
Topics: Aged; Antiparkinson Agents; Belgium; Carbidopa; Drug Combinations; Female; Follow-Up Studies; Gels; Humans; Intestines; Levodopa; Male; Middle Aged; Parkinson Disease; Patient Satisfaction; Treatment Outcome | 2014 |
Emerging issues on selection criteria of levodopa carbidopa infusion therapy: considerations on outcome of 28 consecutive patients.
Topics: Aged; Amantadine; Antiparkinson Agents; Apomorphine; Carbidopa; Caregivers; Drug Administration Routes; Drug Combinations; Drug Delivery Systems; Female; Follow-Up Studies; Humans; Levodopa; Male; Mental Status Schedule; Middle Aged; Parkinson Disease; Patient Selection; Retrospective Studies; Severity of Illness Index; Statistics, Nonparametric; Surveys and Questionnaires; Treatment Outcome | 2014 |
GCH1 heterozygous mutation identified by whole-exome sequencing as a treatable condition in a patient presenting with progressive spastic paraplegia.
Topics: Adult; Carbidopa; Codon, Nonsense; Dopamine Agonists; Drug Combinations; Dystonic Disorders; Exome; Female; GTP Cyclohydrolase; Heterozygote; Humans; Levodopa; Phenotype; Sequence Analysis, DNA; Spastic Paraplegia, Hereditary; Treatment Outcome | 2014 |
Do adipose tissue-derived mesenchymal stem cells ameliorate Parkinson's disease in rat model?
Topics: Adipose Tissue; Amino Acids; Animals; Antigens, CD; Brain; Brain-Derived Neurotrophic Factor; Carbidopa; Cell Differentiation; Cells, Cultured; Chemokine CCL2; Disease Models, Animal; Drug Combinations; Female; Gene Expression; Genes, sry; Levodopa; Male; Mesenchymal Stem Cell Transplantation; Mesenchymal Stem Cells; Ovariectomy; Parkinson Disease; Rats, Sprague-Dawley; Rotenone; Transforming Growth Factor beta; Tyrosine 3-Monooxygenase | 2014 |
Subacute peripheral neuropathy under duodopa therapy without cobalamin deficiency and despite supplementation.
Topics: Aged; Antiparkinson Agents; Carbidopa; Drug Combinations; Humans; Infusions, Parenteral; Jejunum; Levodopa; Male; Parkinson Disease; Polyneuropathies; Vitamin B 12 | 2014 |
Effects of 6-hydroxydopamine exposure on motor activity and biochemical expression in zebrafish (Danio rerio) larvae.
Topics: Animals; Antiparkinson Agents; Anxiety; Biomarkers; Blotting, Western; Carbidopa; Disease Models, Animal; Drug Combinations; Levodopa; Minocycline; Motor Activity; Oxidopamine; Parkinsonian Disorders; Real-Time Polymerase Chain Reaction; Sympatholytics; Vitamin E; Zebrafish; Zebrafish Proteins | 2014 |
Gastric bezoar complication of Duodopa(®) therapy in Parkinson's disease, treated with Coca-Cola(®).
Topics: Aged; Antiparkinson Agents; Bezoars; Carbidopa; Carbonated Beverages; Drug Combinations; Humans; Levodopa; Male; Parkinson Disease; Stomach | 2014 |
Successful treatment of dopamine dysregulation syndrome with valproic acid.
Topics: Antimanic Agents; Carbidopa; Compulsive Behavior; Dopamine Agonists; Drug Combinations; Female; Humans; Levodopa; Middle Aged; Parkinson Disease; Valproic Acid | 2014 |
Teaching NeuroImages: Pisa syndrome in Parkinson disease.
Topics: Aged; Carbidopa; Drug Combinations; Dystonia; Humans; Indoles; Levodopa; Male; Parkinson Disease; Posture; Scoliosis | 2014 |
Serotonin syndrome in stroke patients.
Topics: Carbidopa; Dopamine Agonists; Drug Combinations; Humans; Indoles; Levodopa; Male; Middle Aged; Serotonin Syndrome; Stroke | 2015 |
Parkinsonism after external ventricular drainage in a patient with intraventricular hemorrhage.
Topics: Activities of Daily Living; Carbidopa; Caudate Nucleus; Cerebral Ventricles; Drainage; Drug Combinations; Female; Humans; Intracranial Hemorrhages; Levodopa; Magnetic Resonance Imaging; Middle Aged; Parkinson Disease, Secondary; Positron-Emission Tomography; Predictive Value of Tests; Putamen; Radiopharmaceuticals; Recovery of Function; Time Factors; Tomography, X-Ray Computed; Treatment Outcome; Tropanes; Ventriculoperitoneal Shunt | 2015 |
24 h Levodopa-carbidopa intestinal gel may reduce falls and "unresponsive" freezing of gait in Parkinson's disease.
Topics: Accidental Falls; Aged; Antiparkinson Agents; Carbidopa; Drug Combinations; Female; Gait Disorders, Neurologic; Gels; Humans; Jejunum; Levodopa; Male; Middle Aged; Parkinson Disease; Prospective Studies; Time Factors | 2015 |
Dyskinesias during levodopa-carbidopa intestinal gel (LCIG) infusion: Management inclinical practice.
Topics: Antiparkinson Agents; Carbidopa; Drug Combinations; Dyskinesia, Drug-Induced; Gels; Humans; Jejunum; Levodopa; Parkinson Disease | 2015 |
Making sense: Dopamine activates conscious self-monitoring through medial prefrontal cortex.
Topics: Adult; Awareness; Brain Waves; Carbidopa; Consciousness; Dopamine; Dopamine Agonists; Double-Blind Method; Drug Combinations; Humans; Judgment; Levodopa; Magnetoencephalography; Male; Metacognition; Neuropsychological Tests; Prefrontal Cortex; Self Concept; Young Adult | 2015 |
Initiating intrajejunal infusion of levodopa/carbidopa intestinal gel: an outpatient model.
Topics: Carbidopa; Drug Combinations; Gels; Humans; Jejunum; Levodopa; Outpatients; Parkinson Disease | 2015 |
New and emerging treatments for Parkinson disease.
Topics: Antiparkinson Agents; Carbidopa; Clinical Trials as Topic; Deep Brain Stimulation; Dopamine Agonists; Drug Combinations; Drug Therapy, Combination; Evidence-Based Medicine; Humans; Levodopa; Monoamine Oxidase Inhibitors; Parkinson Disease; Quality of Life; Randomized Controlled Trials as Topic; Treatment Outcome | 2015 |
Knotting of Duodopa® duodenal infusion system.
Topics: Aged; Antiparkinson Agents; Carbidopa; Catheterization; Catheters; Drug Combinations; Duodenum; Equipment Failure; Female; Humans; Infusion Pumps; Levodopa; Male; Middle Aged; Parkinson Disease | 2015 |
Dopamine agonist withdrawal syndrome (DAWS) symptoms in Parkinson's disease patients treated with levodopa-carbidopa intestinal gel infusion.
Topics: Aged; Anhedonia; Apathy; Carbidopa; Dopamine Agonists; Drug Combinations; Female; Gels; Humans; Infusions, Parenteral; Levodopa; Male; Middle Aged; Parkinson Disease; Substance Withdrawal Syndrome | 2015 |
Depression, anxiety and non-motor symptoms on initiation of intrajejunal levodopa/carbidopa therapy.
Topics: Adult; Aged; Antiparkinson Agents; Anxiety; Carbidopa; Depression; Drug Combinations; Female; Humans; Jejunum; Levodopa; Male; Middle Aged; Parkinson Disease; Prospective Studies; Psychiatric Status Rating Scales; Time Factors | 2016 |
Electroencephalographic lateralization, clinical correlates and pharmacological response in untreated Parkinson's disease.
Topics: Aged; Alpha Rhythm; Antiparkinson Agents; Beta Rhythm; Carbidopa; Drug Combinations; Electroencephalography; Female; Frontal Lobe; Functional Laterality; Humans; Levodopa; Male; Middle Aged; Occipital Lobe; Parkinson Disease; Severity of Illness Index | 2015 |
Dissociative disorder manifesting for underlying adolescent hemi-parkinsonism: New chronology for old mummies.
Topics: Adult; Age of Onset; Antiparkinson Agents; Carbidopa; Dissociative Disorders; Drug Combinations; Female; Humans; Levodopa; Parkinsonian Disorders; Young Adult | 2015 |
Dopamine dysregulation syndrome and punding in levodopa-carbidopa intestinal gel (LCIG) infusion: A serious but preventable complication.
Topics: Aged; Antiparkinson Agents; Carbidopa; Drug Combinations; Drug Delivery Systems; Humans; Infusions, Parenteral; Levodopa; Male; Parkinson Disease | 2015 |
Delayed chorea after recovery from severe akinetic-rigid parkinsonism caused by extrapontine myelinolysis.
Topics: Carbidopa; Chorea; Disease Progression; Dopamine Agonists; Drug Combinations; Humans; Hypokinesia; Levodopa; Male; Middle Aged; Muscle Rigidity; Myelinolysis, Central Pontine; Parkinsonian Disorders | 2015 |
Continuous duodenal levodopa infusion in a patient with Crohn's disease and small bowel surgery - Case report.
Topics: Antiparkinson Agents; Carbidopa; Crohn Disease; Drug Combinations; Duodenum; Humans; Intestine, Small; Levodopa; Male; Middle Aged; Parkinson Disease | 2015 |
Dopamine dysregulation syndrome in Parkinson's disease patients on levodopa-carbidopa intestinal gel.
Topics: Behavior, Addictive; Carbidopa; Dopamine Agonists; Drug Combinations; Humans; Levodopa; Parkinson Disease; Syndrome | 2015 |
Peripheral neuropathy associated with levodopa-carbidopa intestinal infusion: a long-term prospective assessment.
Topics: Aged; Antiparkinson Agents; Carbidopa; Drug Combinations; Female; Gels; Humans; Infusions, Parenteral; Levodopa; Male; Middle Aged; Parkinson Disease; Peripheral Nervous System Diseases; Prospective Studies | 2016 |
Levodopa-Carbidopa Intestinal Gel Infusion Therapy in Advanced Parkinson's Disease: Single Middle Eastern Center Experience.
Topics: Adult; Aged; Antiparkinson Agents; Carbidopa; Disability Evaluation; Drug Combinations; Duodenum; Female; Gels; Humans; Infusions, Parenteral; Intubation, Gastrointestinal; Levodopa; Long-Term Care; Male; Middle Aged; Neurologic Examination; Parkinson Disease; Prospective Studies; Quality of Life | 2015 |
Integrated safety of levodopa-carbidopa intestinal gel from prospective clinical trials.
Topics: Aged; Antiparkinson Agents; Carbidopa; Clinical Trials, Phase III as Topic; Drug Combinations; Female; Gastric Bypass; Gels; Humans; Infusions, Parenteral; Levodopa; Male; Middle Aged; Multicenter Studies as Topic; Outcome Assessment, Health Care; Parkinson Disease; Prospective Studies | 2016 |
The effect of levodopa-carbidopa intestinal gel infusion long-term therapy on motor complications in advanced Parkinson's disease: a multicenter Romanian experience.
Topics: Adult; Aged; Antiparkinson Agents; Carbidopa; Drug Combinations; Female; Gastric Bypass; Gels; Humans; Levodopa; Male; Middle Aged; Movement Disorders; Parkinson Disease; Quality of Life; Retrospective Studies; Romania | 2016 |
Compensatory striatal-cerebellar connectivity in mild-moderate Parkinson's disease.
Topics: Aged; Brain Mapping; Carbidopa; Caudate Nucleus; Cerebellum; Drug Combinations; Humans; Levodopa; Magnetic Resonance Imaging; Middle Aged; Motor Activity; Motor Cortex; Neural Pathways; Parkinson Disease; Putamen; Severity of Illness Index | 2016 |
Possible serotonin syndrome with carbidopa-levodopa and linezolid.
Topics: Aged, 80 and over; Anti-Bacterial Agents; Carbidopa; Dopamine Agonists; Drug Combinations; Drug Interactions; Female; Humans; Levodopa; Linezolid; Serotonin Agents; Serotonin Syndrome | 2016 |
A case of severe leg oedema in a patient with Parkinson's disease treated with pramipexole.
Topics: Antiparkinson Agents; Benzothiazoles; Carbidopa; Drug Combinations; Drug Therapy, Combination; Edema; Humans; Leg; Levodopa; Male; Middle Aged; Parkinson Disease; Pramipexole; Treatment Outcome | 2016 |
24-Hour infusion of levodopa/carbidopa intestinal gel for nocturnal akinesia in advanced Parkinson's disease.
Topics: Aged; Antiparkinson Agents; Carbidopa; Drug Combinations; Female; Follow-Up Studies; Gels; Humans; Infusions, Parenteral; Levodopa; Male; Middle Aged; Muscle Rigidity; Outcome Assessment, Health Care; Parkinson Disease; Sleep Wake Disorders | 2016 |
Vocal training, levodopa, and environment effects on ultrasonic vocalizations in a rat neurotoxin model of Parkinson disease.
Topics: Animals; Antiparkinson Agents; Apomorphine; Carbidopa; Communication Disorders; Disease Models, Animal; Dopamine; Dopamine Agonists; Drug Combinations; Fourier Analysis; Levodopa; Male; Neurotoxins; Oxidopamine; Parkinson Disease, Secondary; Rats; Rats, Long-Evans; Stereotyped Behavior; Time Factors; Ultrasonics; Vocalization, Animal | 2016 |
Physicians' experience with RYTARY (carbidopa and levodopa) extended-release capsules in patients who have Parkinson disease.
Topics: Antiparkinson Agents; Capsules; Carbidopa; Delayed-Action Preparations; Drug Combinations; Drug Substitution; Humans; Levodopa; Parkinson Disease; Physicians | 2016 |
Clinical management of patients with advanced Parkinson's disease treated with continuous intestinal infusion of levodopa/carbidopa.
Topics: Antiparkinson Agents; Carbidopa; Caregivers; Clinical Trials as Topic; Databases, Bibliographic; Drug Administration Schedule; Drug Combinations; Female; Follow-Up Studies; Gels; Humans; Intestines; Levodopa; Male; Parkinson Disease; Treatment Outcome | 2016 |
What Is Not in the Name? Dopa-Responsive Dystonia May Respond to More Than L-Dopa.
Topics: 5-Hydroxytryptophan; Adolescent; Anti-Dyskinesia Agents; Carbidopa; Diseases in Twins; Dopamine Agonists; Drug Combinations; Dystonia; Female; Humans; Levodopa; Male; Metabolism, Inborn Errors; Psychomotor Disorders; Serotonin Agents | 2016 |
Advanced therapies in Parkinson's disease: Long-term retrospective study.
Topics: Activities of Daily Living; Aged; Antiparkinson Agents; Carbidopa; Cohort Studies; Deep Brain Stimulation; Drug Combinations; Female; Gels; Humans; Intestines; Levodopa; Male; Middle Aged; Motor Activity; Neuropsychological Tests; Parkinson Disease; Severity of Illness Index; Thalamus; Treatment Outcome | 2016 |
Outpatient titration of carbidopa/levodopa enteral suspension (Duopa).
Topics: Aged; Antiparkinson Agents; Carbidopa; Drug Combinations; Humans; Infusions, Parenteral; Levodopa; Male; Middle Aged; Outpatients; Parkinson Disease; Suspensions; Treatment Outcome | 2017 |
Endoscopic alternative to buried bumper syndrome secondary to Duodopa
Topics: Aged; Antiparkinson Agents; Carbidopa; Catheters, Indwelling; Device Removal; Drug Combinations; Emergencies; Equipment Design; Foreign-Body Migration; Gastroscopes; Gastroscopy; Gastrostomy; Humans; Infusion Pumps, Implantable; Levodopa; Male; Parkinson Disease; Tomography, X-Ray Computed | 2017 |
Levodopa-carbidopa intestinal gel (LCIG) treatment in routine care of patients with advanced Parkinson's disease: An open-label prospective observational study of effectiveness, tolerability and healthcare costs.
Topics: Aged; Antiparkinson Agents; Carbidopa; Cohort Studies; Drug Combinations; Female; Gels; Health Care Costs; Humans; Intestines; Levodopa; Male; Middle Aged; Parkinson Disease; Severity of Illness Index; Statistics, Nonparametric; Visual Analog Scale | 2016 |
Continuous intra jejunal infusion of levodopa-carbidopa intestinal gel by jejunal extension tube placement through percutaneous endoscopic gastrostomy for patients with advanced Parkinson's disease: a preliminary study.
Topics: Activities of Daily Living; Antiparkinson Agents; Carbidopa; Drug Combinations; Endoscopy, Gastrointestinal; Gastrostomy; Humans; Levodopa; Parkinson Disease | 2016 |
A potential case of remission of Parkinson's disease.
Topics: Aged; Brain; Carbidopa; Dopamine; Drug Combinations; Humans; Levodopa; Male; Meditation; Parkinson Disease; Psychophysiology; Remission Induction | 2016 |
Wearable Sensors for Advanced Therapy Referral in Parkinson's Disease.
Topics: Aged; Antiparkinson Agents; Carbidopa; Deep Brain Stimulation; Drug Combinations; Female; Follow-Up Studies; Humans; Levodopa; Male; Middle Aged; Monitoring, Ambulatory; Parkinson Disease; Referral and Consultation; Retrospective Studies; Severity of Illness Index | 2016 |
Motor outcomes in patients with advanced Parkinson's disease treated with levodopa/carbidopa intestinal gel in Italy: an interim analysis from the GREENFIELD observational study.
Topics: Activities of Daily Living; Aged; Aged, 80 and over; Antiparkinson Agents; Carbidopa; Drug Combinations; Female; Gels; Humans; Infusions, Parenteral; Italy; Levodopa; Male; Middle Aged; Outcome Assessment, Health Care; Parkinson Disease; Quality of Life | 2016 |
Plantar cutaneous function in Parkinson's disease patients ON and OFF L-dopa.
Topics: Aged; Carbidopa; Discrimination, Psychological; Drug Combinations; Electromyography; Female; Foot; Humans; Levodopa; Lower Extremity; Male; Middle Aged; Muscle, Skeletal; Parkinson Disease; Physical Stimulation; Reflex, Abnormal; Touch; Touch Perception; Vibration | 2016 |
Long-term effectiveness of levodopa-carbidopa intestinal gel in 177 Spanish patients with advanced Parkinson's disease.
Topics: Aged; Antiparkinson Agents; Carbidopa; Cross-Sectional Studies; Drug Combinations; Female; Gels; Humans; Intestines; Levodopa; Longitudinal Studies; Male; Middle Aged; Motor Activity; Parkinson Disease; Retrospective Studies; Severity of Illness Index; Spain | 2016 |
Choosing an Advanced Therapy in Parkinson's Disease; is it an Evidence-Based Decision in Current Practice?
Topics: Apomorphine; Carbidopa; Caregivers; Clinical Decision-Making; Consumer Health Information; Deep Brain Stimulation; Dopamine Agonists; Drug Combinations; Evidence-Based Practice; Humans; Levodopa; Neurologists; Parkinson Disease; Patient Preference; Qualitative Research | 2016 |
Levodopa/carbidopa intestinal gel therapy for advanced Parkinson Disease: AN early toxic effect for small nerve fibers?
Topics: Aged; Antiparkinson Agents; Carbidopa; Drug Combinations; Female; Gels; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Treatment Outcome | 2016 |
Authors' Reply to Lambarth: "Levodopa-Carbidopa Intestinal Gel in Patients with Parkinson's Disease: A Systematic Review".
Topics: Antiparkinson Agents; Carbidopa; Drug Combinations; Gels; Humans; Intestines; Levodopa; Parkinson Disease; Review Literature as Topic | 2016 |
Weight loss and decubitus duodenal ulcer in Parkinson's disease treated with levodopa-carbidopa intestinal gel infusion.
Topics: Aged; Antiparkinson Agents; Carbidopa; Drug Combinations; Duodenal Ulcer; Duodenum; Dyskinesias; Endoscopes, Gastrointestinal; Humans; Levodopa; Male; Parkinson Disease; Tomography, X-Ray Computed; Weight Loss | 2016 |
Jejunal catheter placement for levodopa-carbidopa infusion in a patient with Billroth I gastrectomy.
Topics: Antiparkinson Agents; Carbidopa; Drug Combinations; Endoscopy, Gastrointestinal; Gastrectomy; Gastroenterostomy; Humans; Infusion Pumps; Intubation, Gastrointestinal; Jejunum; Levodopa; Male; Middle Aged; Parkinson Disease | 2016 |
Beneficial anti-Parkinson effects of camel milk in Chlorpromazineinduced animal model: Behavioural and histopathological study.
Topics: Animals; Antiparkinson Agents; Behavior, Animal; Brain; Camelus; Carbidopa; Catalepsy; Chlorpromazine; Drug Combinations; Female; Levodopa; Male; Milk; Parkinsonian Disorders; Rats, Wistar; Time Factors | 2016 |
Necessity of long-term alertness in levodopa-carbidopa intestinal gel infusion for PD patients.
Topics: Aged; Antiparkinson Agents; Carbidopa; Drug Combinations; Duodenal Ulcer; Female; Gastrostomy; Humans; Infusions, Parenteral; Intestines; Levodopa; Male; Middle Aged; Parkinson Disease | 2017 |
Jejunitis secondary to Duodopa® probe, a different complication.
Topics: Aged; Antiparkinson Agents; Bezoars; Carbidopa; Drug Combinations; Endoscopy, Gastrointestinal; Female; Humans; Infusion Pumps, Implantable; Jejunal Diseases; Levodopa; Parkinson Disease | 2016 |
Diphasic dyskinesias during levodopa-carbidopa intestinal gel (LCIG) infusion in Parkinson's disease.
Topics: Aged; Antiparkinson Agents; Carbidopa; Disability Evaluation; Drug Combinations; Dyskinesia, Drug-Induced; Female; Follow-Up Studies; Gels; Humans; Intestines; Levodopa; Male; Middle Aged; Parkinson Disease; Severity of Illness Index | 2017 |
Fahr's Disease Presenting as Late-Onset Levodopa-Responsive Parkinsonism.
Topics: Aged; Antiparkinson Agents; Basal Ganglia Diseases; Calcinosis; Carbidopa; Drug Combinations; Humans; Levodopa; Male; Neurodegenerative Diseases | 2017 |
Dyskinesias in levodopa-carbidopa intestinal gel infusion era: New challenges, new features.
Topics: Antiparkinson Agents; Carbidopa; Drug Combinations; Dyskinesia, Drug-Induced; Humans; Levodopa; Male; Middle Aged; Parkinson Disease | 2017 |
Levodopa/carbidopa intestinal gel can improve both motor and non-motor experiences of daily living in Parkinson's disease: An open-label study.
Topics: Activities of Daily Living; Aged; Antiparkinson Agents; Carbidopa; Disability Evaluation; Drug Combinations; Female; Follow-Up Studies; Gels; Humans; Intestines; Levodopa; Male; Middle Aged; Parkinson Disease; Severity of Illness Index; Treatment Outcome | 2017 |
Parkinson's disease and Parkinson's disease medications have distinct signatures of the gut microbiome.
Topics: Age Factors; Antiparkinson Agents; Bifidobacterium; Carbidopa; Case-Control Studies; Catechol O-Methyltransferase Inhibitors; Cholinergic Antagonists; Confounding Factors, Epidemiologic; Diet; Drug Combinations; Dysbiosis; Female; Fruit; Gastrointestinal Microbiome; Humans; Lactobacillaceae; Levodopa; Male; Parkinson Disease; Pasteurellaceae; Risk Factors; RNA, Ribosomal, 16S; Sex Factors; United States; Vegetables; Verrucomicrobia | 2017 |
Levodopa/carbidopa intestinal gel (LCIG) infusion as mono- or combination therapy.
Topics: Algorithms; Antiparkinson Agents; Carbidopa; Combined Modality Therapy; Decision Support Systems, Clinical; Drug Combinations; Drug Therapy, Combination; Humans; Infusion Pumps; Levodopa; Parkinson Disease | 2017 |
Which patients discontinue? Issues on Levodopa/carbidopa intestinal gel treatment: Italian multicentre survey of 905 patients with long-term follow-up.
Topics: Antiparkinson Agents; Carbidopa; Disease Progression; Drug Combinations; Female; Gels; Health Surveys; Humans; Intestines; Italy; Levodopa; Longitudinal Studies; Male; Parkinson Disease; Retrospective Studies; Substance Withdrawal Syndrome | 2017 |
Prevalence and burden of dysautonomia in advanced Parkinson's disease.
Topics: Activities of Daily Living; Antiparkinson Agents; Carbidopa; Cross-Sectional Studies; Deep Brain Stimulation; Drug Combinations; Female; Humans; Levodopa; Logistic Models; Male; Parkinson Disease; Prevalence; Primary Dysautonomias; Severity of Illness Index; Subthalamic Nucleus; Surveys and Questionnaires | 2017 |
First clinical experience with levodopa/carbidopa microtablets in Parkinson's disease.
Topics: Aged; Antiparkinson Agents; Carbidopa; Drug Combinations; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Tablets | 2017 |
Small bowel obstruction secondary to distal migration of the intestinal probe in a patient with an endoscopic gastrostomy for continuous carbidopa-levodopa infusion.
Topics: Aged; Antiparkinson Agents; Carbidopa; Drug Combinations; Female; Foreign-Body Migration; Gastrostomy; Humans; Ileal Diseases; Ileum; Intestinal Obstruction; Levodopa | 2018 |
SCL20A2 mutation mimicking fluctuating Parkinson's disease.
Topics: Aged; Antiparkinson Agents; Carbidopa; Drug Combinations; Female; Humans; Levodopa; Mutation; Parkinson Disease; Sodium-Phosphate Cotransporter Proteins, Type III | 2017 |
A polysomnographic study in parkinsonian patients treated with intestinal levodopa infusion.
Topics: Aged; Antiparkinson Agents; Carbidopa; Drug Combinations; Female; Gels; Humans; Intestines; Levodopa; Male; Mental Status and Dementia Tests; Middle Aged; Parkinsonian Disorders; Polysomnography; Severity of Illness Index; Sleep Wake Disorders; Statistics, Nonparametric; Surveys and Questionnaires; Treatment Outcome | 2017 |
Use of advanced therapies for Parkinson's disease in Norway.
Topics: Antiparkinson Agents; Apomorphine; Carbidopa; Deep Brain Stimulation; Drug Combinations; Drug Utilization; Gels; Healthcare Disparities; Humans; Infusions, Parenteral; Levodopa; Norway; Parkinson Disease; Patient Education as Topic | 2017 |
Liquid levodopa-carbidopa in advanced Parkinson's disease with motor complications.
Topics: Aged; Antiparkinson Agents; Ascorbic Acid; Carbidopa; Drug Combinations; Dyskinesia, Drug-Induced; Female; Humans; Kaplan-Meier Estimate; Levodopa; Longitudinal Studies; Male; Middle Aged; Parkinson Disease; Retrospective Studies; Treatment Outcome | 2017 |
Effects of levodopa/carbidopa intestinal gel versus oral levodopa/carbidopa on B vitamin levels and neuropathy.
Topics: Administration, Oral; Aged; Antiparkinson Agents; Carbidopa; Drug Combinations; Female; Gels; Humans; Levodopa; Male; Parkinson Disease; Peripheral Nervous System Diseases; Vitamin B Complex | 2017 |
Peripheral neuropathy in 30 duodopa patients with vitamins B supplementation.
Topics: Aged; Antiparkinson Agents; Carbidopa; Drug Combinations; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Peripheral Nervous System Diseases; Pilot Projects; Prospective Studies; Vitamin B Complex; Vitamin D Deficiency | 2017 |
Central conduction abnormalities in patients receiving levodopa-carbidopa intestinal gel infusion.
Topics: Aged; Antiparkinson Agents; Carbidopa; Central Nervous System; Drug Combinations; Female; Follow-Up Studies; Gels; Humans; Infusions, Parenteral; Levodopa; Male; Neural Conduction; Parkinson Disease; Peripheral Nervous System; Polyneuropathies; Prospective Studies | 2017 |
Sulfasalazine-Induced Crystalluria Causing Severe Acute Kidney Injury.
Topics: Acute Kidney Injury; Aged; Anti-Inflammatory Agents, Non-Steroidal; Antiparkinson Agents; Carbidopa; Cholinesterase Inhibitors; Crohn Disease; Donepezil; Drug Combinations; Fluid Therapy; Humans; Indans; Kidney Calculi; Levodopa; Male; Parkinson Disease; Piperidines; Severity of Illness Index; Sulfasalazine; Ultrasonography | 2017 |
Enteral feeding in Parkinson's patients receiving levodopa/carbidopa intestinal gel.
Topics: Aged; Antiparkinson Agents; Carbidopa; Drug Combinations; Enteral Nutrition; Gels; Humans; Levodopa; Male; Parkinson Disease | 2017 |
Problems related to levodopa-carbidopa intestinal gel treatment in advanced Parkinson's disease.
Topics: Aged; Antiparkinson Agents; Carbidopa; Drug Combinations; Female; Gels; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Retrospective Studies; Treatment Outcome; Weight Loss | 2017 |
Cascade stomach associated with delayed-on or no-on phenomenon in a patient with Parkinson's disease.
Topics: Aged; Antiparkinson Agents; Barium; Carbidopa; Drug Combinations; Female; Humans; Levodopa; Parkinson Disease; Radiography; Stomach Diseases | 2017 |
Clinical Metabolomics to Segregate Aromatic Amino Acid Decarboxylase Deficiency From Drug-Induced Metabolite Elevations.
Topics: Amino Acid Metabolism, Inborn Errors; Aromatic-L-Amino-Acid Decarboxylases; Carbidopa; Child; Child, Preschool; Cohort Studies; Dopamine; Dopamine Agonists; Drug Combinations; Edetic Acid; Female; Humans; Infant; Levodopa; Male; Metabolic Networks and Pathways; Metabolomics; Vanilmandelic Acid | 2017 |
Long-term safety and effectiveness of levodopa-carbidopa intestinal gel infusion.
Topics: Aged; Antiparkinson Agents; Carbidopa; Drug Administration Routes; Drug Combinations; Drug Monitoring; Female; Gels; Humans; Intestinal Absorption; Levodopa; Male; Middle Aged; Neuropsychological Tests; Parkinson Disease; Prospective Studies; Quality of Life; Spain; Time; Treatment Outcome | 2017 |
Continuous dopaminergic stimulation in a patient treated with daytime Levodopa-carbidopa intestinal gel and overnight Rotigotine: a case report.
Topics: Aged; Carbidopa; Drug Combinations; Gels; Humans; Levodopa; Male; Parkinson Disease; Receptors, Dopamine; Tetrahydronaphthalenes; Thiophenes; Transdermal Patch | 2017 |
Ninety-day Local Tolerability and Toxicity Study of ND0612, a Novel Formulation of Levodopa/Carbidopa, Administered by Subcutaneous Continuous Infusion in Minipigs.
Topics: Animals; Carbidopa; Dopamine Agonists; Drug Combinations; Drug Evaluation, Preclinical; Drug Tolerance; Female; Infusions, Subcutaneous; Injection Site Reaction; Levodopa; Male; Necrosis; Swine; Swine, Miniature; Toxicity Tests, Chronic | 2017 |
The cost-effectiveness of levodopa/carbidopa intestinal gel compared to standard care in advanced Parkinson's disease.
Topics: Antiparkinson Agents; Carbidopa; Cost-Benefit Analysis; Drug Combinations; Female; Gels; Health Expenditures; Health Resources; Humans; Ireland; Levodopa; Male; Markov Chains; Parkinson Disease; Quality-Adjusted Life Years | 2017 |
Initiation of Levodopa-Carbidopa Intestinal Gel Infusion Using Telemedicine (Video Communication System) Facilitates Efficient and Well-Accepted Home Titration in Patients with Advanced Parkinson's Disease.
Topics: Aged; Antiparkinson Agents; Carbidopa; Drug Combinations; Female; Gels; Humans; Intestines; Levodopa; Male; Middle Aged; Parkinson Disease; Sweden; Telemedicine; Time Factors; Treatment Outcome; Video Recording | 2017 |
Levodopa-carbidopa intestinal gel in advanced Parkinson's: Final results of the GLORIA registry.
Topics: Aged; Antiparkinson Agents; Carbidopa; Drug Combinations; Female; Gels; Humans; Intubation, Gastrointestinal; Levodopa; Male; Middle Aged; Parkinson Disease; Registries | 2017 |
Dopaminergic tone does not influence pain levels during placebo interventions in patients with chronic neuropathic pain.
Topics: Adult; Aged; Anesthetics, Local; Carbidopa; Chronic Pain; Dopamine; Dopamine Agents; Drug Combinations; Female; Haloperidol; Humans; Levodopa; Lidocaine; Male; Middle Aged; Motivation; Neuralgia; Placebo Effect; Placebos; Psychological Tests; Retrospective Studies; Suggestion | 2018 |
Levodopa-carbidopa intestinal gel therapy after deep brain stimulation.
Topics: Aged; Antiparkinson Agents; Carbidopa; Deep Brain Stimulation; Drug Combinations; Female; Gels; Humans; Intestines; Levodopa; Male; Middle Aged; Parkinson Disease; Severity of Illness Index; Treatment Outcome | 2018 |
The Design and Evaluation of an l-Dopa-Lazabemide Prodrug for the Treatment of Parkinson's Disease.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Biological Availability; Carbidopa; Corpus Striatum; Dopamine; Drug Combinations; HeLa Cells; Humans; Levodopa; Male; Mice, Inbred C57BL; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Parkinson Disease; Permeability; Picolinic Acids; Prodrugs; Solubility; Structure-Activity Relationship | 2017 |
Post encephalitic parkinsonism following dengue viral infection.
Topics: Aged; Antibodies, Viral; Antiparkinson Agents; Carbidopa; Drug Combinations; Humans; Immunoglobulin M; Levodopa; Male; Parkinson Disease, Postencephalitic; Severe Dengue; Sri Lanka | 2017 |
l-Dopa/carbidopa intestinal gel and subthalamic nucleus stimulation: Effects on cognition and behavior.
Topics: Aged; Antiparkinson Agents; Carbidopa; Cognition; Deep Brain Stimulation; Drug Combinations; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Prospective Studies; Subthalamic Nucleus; Treatment Outcome | 2017 |
Case 38-2017. A 20-Year-Old Woman with Seizures and Progressive Dystonia.
Topics: Basal Ganglia Diseases; Biotin; Brain; Carbidopa; Diagnosis, Differential; Drug Combinations; Dystonia; Female; Humans; Levodopa; Macula Lutea; Magnetic Resonance Imaging; Membrane Transport Proteins; Metabolism, Inborn Errors; Mutation; Optic Nerve; Seizures; Thiamine; Young Adult | 2017 |
Patient Preferences for Device-Aided Treatments Indicated for Advanced Parkinson Disease.
Topics: Adult; Aged; Aged, 80 and over; Antiparkinson Agents; Carbidopa; Choice Behavior; Deep Brain Stimulation; Drug Combinations; Drug Delivery Systems; Duodenum; Equipment Design; Female; Humans; Infusion Pumps; Internet; Levodopa; Male; Middle Aged; Parkinson Disease; Patient Preference; Surveys and Questionnaires; United States | 2017 |
Improvement of Self-Injury With Dopamine and Serotonin Replacement Therapy in a Patient With a Hemizygous PAK3 Mutation: A New Therapeutic Strategy for Neuropsychiatric Features of an Intellectual Disability Syndrome.
Topics: 5-Hydroxytryptophan; Adolescent; Brain; Carbidopa; Dopamine; Drug Combinations; Humans; Intellectual Disability; Levodopa; Male; Mutation; p21-Activated Kinases; Psychotropic Drugs; Self-Injurious Behavior; Serotonin; Syndrome | 2018 |
Neither Cholinergic Nor Dopaminergic Enhancement Improve Spatial Working Memory Precision in Humans.
Topics: Acetylcholine; Adolescent; Adult; Carbidopa; Donepezil; Dopamine; Double-Blind Method; Drug Combinations; Female; Humans; Indans; Levodopa; Male; Memory, Short-Term; Neuropsychological Tests; Nootropic Agents; Piperidines; Psychometrics; Spatial Memory; Treatment Failure; Visual Perception; Young Adult | 2017 |
Report: Preparation of levodopa/carbidopa compound drug resins.
Topics: Antiparkinson Agents; Carbidopa; Delayed-Action Preparations; Drug Combinations; Drug Delivery Systems; Drug Liberation; Drug Stability; Ion Exchange Resins; Levodopa; Technology, Pharmaceutical | 2018 |
Effects of intestinal Levodopa infusion on freezing of gait in Parkinson disease.
Topics: Aged; Antiparkinson Agents; Carbidopa; Drug Combinations; Female; Gait Disorders, Neurologic; Gels; Humans; Intestines; Levodopa; Longitudinal Studies; Male; Middle Aged; Parkinson Disease; Retrospective Studies; Severity of Illness Index; Statistics, Nonparametric; Treatment Outcome | 2018 |
Prelemniscal Lesion for Selective Improvement of Parkinson Disease Tremor.
Topics: Aged; Carbidopa; Drug Combinations; Humans; Levodopa; Male; Parkinson Disease; Treatment Outcome; Tremor; Ventral Thalamic Nuclei | 2018 |
Linagliptin potentiates the effect of l-dopa on the behavioural, biochemical and immunohistochemical changes in experimentally-induced Parkinsonism: Role of toll-like receptor 4, TGF-β1, NF-κB and glucagon-like peptide 1.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Carbidopa; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Combinations; Drug Synergism; Glucagon-Like Peptide 1; Levodopa; Linagliptin; Mice; Mice, Inbred BALB C; NF-kappa B; Parkinsonian Disorders; Toll-Like Receptor 4; Transforming Growth Factor beta1 | 2018 |
Duodopa nasoduodenal tube at intrabronchial position.
Topics: Aged; Bronchi; Carbidopa; Dopamine Agonists; Drug Combinations; Female; Humans; Intubation, Gastrointestinal; Levodopa | 2018 |
Motor fluctuations and levodopa-induced dyskinesias in dopa-responsive dystonia.
Topics: Carbidopa; Dopamine Agonists; Drug Combinations; Dyskinesia, Drug-Induced; Dystonic Disorders; Female; GTP Cyclohydrolase; Humans; Levodopa; Middle Aged | 2018 |
A wrinkle in ON-time - A GI structural abnormality confounding levodopa therapy with Duodopa rescue; a case study.
Topics: Aged; Antiparkinson Agents; Carbidopa; Drug Combinations; Hernia, Hiatal; Humans; Levodopa; Male; Parkinson Disease | 2018 |
Caregiver burden and its related factors in advanced Parkinson's disease: data from the PREDICT study.
Topics: Aged; Aged, 80 and over; Antiparkinson Agents; Apomorphine; Carbidopa; Caregivers; Cost of Illness; Cross-Sectional Studies; Drug Combinations; Family; Female; Humans; Italy; Levodopa; Male; Middle Aged; Parkinson Disease; Patient Satisfaction; Quality of Life; Socioeconomic Factors; Surveys and Questionnaires; Treatment Outcome | 2018 |
Improvement of impulse control disorders associated with levodopa-carbidopa intestinal gel treatment in advanced Parkinson's disease.
Topics: Aged; Aged, 80 and over; Antiparkinson Agents; Carbidopa; Caregivers; Comorbidity; Cost of Illness; Disruptive, Impulse Control, and Conduct Disorders; Drug Combinations; Endoscopy, Gastrointestinal; Female; Follow-Up Studies; Gastrostomy; Gels; Humans; Levodopa; Male; Parkinson Disease; Prospective Studies; Psychotropic Drugs; Quality of Life; Severity of Illness Index; Sleep; Treatment Outcome | 2018 |
Workforce participation and activities in Parkinson's disease patients receiving device-aided therapy.
Topics: Activities of Daily Living; Aged; Antiparkinson Agents; Apomorphine; Carbidopa; Deep Brain Stimulation; Denmark; Drug Combinations; Female; Gels; Humans; Intestines; Levodopa; Male; Middle Aged; Parkinson Disease; Pilot Projects; Retrospective Studies; Sweden | 2018 |
Jejunal pulling syndrome: A peculiar LCIG complication.
Topics: Aged; Antiparkinson Agents; Bezoars; Carbidopa; Drug Combinations; Gastric Bypass; Gels; Humans; Infusions, Parenteral; Intestinal Volvulus; Jejunum; Levodopa; Male; Parkinson Disease | 2018 |
Anticataleptic activity of Zamzam water in chlorpromazine induced animal model of Parkinson disease.
Topics: Animals; Brain; Carbidopa; Catalepsy; Chlorpromazine; Disease Models, Animal; Drug Combinations; Hydrogen-Ion Concentration; Levodopa; Parkinsonian Disorders; Rats; Water | 2018 |
Levodopa-carbidopa intestinal gel: is the naso-jejunal phase a redundant convention?
Topics: Administration, Intranasal; Aged; Antiparkinson Agents; Carbidopa; Drug Combinations; Female; Gastrostomy; Gels; Humans; Infusion Pumps, Implantable; Jejunostomy; Jejunum; Length of Stay; Levodopa; Male; Middle Aged; Parkinson Disease | 2018 |
Age/disease duration influence on activities of daily living and quality of life after levodopa-carbidopa intestinal gel in Parkinson's disease.
Topics: Activities of Daily Living; Age Factors; Aged; Antiparkinson Agents; Carbidopa; Drug Combinations; Europe; Female; Gels; Humans; International Cooperation; Intestines; Levodopa; Male; Middle Aged; Parkinson Disease; Quality of Life; Surveys and Questionnaires; Treatment Outcome | 2018 |
Individualization of levodopa treatment using a microtablet dispenser and ambulatory accelerometry.
Topics: Accelerometry; Aged; Aged, 80 and over; Antiparkinson Agents; Carbidopa; Drug Combinations; Female; Humans; Levodopa; Longitudinal Studies; Male; Medication Adherence; Middle Aged; Parkinson Disease; Precision Medicine; Quality of Life; Single-Blind Method; Tablets; Treatment Outcome | 2018 |
Acute cholecystitis induced by surgery for levodopa-carbidopa intestinal gel therapy: Possible relationship to pre-existing gallstones.
Topics: Aged; Antiparkinson Agents; Carbidopa; Cholecystitis, Acute; Drug Combinations; Gallstones; Humans; Infusions, Parenteral; Jejunostomy; Levodopa; Male; Parkinson Disease | 2018 |
Lesson of the month 2: An unusual adverse reaction associated with pramipexole.
Topics: Carbidopa; Dermatitis, Phototoxic; Dopamine Agonists; Drug Combinations; Drug Substitution; Humans; Levodopa; Male; Middle Aged; Nocturnal Myoclonus Syndrome; Pramipexole | 2018 |
Population pharmacokinetics of levodopa/carbidopa microtablets in healthy subjects and Parkinson's disease patients.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Antiparkinson Agents; Carbidopa; Case-Control Studies; Dose-Response Relationship, Drug; Drug Combinations; Female; Humans; Levodopa; Male; Middle Aged; Models, Biological; Nonlinear Dynamics; Parkinson Disease; Tablets; Young Adult | 2018 |
Independent effects of age and levodopa on reversal learning in healthy volunteers.
Topics: Adult; Aged; Aging; Carbidopa; Cross-Over Studies; Dopamine Agonists; Double-Blind Method; Drug Combinations; Humans; Levodopa; Punishment; Reversal Learning; Reward; Young Adult | 2018 |
[Outpatient establishment and initial management of treatment with intraduodenal levodopa-carbidopa infusion in advanced Parkinson's disease].
Topics: Aged; Algorithms; Ambulatory Care; Antiparkinson Agents; Carbidopa; Clinical Protocols; Disease Management; Drug Combinations; Duodenum; Female; Gastrostomy; Humans; Infusions, Parenteral; Intestinal Absorption; Intubation, Gastrointestinal; Levodopa; Male; Parkinson Disease | 2018 |
Assessment of Duodopa
Topics: Aged; Antiparkinson Agents; Carbidopa; Caregivers; Drug Combinations; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Prospective Studies; Quality of Life; Treatment Outcome | 2018 |
Phytobezoar and duodenal ulcer as complication of Duodopa therapy in a patient affected by Parkinson's disease.
Topics: Aged; Antiparkinson Agents; Bezoars; Carbidopa; Catheters, Indwelling; Drug Combinations; Duodenal Ulcer; Endoscopy, Digestive System; Gastrostomy; Humans; Infusions, Parenteral; Jejunum; Levodopa; Male; Tomography, X-Ray Computed | 2018 |
Developing consensus among movement disorder specialists on clinical indicators for identification and management of advanced Parkinson's disease: a multi-country Delphi-panel approach.
Topics: Activities of Daily Living; Adolescent; Adult; Aged; Antiparkinson Agents; Carbidopa; Consensus; Drug Combinations; Europe; Female; Gels; Humans; Levodopa; Male; Parkinson Disease; Specialization; Young Adult | 2018 |
Levodopa-Carbidopa-Related Rash in Parkinson's Disease: A Case Series.
Topics: Adult; Aged, 80 and over; Antiparkinson Agents; Carbidopa; Drug Combinations; Exanthema; Female; Humans; Levodopa; Middle Aged; Parkinson Disease | 2018 |
[Levodopa-carbidopa intestinal gel treatment introduced by surgical gastrostomy in a patient of Parkinson's disease after Billroth II gastrojejunostomy].
Topics: Aged; Antiparkinson Agents; Carbidopa; Dosage Forms; Drug Combinations; Drug Compounding; Duodenal Ulcer; Gastric Bypass; Gastrostomy; Gels; Humans; Levodopa; Male; Parkinson Disease; Treatment Outcome | 2018 |
The effect of continuous levodopa treatment during the afternoon hours.
Topics: Aged; Antiparkinson Agents; Carbidopa; Drug Combinations; Female; Gels; Humans; Infusion Pumps, Implantable; Intestines; Levodopa; Male; Middle Aged; Parkinson Disease; Retrospective Studies; Time Factors | 2019 |
Possible modulation of concurrent Parkinson's disease in the management of metastatic GIST: a review of two cases.
Topics: Aged; Antineoplastic Agents; Antiparkinson Agents; Carbidopa; Drug Combinations; Gastrectomy; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Levodopa; Liver Neoplasms; Male; Parkinson Disease; Severity of Illness Index; Stomach Neoplasms | 2018 |
[Vitamin B6 deficiency caused by the use of levodopa].
Topics: Administration, Oral; Aged; Antiparkinson Agents; Carbidopa; Drug Combinations; Humans; Levodopa; Middle Aged; Tablets; Vitamin B 6 Deficiency | 2018 |
Substantial renal conversion of L-threo-3,4-dihydroxyphenylserine (droxidopa) to norepinephrine in patients with neurogenic orthostatic hypotension.
Topics: Adult; Aged; Antiparkinson Agents; Carbidopa; Droxidopa; Drug Combinations; Female; Humans; Hypotension, Orthostatic; Kidney; Levodopa; Male; Middle Aged; Norepinephrine | 2019 |
Levodopa/carbidopa intestinal gel infusion and weight loss in Parkinson's disease.
Topics: Aged; Aged, 80 and over; Antiparkinson Agents; Carbidopa; Drug Combinations; Female; Gels; Humans; Infusions, Parenteral; Levodopa; Male; Middle Aged; Parkinson Disease; Weight Loss | 2019 |
Burden of non-motor symptoms in Parkinson's disease patients predicts improvement in quality of life during treatment with levodopa-carbidopa intestinal gel.
Topics: Aged; Antiparkinson Agents; Carbidopa; Cost of Illness; Drug Combinations; Female; Gels; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Quality of Life; Severity of Illness Index; Surveys and Questionnaires; Treatment Outcome | 2019 |
Proposition of zinc supplementation during levodopa-carbidopa intestinal gel treatment.
Topics: Aged; Antiparkinson Agents; Carbidopa; Drug Administration Routes; Drug Combinations; Female; Gels; Humans; Levodopa; Male; Parkinson Disease; Prospective Studies; Zinc | 2018 |
A case of Perry Syndrome responding to intestinal infusion of carbidopa/levodopa.
Topics: Antiparkinson Agents; Carbidopa; Depression; Drug Combinations; Female; Gels; Humans; Hypoventilation; Infusions, Parenteral; Jejunostomy; Levodopa; Middle Aged; Parkinsonian Disorders | 2019 |
Conversion of L-dopa to Extended Release L-dopa (Rytary®) in Patients with Fluctuating Parkinson's Disease: Predictors of Dose.
Topics: Aged; Carbidopa; Delayed-Action Preparations; Drug Combinations; Drug Substitution; Female; Follow-Up Studies; Humans; Levodopa; Male; Middle Aged; Outcome Assessment, Health Care; Parkinson Disease; Patient Preference; Retrospective Studies | 2019 |
Evaluation of D1/D5 Partial Agonist PF-06412562 in Parkinson's Disease following Oral Administration.
Topics: Administration, Oral; Aged; Antiparkinson Agents; Carbidopa; Double-Blind Method; Drug Combinations; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Treatment Outcome | 2018 |
Cost-utility analysis of levodopa carbidopa intestinal gel (Duodopa) in the treatment of advanced Parkinson's disease in patients in Scotland and Wales.
Topics: Antiparkinson Agents; Carbidopa; Cost-Benefit Analysis; Drug Combinations; Gels; Health Expenditures; Health Services; Health Status; Humans; Infusion Pumps, Implantable; Levodopa; Markov Chains; Models, Econometric; Parkinson Disease; Quality-Adjusted Life Years; Scotland; Severity of Illness Index; Wales | 2019 |
Levodopa-carbidopa intestinal gel in a subgroup of patients with dyskinesia at baseline from the GLORIA Registry.
Topics: Aged; Carbidopa; Dopamine Agents; Drug Combinations; Dyskinesias; Female; Gels; Humans; Levodopa; Male; Middle Aged; Outcome Assessment, Health Care; Parkinson Disease; Quality of Life; Registries | 2019 |
Impact of Disease Duration in Effectiveness of Treatment with Levodopa-Carbidopa Intestinal Gel and Factors Leading to Discontinuation.
Topics: Aged; Antiparkinson Agents; Carbidopa; Drug Combinations; Drug-Related Side Effects and Adverse Reactions; Female; Gels; Humans; Infusions, Parenteral; Levodopa; Male; Middle Aged; Parkinson Disease; Retrospective Studies; Severity of Illness Index; Time Factors | 2019 |
Sensor-based algorithmic dosing suggestions for oral administration of levodopa/carbidopa microtablets for Parkinson's disease: a first experience.
Topics: Actigraphy; Administration, Oral; Aged; Aged, 80 and over; Algorithms; Antiparkinson Agents; Carbidopa; Drug Combinations; Feasibility Studies; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Wearable Electronic Devices | 2019 |
Sitagliptin and Liraglutide Modulate L-dopa Effect and Attenuate Dyskinetic Movements in Rotenone-Lesioned Rats.
Topics: Animals; Antiparkinson Agents; Carbidopa; Corpus Striatum; Dopamine; Drug Combinations; Dyskinesia, Drug-Induced; Levodopa; Liraglutide; Male; Motor Activity; Parkinsonian Disorders; Pars Compacta; Random Allocation; Rats, Wistar; Rotenone; Sitagliptin Phosphate | 2019 |
A Man Made Manic: Levodopa-Carbidopa-Induced Mania in Traumatic Brain Injury.
Topics: Bipolar Disorder; Brain Injuries, Traumatic; Carbidopa; Dopamine Agonists; Drug Combinations; Humans; Levodopa; Male; Middle Aged | 2019 |
[Analysis of PEG-J associated complications in 14 adult patients treated with levodopa-carbidopa intestinal gel].
Topics: Adult; Aged; Antiparkinson Agents; Carbidopa; Drug Combinations; Duodenal Diseases; Duodenal Ulcer; Endoscopy, Gastrointestinal; Female; Gastrostomy; Gels; Humans; Intestinal Perforation; Jejunostomy; Levodopa; Male; Middle Aged; Parkinson Disease; Peritonitis; Retrospective Studies; Skin Diseases; Surgical Stomas | 2019 |
[Complications and troubleshooting at the initial introduction of Levodopa-carbidopa continuous infusion gel therapy: A single-center study].
Topics: Aged; Antiparkinson Agents; Carbidopa; Drug Combinations; Female; Gastric Bypass; Gastrostomy; Gels; Glycosides; Humans; Infusion Pumps; Intubation; Levodopa; Male; Middle Aged; Parkinson Disease; Pregnanes; Retrospective Studies; Skin Diseases, Infectious | 2019 |
Long-term effect of levodopa-carbidopa intestinal gel on axial signs in Parkinson's disease.
Topics: Administration, Mucosal; Aged; Antiparkinson Agents; Carbidopa; Drug Combinations; Female; Gait; Gels; Humans; Intestinal Mucosa; Levodopa; Male; Middle Aged; Parkinson Disease; Postural Balance | 2019 |
Acute parkinsonism as an unexpected consequence of pituitary adenoma resection: A case report.
Topics: Adenoma; Adult; Carbidopa; Drug Combinations; Female; Humans; Hyponatremia; Levodopa; Magnetic Resonance Imaging; Myelinolysis, Central Pontine; Parkinsonian Disorders; Pituitary Neoplasms | 2019 |
Dyskinesia-Hyperpyrexia Syndrome in Parkinson's disease with Deep Brain Stimulation and high-dose levodopa/carbidopa and entacapone.
Topics: Antiparkinson Agents; Carbidopa; Catechols; Combined Modality Therapy; Deep Brain Stimulation; Drug Combinations; Drug Therapy, Combination; Fever; Humans; Hyperkinesis; Levodopa; Male; Middle Aged; Nitriles; Parkinson Disease | 2019 |
Dopamine dysregulation syndrome induced by proxy.
Topics: Aged; Carbidopa; Disruptive, Impulse Control, and Conduct Disorders; Drug Combinations; Female; Humans; Levodopa; Parkinson Disease; Substance-Related Disorders; Syndrome | 2019 |
Continuous subcutaneous apomorphine infusion in Parkinson's disease: causes of discontinuation and subsequent treatment strategies.
Topics: Adult; Aged; Aged, 80 and over; Apomorphine; Carbidopa; Cognitive Dysfunction; Deep Brain Stimulation; Dopamine Agonists; Drug Combinations; Drug Substitution; Electronic Health Records; Female; Humans; Infusions, Subcutaneous; Levodopa; Male; Medication Adherence; Middle Aged; Parkinson Disease; Retrospective Studies | 2019 |
Technique and outcome of percutaneous endoscopic transgastric jejunostomy for continuous infusion of levodopa-carbidopa intestinal gel for treatment of Parkinson's disease.
Topics: Aged; Aged, 80 and over; Carbidopa; Drug Combinations; Endoscopy, Gastrointestinal; Female; Gels; Humans; Jejunostomy; Levodopa; Male; Middle Aged; Parkinson Disease; Quality of Life; Retrospective Studies; Treatment Outcome | 2019 |
Motor and non-motor outcomes in patients with advanced Parkinson's disease treated with levodopa/carbidopa intestinal gel: final results of the GREENFIELD observational study.
Topics: Aged; Aged, 80 and over; Antiparkinson Agents; Carbidopa; Cohort Studies; Drug Combinations; Female; Follow-Up Studies; Gastrostomy; Gels; Humans; Infusion Pumps; Italy; Jejunum; Levodopa; Male; Mental Status and Dementia Tests; Middle Aged; Parkinson Disease; Prospective Studies; Retrospective Studies; Treatment Outcome | 2019 |
Levodopa/carbidopa intestinal gel infusion can improve camptocormia in Parkinson's disease.
Topics: Aged; Carbidopa; Dopamine Agonists; Drug Combinations; Gels; Humans; Infusions, Parenteral; Levodopa; Male; Muscular Atrophy, Spinal; Parkinson Disease; Spinal Curvatures; Treatment Outcome | 2019 |
Dynamics of device-based treatments for Parkinson's disease in Germany from 2010 to 2017: application of continuous subcutaneous apomorphine, levodopa-carbidopa intestinal gel, and deep brain stimulation.
Topics: Antiparkinson Agents; Apomorphine; Carbidopa; Deep Brain Stimulation; Drug Combinations; Gels; Germany; Humans; Infusions, Parenteral; Infusions, Subcutaneous; Levodopa; Neurology; Parkinson Disease; Practice Patterns, Physicians' | 2019 |
Levodopa-Carbidopa Intestinal Gel Monotherapy: GLORIA Registry Demographics, Efficacy, and Safety.
Topics: Aged; Antiparkinson Agents; Carbidopa; Drug Combinations; Female; Gastrostomy; Gels; Humans; Infusion Pumps, Implantable; Infusions, Parenteral; Jejunum; Levodopa; Male; Middle Aged; Outcome Assessment, Health Care; Parkinson Disease; Registries; Retrospective Studies | 2019 |
Rescue levodopa-carbidopa intestinal gel (LCIG) therapy in Parkinson's disease patients with suboptimal response to deep brain stimulation.
Topics: Aged; Aged, 80 and over; Antiparkinson Agents; Carbidopa; Combined Modality Therapy; Deep Brain Stimulation; Drug Combinations; Female; Gels; Humans; Levodopa; Male; Middle Aged; Outcome Assessment, Health Care; Parkinson Disease; Retrospective Studies | 2019 |
[Chronic inflammatory demyelinating polyradiculoneuropathy associated with treatment using intraduodenal infusion of levodopa-carbidopa].
Topics: Antiparkinson Agents; Carbidopa; Diagnosis, Differential; Dopamine; Drug Combinations; Duodenum; Female; Folic Acid; Humans; Infusions, Parenteral; Levodopa; Metabolic Networks and Pathways; Methionine; Middle Aged; Parkinson Disease; Polyradiculoneuropathy, Chronic Inflammatory Demyelinating | 2019 |
Endoscopic management of duodenal levodopa-carbidopa therapy of advanced Parkinson's disease.
Topics: Aged; Antiparkinson Agents; Carbidopa; Drug Combinations; Duodenoscopy; Female; Gastrostomy; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Retrospective Studies | 2019 |
Coumarin analogue 3-methyl-7H-furo[3,2-g] chromen-7-one as a possible antiparkinsonian agent
Topics: Animals; Antiparkinson Agents; Carbidopa; Catalepsy; Coumarins; Disease Models, Animal; Drug Combinations; Drug Evaluation, Preclinical; Haloperidol; Levodopa; Locomotion; Male; Mice; Mice, Inbred ICR; Monoamine Oxidase Inhibitors; Parkinson Disease, Secondary; Reserpine | 2019 |
Investigating Stochastic Differential Equations Modelling for Levodopa Infusion in Patients with Parkinson's Disease.
Topics: Aged; Antiparkinson Agents; Biological Availability; Carbidopa; Drug Combinations; Female; Humans; Levodopa; Male; Middle Aged; Models, Biological; Parkinson Disease; Precision Medicine; Stochastic Processes | 2020 |
Long-term safety and efficacy of 24-hour levodopa-carbidopa intestinal gel in Parkinson's disease.
Topics: Aged; Antiparkinson Agents; Carbidopa; Drug Combinations; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Treatment Outcome | 2019 |
Beyond 10 years of levodopa intestinal infusion experience: Analysis of mortality and its predictors.
Topics: Adult; Aged; Aged, 80 and over; Antiparkinson Agents; Carbidopa; Cause of Death; Drug Combinations; Female; Humans; Infusions, Parenteral; Levodopa; Longitudinal Studies; Male; Mental Status and Dementia Tests; Middle Aged; Parkinson Disease; Prognosis; Retrospective Studies | 2020 |
Safety and effectiveness of levodopa-carbidopa intestinal gel for advanced Parkinson's disease: A large single-center study.
Topics: Adult; Aged; Aged, 80 and over; Antiparkinson Agents; Carbidopa; Catheters, Indwelling; Drug Combinations; Drug-Related Side Effects and Adverse Reactions; Endoscopy, Gastrointestinal; Female; France; Gastrostomy; Gels; Humans; Infusion Pumps; Intestinal Absorption; Levodopa; Male; Mental Status and Dementia Tests; Middle Aged; Parkinson Disease; Retrospective Studies; Severity of Illness Index; Treatment Outcome | 2020 |
Multicenter study of levodopa carbidopa intestinal gel in Parkinson’s disease: the Turkish experience
Topics: Activities of Daily Living; Aged; Carbidopa; Drug Combinations; Female; Gels; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Reproducibility of Results | 2020 |
Complex dyskinesias in Parkinson patients on levodopa/carbidopa intestinal gel.
Topics: Aged; Antiparkinson Agents; Carbidopa; Case-Control Studies; Cross-Sectional Studies; Drug Combinations; Dyskinesia, Drug-Induced; Female; Gels; Humans; Intestines; Levodopa; Longitudinal Studies; Male; Middle Aged; Parkinson Disease; Retrospective Studies | 2019 |
Neurochemical supplementation in patients with depressed levels of participation after brain tumor surgery: Rationale and preliminary results.
Topics: Adult; Basal Ganglia; Brain; Brain Neoplasms; Carbidopa; Dietary Supplements; Drug Combinations; Female; Frontal Lobe; Humans; Levodopa; Male; Methylphenidate; Middle Aged; Patient Participation; Postoperative Period; Retrospective Studies | 2020 |
Which Scale Best Detects Treatment Response of Tremor in Parkinsonism?
Topics: Adult; Aged; Antiparkinson Agents; Carbidopa; Deep Brain Stimulation; Drug Combinations; Female; Follow-Up Studies; Humans; Levodopa; Male; Middle Aged; Outcome Assessment, Health Care; Parkinsonian Disorders; Sensitivity and Specificity; Severity of Illness Index; Tremor | 2020 |
Clinical Trial Highlights - Infusion Therapies.
Topics: Apomorphine; Carbidopa; Clinical Trials as Topic; Dopamine Agonists; Drug Combinations; Gels; Humans; Infusion Pumps, Implantable; Infusions, Subcutaneous; Jejunum; Levodopa; Parkinson Disease | 2020 |
Transient parkinsonism associated with acute Legionnaires' disease.
Topics: Adult; Anti-Bacterial Agents; Antiparkinson Agents; Carbidopa; Ciprofloxacin; Drug Combinations; Drug Therapy, Combination; Dysarthria; Humans; Legionella; Legionnaires' Disease; Levodopa; Male; Parkinsonian Disorders; Respiratory Insufficiency | 2020 |
Supplementary management with Pycnogenol® in Parkinson's disease to prevent cognitive impairment.
Topics: Carbidopa; Cognition; Cognitive Dysfunction; Dietary Supplements; Drug Combinations; Female; Free Radicals; Humans; Levodopa; Male; Middle Aged; Oxidative Stress; Parkinson Disease; Registries | 2020 |
An Evaluation of the Effects of Pyridoxal Phosphate in Chlorpromazineinduced Parkinsonism using Mice.
Topics: Animals; Antioxidants; Antiparkinson Agents; Antipsychotic Agents; Behavior, Animal; Body Weight; Carbidopa; Chlorpromazine; Diet; Drug Combinations; Eating; Grooming; Levodopa; Lipid Peroxidation; Mice; Motor Activity; Parkinson Disease, Secondary; Pyridoxal Phosphate | 2020 |
Child Neurology: A young child with an undiagnosed case of dystonia responsive to l-dopa.
Topics: Anti-Dyskinesia Agents; Carbidopa; Child, Preschool; Diagnosis, Differential; Drug Combinations; Dystonic Disorders; Humans; Levodopa; Male | 2020 |
Compliance with levodopa-carbidopa intestinal gel in a selected population in central south Italy: Beyond sex, a possible gender effect.
Topics: Aged; Antiparkinson Agents; Carbidopa; Drug Combinations; Female; Follow-Up Studies; Gels; Humans; Infusions, Parenteral; Italy; Levodopa; Male; Medication Adherence; Middle Aged; Parkinson Disease; Patient Dropouts; Sex Factors | 2020 |
Case Report: Dengue Virus-Triggered Parkinsonism in an Adolescent.
Topics: Adolescent; Antiparkinson Agents; Brain; Carbidopa; Dengue; Diffusion Magnetic Resonance Imaging; Drug Combinations; Electroencephalography; Humans; India; Levodopa; Magnetic Resonance Imaging; Male; Parkinson Disease, Secondary; Treatment Outcome | 2020 |
Levodopa infusion in Parkinson's disease: Individual quality of life.
Topics: Adult; Aged; Aged, 80 and over; Antiparkinson Agents; Carbidopa; Caregivers; Cost of Illness; Drug Combinations; Female; Humans; Infusions, Parenteral; Jejunum; Levodopa; Male; Middle Aged; Movement; Parkinson Disease; Prospective Studies; Psychomotor Performance; Quality of Life; Treatment Outcome | 2020 |
Biphasic Levodopa-Induced Freezing of Gait in Parkinson's Disease.
Topics: Aged; Carbidopa; Dopamine Agonists; Drug Combinations; Gait Disorders, Neurologic; Humans; Levodopa; Male; Parkinson Disease | 2020 |
Carbidopa and Levodopa Extended Release Capsules in Patients with and without Troublesome and Non-Troublesome Dyskinesia.
Topics: Aged; Aged, 80 and over; Antiparkinson Agents; Capsules; Carbidopa; Delayed-Action Preparations; Drug Administration Schedule; Drug Combinations; Dyskinesias; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease | 2020 |
Opicapone and Levodopa-Carbidopa Intestinal Gel Infusion: The Way Forward Towards Cost Savings for Healthcare Systems?
Topics: Aged; Carbidopa; Catechol O-Methyltransferase Inhibitors; Cost Savings; Delivery of Health Care; Dopamine Agonists; Drug Combinations; Female; Gels; Humans; Infusion Pumps, Implantable; Infusions, Parenteral; Levodopa; Male; Middle Aged; Oxadiazoles; Parkinson Disease; Retrospective Studies | 2020 |
Quality Improvement in Parkinson's Disease: A Successful Program to Enhance Timely Administration of Levodopa in the Hospital.
Topics: Aged; Carbidopa; Dopamine Agonists; Drug Combinations; Female; Hospital Departments; Hospitalization; Hospitals, Urban; Humans; Length of Stay; Levodopa; Male; Middle Aged; Parkinson Disease; Process Assessment, Health Care; Quality Improvement; Time Factors | 2020 |
Levodopa Positively Affects Neovascular Age-Related Macular Degeneration.
Topics: Aged; Aged, 80 and over; Carbidopa; Cohort Studies; Dopamine Agents; Drug Combinations; Female; Humans; Levodopa; Macular Degeneration; Male; Middle Aged; Pilot Projects; Treatment Outcome | 2021 |
Real-Life Use of Levodopa/Carbidopa Intestinal Gel in Parkinson's Disease According to Analysis of Pump Data.
Topics: Aged; Carbidopa; Dopamine Agonists; Drug Combinations; Female; Gels; Humans; Infusion Pumps, Implantable; Infusions, Parenteral; Levodopa; Male; Medication Adherence; Middle Aged; Parkinson Disease | 2020 |
Predictors of Time to Discontinuation of Levodopa-Carbidopa Intestinal Gel Infusion: A Retrospective Cohort Study.
Topics: Aged; Antiparkinson Agents; Carbidopa; Drug Combinations; Female; Gels; Humans; Infusions, Parenteral; Levodopa; Male; Middle Aged; Parkinson Disease; Retrospective Studies | 2020 |
Comprehensive assessment of levodopa-carbidopa intestinal gel for Turkish advanced Parkinson’s disease patients
Topics: Abdomen, Acute; Aged; Carbidopa; Catheterization; Deglutition Disorders; Drug Combinations; Drug-Related Side Effects and Adverse Reactions; Dysarthria; Dyskinesias; Endoscopy; Female; Gait; Gels; Humans; Intestines; Levodopa; Male; Mental Status and Dementia Tests; Middle Aged; Parkinson Disease; Quality of Life; Severity of Illness Index; Treatment Outcome; Turkey | 2021 |
Intrajejunal vs oral levodopa-carbidopa therapy in Parkinson disease: A retrospective cohort study.
Topics: Administration, Oral; Aged; Aged, 80 and over; Carbidopa; Cohort Studies; Drug Combinations; Female; Humans; Injections; Jejunum; Levodopa; Male; Middle Aged; Parkinson Disease; Retrospective Studies; Romania | 2020 |
Parkinson Disease.
Topics: Antiparkinson Agents; Carbidopa; Combined Modality Therapy; Deep Brain Stimulation; Disease Progression; Drug Combinations; Family Practice; Humans; Levodopa; Parkinson Disease; Physical Therapy Modalities | 2020 |
Real-world assessment of the impact of "OFF" episodes on health-related quality of life among patients with Parkinson's disease in the United States.
Topics: Aged; Carbidopa; Cross-Sectional Studies; Drug Combinations; Female; Health Status; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Quality of Life; Regression Analysis; Surveys and Questionnaires; Symptom Flare Up; United States | 2021 |
Melanocytic Hyperactivation Simulating an Acral Lentiginous Melanoma in a Patient With Parkinson Disease Treated by Levodopa.
Topics: Aged; Antiparkinson Agents; Carbidopa; Diagnosis, Differential; Drug Combinations; Female; Humans; Hyperpigmentation; Levodopa; Melanins; Melanocytes; Melanoma; Parkinson Disease; Predictive Value of Tests; Skin; Skin Neoplasms; Skin Pigmentation; Treatment Outcome | 2021 |
Therapeutic effects of Wharton's jelly-derived Mesenchymal Stromal Cells on behaviors, EEG changes and NGF-1 in rat model of the Parkinson's disease.
Topics: Animals; Antiparkinson Agents; Behavior, Animal; Carbidopa; Dopaminergic Neurons; Drug Combinations; Electroencephalography; Insulin-Like Growth Factor I; Levodopa; Male; Medial Forebrain Bundle; Mesenchymal Stem Cell Transplantation; Motor Activity; Nerve Growth Factor; Oxidopamine; Parkinson Disease, Secondary; Rats; Rats, Wistar; Substantia Nigra; Wharton Jelly | 2021 |
Treatment of unexplained coma and hypokinetic-rigid syndrome in a patient with COVID-19.
Topics: Blood Coagulation; Brain Diseases; Carbidopa; Central Nervous System Stimulants; Cognitive Dysfunction; COVID-19; Critical Care; Drug Combinations; Humans; Hypokinesia; Ischemic Stroke; Levodopa; Magnetic Resonance Imaging; Male; Middle Aged; Modafinil; Rehabilitation; Respiration, Artificial; SARS-CoV-2; Severity of Illness Index; Treatment Outcome; Ventilator Weaning | 2021 |
Buried Bumper Syndrome: A common complication of levodopa intestinal infusion for Parkinson disease.
Topics: Aged; Aged, 80 and over; Antiparkinson Agents; Carbidopa; Drug Combinations; Endoscopy, Gastrointestinal; Enteral Nutrition; Equipment Failure; Female; Gastrostomy; Gels; Humans; Infusions, Parenteral; Levodopa; Male; Middle Aged; Parkinson Disease; Postoperative Complications; Prospective Studies; Retrospective Studies | 2021 |
Effect of levodopa/carbidopa on stress response in zebrafish.
Topics: Adrenal Glands; alpha-Methyltyrosine; Animals; Carbidopa; Dopamine; Dopamine Agonists; Dopaminergic Neurons; Drug Combinations; Enzyme Inhibitors; Female; Hydrocortisone; Hypothalamo-Hypophyseal System; Levodopa; Male; Stress, Physiological; Tyrosine 3-Monooxygenase; Zebrafish; Zebrafish Proteins | 2021 |
Foslevodopa/Foscarbidopa: A New Subcutaneous Treatment for Parkinson's Disease.
Topics: Antiparkinson Agents; Carbidopa; Drug Combinations; Humans; Levodopa; Parkinson Disease | 2021 |
Monozygotic twins with DYT-TOR1A showing jerking movements and levodopa responsiveness.
Topics: Adolescent; Carbidopa; Dopamine Agents; Drug Combinations; Dystonic Disorders; Humans; Levodopa; Male; Molecular Chaperones; Twins, Monozygotic | 2021 |
Coadministration With Carbidopa Enhances the Antimyopic Effects of Levodopa in Chickens.
Topics: Administration, Topical; Animals; Animals, Newborn; Biomarkers; Carbidopa; Chickens; Disease Models, Animal; Dopamine; Dopamine Agents; Dose-Response Relationship, Drug; Drug Combinations; Injections, Intraperitoneal; Levodopa; Male; Mitosis; Myopia; Ophthalmic Solutions; Sensory Deprivation; Vitreous Body | 2021 |
Levodopa/dopa decarboxylase inhibitor associated microscopic colitis: An under-recognized drug reaction.
Topics: Aged; Aged, 80 and over; Antiparkinson Agents; Benserazide; Carbidopa; Cohort Studies; Colitis, Microscopic; Drug Combinations; Enzyme Inhibitors; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Retrospective Studies | 2021 |
Pharmacological evaluation of vanillic acid in rotenone-induced Parkinson's disease rat model.
Topics: Animals; Antioxidants; Antiparkinson Agents; Behavior, Animal; Body Weight; Carbidopa; Catalase; Catalepsy; Disease Models, Animal; Dopamine; Drug Combinations; Female; Glutathione; Levodopa; Locomotion; Male; Mesencephalon; Muscular Diseases; Oxidative Stress; Parkinson Disease; Postural Balance; Rats, Sprague-Dawley; Rotenone; Superoxides; Thiobarbituric Acid Reactive Substances; Vanillic Acid | 2021 |
The Social Value of Improvement in Activities of Daily Living among the Advanced Parkinson's Disease Population.
Topics: Activities of Daily Living; Aged; Aged, 80 and over; Antiparkinson Agents; Carbidopa; Drug Combinations; Female; Gels; Humans; Levodopa; Male; Parkinson Disease; Social Values | 2020 |
The impact of tube replacement timing during LCIG therapy on PEG-J associated adverse events: a retrospective multicenter observational study.
Topics: Antiparkinson Agents; Carbidopa; Drug Combinations; Gastric Bypass; Gels; Humans; Levodopa; Parkinson Disease; Retrospective Studies | 2021 |
Secondary biogenic amine deficiencies: genetic etiology, therapeutic interventions, and clinical effects.
Topics: Adolescent; Adult; Biogenic Amines; Carbidopa; Child; Child, Preschool; Drug Combinations; Female; Humans; Kinesins; Levodopa; Male; Neurotransmitter Agents; p21-Activated Kinases; Young Adult | 2021 |
Per-oral image guided gastrojejunostomy insertion for levodopa-carbidopa intestinal gel in Parkinson's disease is safe and may be advantageous.
Topics: Aged; Antiparkinson Agents; Carbidopa; Digestive System Surgical Procedures; Drug Combinations; Female; Gastrostomy; Gels; Humans; Jejunum; Levodopa; Male; Middle Aged; Outcome and Process Assessment, Health Care; Parkinson Disease; Surgery, Computer-Assisted | 2021 |
Recessive GCH1 Deficiency Causing DOPA-Responsive Dystonia Diagnosed by Reported Negative Exome.
Topics: Carbidopa; Child; Dopamine Agonists; Drug Combinations; Dystonic Disorders; Exome; Exome Sequencing; GTP Cyclohydrolase; Humans; Levodopa; Male | 2022 |
Levodopa Carbidopa Intestinal Gel in Advanced Parkinson's Disease: DUOGLOBE Final 3-Year Results.
Topics: Antiparkinson Agents; Carbidopa; Drug Combinations; Gels; Humans; Levodopa; Parkinson Disease; Prospective Studies; Quality of Life | 2023 |